WO1991012024A1 - Triarylmethyl radicals and the use of inert carbon free radicals in mri - Google Patents

Triarylmethyl radicals and the use of inert carbon free radicals in mri Download PDF

Info

Publication number
WO1991012024A1
WO1991012024A1 PCT/EP1991/000285 EP9100285W WO9112024A1 WO 1991012024 A1 WO1991012024 A1 WO 1991012024A1 EP 9100285 W EP9100285 W EP 9100285W WO 9112024 A1 WO9112024 A1 WO 9112024A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
group
mmol
bis
compound
Prior art date
Application number
PCT/EP1991/000285
Other languages
French (fr)
Inventor
Mikkel JØRGENSEN
Frode Rise
Sven Andersson
Torsten Almén
Arne Aabye
Lars-Göran Wistrand
Håkan WIKSTRÖM
Klaes Golman
Rolf Servin
Peter Michelsen
Original Assignee
Hafslund Nycomed Innovation Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909003105A external-priority patent/GB9003105D0/en
Priority claimed from GB909012300A external-priority patent/GB9012300D0/en
Application filed by Hafslund Nycomed Innovation Ab filed Critical Hafslund Nycomed Innovation Ab
Priority to AU72350/91A priority Critical patent/AU651570B2/en
Priority to US07/916,974 priority patent/US5599522A/en
Priority to EP91903934A priority patent/EP0515458B1/en
Priority to DE69112384T priority patent/DE69112384T2/en
Publication of WO1991012024A1 publication Critical patent/WO1991012024A1/en
Priority to FI923589A priority patent/FI923589A/en
Priority to NO92923117A priority patent/NO923117L/en
Priority to GR950403056T priority patent/GR3017947T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/20Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations containing free radicals, e.g. trityl radical for overhauser
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Definitions

  • the present invention relates to the use of stable free radicals, in particular inert carbon radicals, as image enhancing agents in magnetic resonance imaging (MRI) as well as to contrast media containing such radicals and to the use of such radicals and their non- radical precursors in the manufacture of MRI contrast media.
  • MRI magnetic resonance imaging
  • MRI is a diagnostic technique that has become particularly attractive to physicians as it is non- invasive and does not involve exposing the patient under study to potentially harmful radiation, such as for example the X-radiation of conventional radiography.
  • MR images are generated by manipulation of the MR signals detected from the sample, for example a human or animal body, placed in a magnetic field and exposed to pulses of radiation of a frequency (typically
  • radiofrequency (RF) selected to excite MR transitions in selected non-zero spin nuclei (the "imaging nuclei", which are generally water protons in body fluids) in the sample.
  • the amplitude of the induced MR signals is
  • the strength of the magnetic field experienced by the sample dependent upon various factors such as the strength of the magnetic field experienced by the sample, the temperature of the sample, the density of the imaging nuclei within the sample, the isotopic nature and chemical environment of the imaging nuclei and the local inhomogeneities in magnetic field experienced by the imaging nuclei.
  • enhancing MR image quality for example by increasing MR signal amplitude or by increasing the difference in MR signal amplitude between different tissue types.
  • the imaging parameters may be altered and many
  • MRI contrast agents are paramagnetic they produce significant reduction in the T 1 of the water protons in the body zones into which they are administered or at which they congregate, and where the materials are ferromagnetic or superparamagnetic (for example as suggested by Jacobsen) they produce a significant reduction in the T 2 of the water protons. In either case the result is enhanced (positive or negative) contrast in the MR images of such zones.
  • contrast enhancement achievable by such agents in conventional MRI is relatively limited and it is generally not such as to allow a reduction in the image acquisition period or in the field strength of the primary magnet.
  • This new technique for generating a MR image of the sample which is hereinafter termed electron spin resonance enhanced magnetic resonance imaging (ESREMRI), or Overhauser MRI, involves exposing the sample to a first radiation of a frequency selected to excite nuclear spin transitions in selected nuclei in the sample (radiation which is generally of radiofrequency or thereabouts and thus for convenience will be referred to hereinafter as RF radiation) and also exposing the sample to a second radiation of a frequency selected to excite electron spin transitions coupled to nuclear spin transitions for at least some of the selected nuclei (radiation which is generally of microwave frequency or thereabouts and thus for convenience is referred to hereinafter as MW or UHF radiation), the MR images being generated from the resulting amplified MR signals (free induction decay signals) emitted by the sample.
  • RF radiation radiofrequency or thereabouts and thus for convenience will be referred to hereinafter as RF radiation
  • MW or UHF radiation the MR images being generated from the resulting amplified MR signals (free
  • the paramagnetic substance which possesses the ESR transition which couples with the NMR transition of the image nuclei may be naturally present within the imaging sample or more usually may be administered as an ESREMRI contrast agent.
  • Hafslund Nycomed Innovation AB proposed the use of deuterated stable free radicals, in particular deuterated nitroxide stable free radicals, as ESREMRI contrast agents.
  • Organic free radicals however frequently have properties which render them unsuitable for use as
  • ESREMRI contrast agents Thus free radicals commonly are unstable in physiological conditions, or have very short half-lives leading to toxicity problems. A further drawback is the low relaxivity exhibited by many free radicals, which results in poor coupling of the electron and nuclear spin transitions and thus a poor enhancement of the magnetic resonance signal. A need therefore exists for improved free radical ESREMRI contrast agents.
  • the ESREMRI contrast agents so far proposed in the literature have all been "oxygen free radicals" that is to say radicals where the unpaired electron or electrons are associated with oxygen atoms.
  • free radicals For such free radicals to be effective, they should be relatively long lived and to distinguish from free radicals which have a momentary existence, those usable as ESREMRI contrast agents will be referred to herein as being "inert" free radicals, that is having a half life of at least one minute at ambient temperature.
  • the present invention thus provides the use of an inert carbon free radical for the manufacture of a contrast medium for use in ESREMRI.
  • the invention also provides a method of magnetic resonance investigation of a sample, said method comprising introducing into said sample an inert carbon free radical, exposing said sample to a first radiation of a frequency selected to excite electron spin transitions in said free radical, exposing said sample to a second radiation of a
  • the invention also provides a magnetic resonance imaging contrast medium comprising a physiologically tolerable inert carbon free radical together with at least one
  • the inert carbon free radical should of course preferably be a physiologically
  • tolerable radical or one presented in a physiologically tolerable, e.g. encapsulated, form.
  • Inert carbon free radicals are well known and a renge of these has been described for example by
  • Preferred inert carbon free radicals for use according to the invention exhibit high stability to oxygen, to pH, for example in the range pH 5-9, and in aqueous solution, particularly stability up to a
  • dimerization long half-life, preferably greater than 1 minute, particularly preferably greater than 1 hour and especially preferably 1 year, long relaxation times, both T 1e and T 2e preferably being greater than 1 ⁇ sec, high relaxivity, for example greater than 0.3 mM -1 sec -1 and a small number of esr transition lines.
  • Particularly preferred inert carbon free radicals include the substituted methyl radicals, in particular triarylmethyl radicals where each of the three aromatic substituent groups may be the same or different and where two or three such groups may optionally be linked together.
  • Particularly preferably the radical comprises optionally substituted six-membered carbocyclic or heterocyclic aromatic rings optionally carrying one or more fused carbocyclic or heterocyclic rings.
  • aromatic rings of the triarylmethyl radical advantageously are substituted and the nuclear identities of nuclei in all substituents and their position within the molecule should be selected so as to minimise their effect (line splitting or broadening) on the esr transition.
  • a six-membered aromatic ring is preferably substituted at the ortho and para positions. This is desirable in order to minimise dimerisation and oxygen attack on the molecule.
  • the meta position is optionally substituted, preferably with a bulky
  • substituents again to minimise attack by oxygen and at least one of the substituents should conveniently comprise a water solubilizing moiety.
  • substituents preferably have no magnetic moment, or have a very low effective spin density.
  • Particularly preferred inert carbon free radicals include the triarylmethyl radicals of formula I
  • radicals include those of formula la
  • each Ar 12 which may be the same or different, comprises an optionally substituted 5-7 membered
  • carbocyclic or heterocyclic aromatic ring optionally carying one or more fused carbocyclic or heterocyclic rings, one or more such Ar 12 groups preferably being a group Ar 1 as defined herein.
  • each group Ar 1 represents a 6 membered carbon-attached carbocyclic or heterocyclic aromatic ring containing up to 2 non-adjacent ring nitrogens optionally substituted at the or any ortho carbon by a group R 1 to R 4 , at the or any meta carbon by a group R 2 or R 3 and at any para carbon by a group
  • R 1 ,R 2 ,R 3 or R 4 with the proviso that no more than two ring carbons are unsubstituted, preferably only one ring carbon at most being unsubstituted;
  • each of R 1 to R 4 which may be the same or different, independently represents a group of formula -M, -XM,
  • M represents a water solubilizing group, each group X, which may be the same or different, represents an oxygen or sulphur atom or a NH or CH 2 group;
  • Ar 2 represents a 5 to 10 membered aromatic ring
  • R 5 represents a hydrogen atom or an optionally hydroxylated, optionally aminated
  • R 2 and R 3 may also represent hydrogen atoms or alkyl groups
  • R 1 , R 2 , R 3 or R 4 preferably groups at the ortho and meta portions, together with the two intervening carbon atoms may represent groups of formula
  • R 6 represents a hydrogen atom, a hydroxyl group, an optionally alkoxylated, optionally hydroxylated acyloxy or alkyl group or a solubilising group M;
  • Z represents an oxygen or sulphur atom or a group NR 5 , CR 7 2 , or SiR 7 2 ;
  • each R 7 which may be the same or different, represents a hydrogen atom, an alkyl, hydroxyalkyl, alkoxycarbonyl or carbamoyl group or two groups R 7 together with the atom to which they are bound represent a carbonyl group or a 5 to 8 membered cycloalkylidene, mono- or di- oxacycloalkylidene, mono- or di-azacycloalkylidene or mono- or di-thiacycloalkylidene group optionally with the ring attachment carbon replaced by a silicon atom (preferably however in any spiro structure the ring linking atom will be bonded to no more than
  • the groups Ar 1 are preferably groups of formula
  • each Y independently represents CH, or more preferably CM, C-XM, C-Ar 2 , C-XAr 2 or a nitrogen atom.
  • radicals of formula I are new and they, their salts and their non-radical precursors (i.e, compounds of formula (Ar 12 ) 3 CX 4 or (Ar 1 ) 3 CX 4 where X 4 is a leaving group, e.g. hydrogen, hydroxyl, halogen,
  • the solubilizing groups M may be any of the solubilizing groups conventionally used in diagnostic and
  • solubilizing groups M include optionally hydroxylated, optionally alkoxylated alkyl or oxo-alkyl groups and groups of formulae R 5 , COOR 5 , OCOR 5 , CHO, CN, CH 2 S(O)R 5 , CONR 5 2 , NR 5 COR 5 , NR 5 2 , SO 2 NR 5 2 , OR 5 , PO 3 2- , SOR 5 , SO 2 R 5 , SO 3 M 1 , COOM 1 (where M 1 is one equivalent of a physiologically tolerable cation, for example an alkali or alkaline earth metal cation, an ammonium ion or an organic amine cation, for example a meglumine ion), -(O(CH 2 ) n ) m OR 5 (where n is an integer having a value of from 1 to 3 and m is an integer having a value of from 1 to 5),
  • R 10 is a group R 5 or an alkyl group
  • solubilizing groups M are groups of formula C(H) 3-n (CH 2 OH) n , R 9 , COR 9 , SR 9 , SOR 9 ,
  • R 9 group attached to a sulphur, nitrogen or oxygen atom is preferably not hydroxylated at the ⁇ carbon
  • groups of formula SR 12 where R 12 is a group CH 2 COOR 13 , CH(COOR 13 ) 2 , CH 2 CONHR 9 , CH 2 CONR 9 2 ,
  • solubilising groups M or XM include groups of formula X' C((CH 2 ) n COOR 13 ) 2 R 14 , X'C((CH 2 ) n COOR 13 ) 3 and X'C((CH 2 ) n COOR 13 )R 14 2 , where R 13 is as defined above, n is an integer from 1 to 3, X' is an oxygen or sulphur atom, and R 14 is a hydroxyalkyl group such as a group R 9 as earlier defined.
  • R 1 groups include for example the following structures
  • n 1 is 0, 1 or 2 and R 19 is hydrogen or C 1-4 alkyl
  • R 23 is C 1-4 alkyl (e.g.
  • NR 2 21 or OR 21 and R 21 is C 1-4 alkyl
  • M represents a group containing a moiety NR 5 2
  • this may also represent an optionally substituted nitrogen-attached 5 to 7 membered heterocyclic ring optionally containing at least one further ring
  • heteroatom e.g. N or O, for example a group of formula
  • any alkyl or alkenyl moiety conveniently will contain up to 6, especially up to 4, carbon atoms and any aryl moiety will preferably contain 5 to 7 ring atoms in the or any aromatic ring and especially preferably will comprise an aromatic ring with 0, 1 or 2 further aromatic rings fused directly or indirectly thereto.
  • Preferred structures for the aryl substituents on the carbon radical centre include those in which at least one of such substituents carries at least one, and preferably two, fused rings of formula
  • X is oxygen or sulphur and R 7 is hydrogen or optionally hydroxylated methyl.
  • X oxygen or sulphur
  • Y is N
  • CCOOR 5 CSR 5 , CM or C-XM and M
  • R 5 and Z are as earlier defined.
  • Particularly preferred structures include those in which CR 7 2 represents CH 2 , C(CH 2 OH) 2 or C(CH 3 ) 2 , X
  • R 1 is a group M or XM as hereinbefore defined and M 2 represents a solubilising group M or a group SCH 3 , S(O)CH 3 , S(O 2 )CH 3 , SCH 2 CH 2 N(CH 3 ) 2 , SCH 2 COOH, SCH 2 COOCH 3 , SCH 2 COOCH 2 CH 3 and SC(H) 3-n (CH 2 OH) n where n is an integer of from 1 to 3.
  • Ar 1 include optionally substituted benzo [1,2-d:4,5-d']bis[1,3]dioxole, benzo[1,2-d:4,5-d']bis[1,3]dithiole, and benzo[1,2- d:4,5-d']bis[1,3]oxathiole groups.
  • Preferred inert carbon free radicals for use according to the invention include the following:
  • Especially preferred inert cation free radicals include
  • R 42 , R 43 and R 44 are non-ionic solubilising groups e.g. hydroxyalkyl or alkoxyalkyl groups
  • Inert free radicals which have relatively few transitions, e.g. less than 15, preferably less than 10, in their ESR spectra and radicals having narrow
  • linewidth ESR transitions e.g. up to 500 mG, preferably less than 150 mG, especially less than 60 mG and
  • ESREMRI contrast agents particularly less than 25mG, are especially preferred for use as ESREMRI contrast agents.
  • the linewidths referred to are conveniently the intrinsic linewidths (full width at half maximum in the absorption spectrum) at ambient conditions).
  • triarylmethyl free radicals of formula I are themselves novel and in a further aspect the present invention also provides novel inert carbon free radicals of formula I or salts thereof.
  • contrast agents generally be considered for use as contrast agents.
  • triaryl methyl radicals are water- insoluble and are therefore generally not suited for administration to the body.
  • the choice of triaryl methyl radicals as ESREMRI contrast agents is therefore not an obvious one.
  • novel triarylmethyl radicals of the invention include radicals which surprisingly are stable at physiological pH, have long half lives (at least one minute, and preferably at least one hour), long
  • Water-soluble triaryl methyl radicals are a particularly important aspect of the invention.
  • the triarylmethyl radicals may be coupled to further molecules for example to lipophilic moieties such as long chain fatty acids or to macromolecules, such as polymers, proteins, polysaccharides (e.g.
  • the macromolecule may be a tissue-specific biomolecule such as an antibody or a backbone polymer such as polylysine capable of carrying a number of independent radical groups which may itself be attached to a further tissue-specific biomolecule such as an antibody or a backbone polymer such as polylysine capable of carrying a number of independent radical groups which may itself be attached to a further tissue-specific biomolecule such as an antibody or a backbone polymer such as polylysine capable of carrying a number of independent radical groups which may itself be attached to a further
  • novel triarylmethyl radicals of the invention may also be used as ESR spin labels in ESR imaging or in magnetometry.
  • the inert carbon free radicals may be prepared from their non-radical precursor compounds by conventional radical generation methods.
  • Suitable non-radical precursor compounds include the corresponding triaryl methanes, triaryl methyl halides and triaryl methanols, and derivatives, e.g. ethers, of the triaryl methanols.
  • the invention provides a process for the preparation of the novel triarylmethyl radicals of the invention which comprises subjecting a radical precursor therefor to a redical generation step and optionally subsequently modifying the substitution on the aryl moieties, e.g. by oxidation or reduction.
  • a radical precursor therefor e.g. -SCH 3 or -SCH 2 COOEt
  • sulphide substituents e.g. -SCH 3 or -SCH 2 COOEt
  • lipophilic substituents such as -SCH 2 COOEt
  • hydrophilic substituents such as -SCH 2 COOEt
  • radical-precursor can be represented by formula XXXV
  • corresponding triaryl methyl halides by reduction with a metal catalyst, such as copper, zinc or silver, or by electrolytic reaction on an electrode or by photochemical reaction in the presence of a chlorine radical scavenger, e.g. an olefin.
  • a chlorine radical scavenger e.g. an olefin.
  • carbon free radicals may be prepared from the corresponding triaryl methanes by reaction with a base, e.g. in the presence of sodium hydride followed by a reaction with an oxidant, e.g. iodine in the presence of oxygen or a quinone such as chloranil, following for example the method described in US-A-3347941.
  • triarylmethyl radicals Another method to prepare triarylmethyl radicals is to react triarylmethanes with other, less stable radicals such as tert-butoxyl radicals.
  • the latter radicals are generated in situ via thermolysis or photolysis of an appropriate precursor, such as a peroxide or an azo compound.
  • a further example of a method by which radical preparation may be effected is reaction of the corresponding triaryl methanols in the presence of an acid to form a carbonium ion followed by reduction to the free radical in the presence of a suitable reducing agent, such as metal ions e.g. Cr 2+ , Fe 2+ , or by electrochemical reduction.
  • the carbon free radicals may also be generated by a comproportionation reaction between cations and anions of a corresponding radical precursor. In such a reaction an electron is exchanged between the anion and the cation, and two radicals are generated.
  • Triarylmethyl radicals may thus be prepared by mixing together a triarylmethyl radical precursor
  • Triarylmethyl radicals may also be prepared by
  • thermolysis or photolysis or a corresponding dimeric triarylmethyl structure for example an
  • radicals with long half lives in aqueous solution for example at least one hour, preferably ten days, more preferably fifty days and especially
  • At least one year are clearly particularly desirable for use in in vivo imaging, shorter lived inert free radicals may still be utilised in imaging (e.g. of inanimate samples) and these may particularly conveniently be prepared immediately pre-administration.
  • non-radical precursors may themselves be prepared by methods conventional in the art.
  • a process for the preparation of a triaryl methyl radical precursor may comprise one or more of the following steps:- a) (to prepare a triarylmethanol of Formula II
  • the starting ketone of formula XXVII may be prepared by oxidation, e.g. with CrO 3 , of the corresponding alcohol (Ar 12 ) 2 CHOH (itself preparable by reaction of the monoaldehyde Ar 12 CHO with an Ar 12 containing organometallic, e.g. Ar 12 Li or
  • Ar 12 MgHal a compound formed by reaction of such an organometallic with the corresponding carboxylic acid Ar 12 COOH, or by reaction of the acid chloride Ar 12 COCl with Ar 12 H, e.g. in the presence of AlCl 3 .
  • the starting material of formula XXXIV may be prepared by reaction of a
  • step (g) may be effected using borane or LiAlH 4 and AlCl 3 .
  • Triaryl methyl halides may be prepared following the procedures described by Dünnebacke et al. in Chem. Ber. 122:533-535 (1989).
  • the substituents may be introduced onto individual Ar 12 groups before they are trimerized to form the triaryl radical precursor compounds, or they may be introduced directly onto the triaryl precursor compound or the actual radical itself. It is also possible to effect the substitution and trimerization steps
  • the Ar 12 groups may be prepared by following:
  • R 7 ' is a hydrogen atom or a group R 7 as hereinbefore defined, optionally protected by a protecting group.
  • reaction schemes such as the following may be used
  • R 1 ' to R 4 ' are optionally protected groups R 1 to R 4 and R 5 is as hereinbefore defined.
  • R 1 ' and R 2 ' and R 3 ' and R 4 ' may represent ring-forming groups -X-CR 7 ' 2 -X-, e.g. OC(CH 3 ) 2 O-.
  • a particularly interesting group of radicals for use according to the invention includes compounds of Formula .C(Ar 12 ) 3 , where one, two or three Ar 12 groups comprises a central 5-6 membered carbocyclic or heterocyclic aromatic ring bearing two five-membered fused rings, each said fused ring
  • the "monomer” and “dimer” compounds, having this structure are particularly useful for the preparation of the radical precursors and thus in a further aspect the invention provides tricylic compound comprising a central 5-6 membered carbocyclic or heterocyclic
  • Particularly preferred embodiments of such compounds are the compounds of formula XL
  • Y 1 is a group CH, N, CCOOR 5 , CSR 5 , CM or CXM, R 5 and M are as defined in claim 6 and R 40 is a hydrogen atom, or a optionally substituted hydroxyl, methyl or formyl group or group
  • Particularly preferred compounds of formula XL include those wherein each X is oxygen, each R 7 is optionally hydroxylated methyl and Y 1 is other than N.
  • the invention also provides, in another aspect, process for the preparation of a compound of formula XL, said process comprising condensing a compound of formula XLI
  • R 40 ' and Y'' are groups R 40 or Y 1 as defined in claim 23 or protected such groups, and X is as defined in claim 23
  • a compound of formula (R 7 ') 2 CX where R 7 ' is a group R 7 as defined in claim 23 or a protected R 7 group
  • contrast media for use in ESREMRI, the inert carbon free radicals are conveniently formulated into contrast media together with conventional pharmaceutical carriers or excipients.
  • Contrast media manufactured or used according to this invention may contain, besides the inert free radicals (or the non-radical precursor where radical formation is to be effected immediately before administration), formulation aids such as are conventional for
  • the media may for example include solubilizing agents, emulsifiers, viscosity enhancers, buffers, etc.
  • the media may be in forms suitable for parenteral (e.g. intravenous) or enteral (e.g. oral) application, for example for application directly into body cavities having external voidance ducts (such as the gastrointestinal tract, the bladder and the uterus), or for injection or infusion into the cardiovascular system.
  • parenteral e.g. intravenous
  • enteral e.g. oral
  • solutions, suspensions and dispersions in physiological tolerable media will generally be preferred.
  • Free radicals which are relatively unstable or insoluble in the sample environment may be encapsulated, e.g. in gastric juice resistant capsules containing a medium in which they are stable.
  • the radical may be presented as an encapsulated freeze dried powder in a soluble capsule. Such formulations might conveniently be dissolved shortly before in vivo use.
  • the medium which preferably will be substantially isotonic, may conveniently be administered at a concentration
  • concentration of the free radical in the imaging zone is a balance between various factors. In general, optimum concentrations would in most cases lie in the range 0.1 to 100mM, especially 0.2 to 10mM, more especially 0.5 to 5mM.
  • Compositions for intravenous administration would preferably contain the free radical in concentrations of 10 to 1000mM
  • the concentration will particularly preferably be in the range 50 to 200mM, especially 130 to 170mM and for non- ionic materials 200 to 400mM, especially 290 to 330mM.
  • compositions may perhaps be used having concentrations of for example 10 to 100mM for ionic or 20 to 200mM for non-ionic materials.
  • concentration may conveniently be 0.1 to 100mM, preferably 5 to 25mM, especially preferably 6 to 15mM.
  • the image was acquired under the following
  • TR 0.5 sec
  • UHF Irradiation Time 0.38 sec
  • 256 excitations 256 x 256 matrix).
  • Slice thickness 1 cm.
  • Field of view 25 cm.90° flip angle (SR).
  • the UHF-resonator had a very low loaded Q ⁇ 10 (200 g rat), and a volume of approximately 1L (diameter 10 cm).
  • the applied UHF power was ⁇ 30 W of which only a small fraction was deposited in the animal ( ⁇ 1/10).
  • the proton coil had a diameter of 126 cm and thus a very low filling factor when loaded, with a rat (5 cm).
  • the Q factor of this coil was high (> 1000), but loaded with both UHF-resonator and animal decreased to below 500.
  • the signal/noise (S/N) ratio was approximately 100.
  • the perorlly applied volume of contrast medium was approximately 5ml and the concentration of radical was less than 05mM.
  • Ammonia was condensed (ca 200ml) into 150 ml of dry diethylether in a 3-necked flask, with external cooling. Then 9.0 g (0.0256 mole) of 2,5-dibenzylmercapto-p- benzoquinone was dissolved into the liquid. Sodium (5.9 g, 0.256 mole) cut into fine pieces was added portionwise with efficient stirring. After stirring for an additional 2.5 hours, abs. ethanol (20 ml) was added and the ammonia was evaporated. Water (170 ml) was added to the reaction product and it was extracted with 2 x 30 ml of ether. The aqueous phase was then
  • 1,3,5,7-Tetrathia-S-indacene-2,6-dione (4.0 g, 0.016 mole, prepared according to Larsen and Bechgaard J. Org Chem 52 : 3287 (1987)) was suspended in 60 ml of a IM solution of sodium methoxide in methanol. Stirring was maintained for 1/2 hour at ambient temp, until a clear solution was formed. The reaction mixture was then evaporated to dryness and the residue acidified with 5 N hydrochloric acid to pH 1. The aqueous phase was extracted with 3 x 70 ml of methylene chloride. The organic phases were dried (Na 2 SO 4 ), the solvent
  • the corresponding radical showed a linewidth of 500 mG in its ESR spectrum and an Overhauser enhancement of 8 at 5hr UHF power.
  • Tris-(3-methylthio-2,2,6,6-tetramethylbenzo[1,2- d:4,5-d']bis(1,3)dioxole)methanol (0.3 mmol. Example 7) was dissolved in 50 ml dry THF (Al 2 O 3 , super I, basic) under Argon. 0.5 g CrCl 2 and then 0.5 ml BF 3 etherate was added to the vigorously stirred mixture. After 15 minutes the reaction mixture was poured over 50 ml 4 M NaOH. The organic phase was separated and filtered through a short column of SiO 2 and eluted with dry ether. The dark violet solution was evaporated to dryness yielding 176 mg (71%) of the title compound as a black powder. A solution of this material in tetrahydrofuran was shown to contain 41% radical according to the method of Evans (J. Chem. Soc. 2003 (1959)).
  • reaction mixture was left to stand with stirring at ambient temperature for an additional 30 minutes. After cooling to -78°C, 2.5ml BuLi 2.5m) was added. After stirring for 1 hour at room temperature a white, thin, slurry had formed. It was cooled to 78°C and 0.81 ml diethylcarbonate was added slowly. The mixture was left to stir at ambient temperature and the white suspension thickened and changed colour from yellow to brown. After 1.5 hours the reaction mixture was poured into 100 ml diethylether with about 30g NaH 2 PO 4 saturated with N 2 . The phases were separated and the H 2 O-phase was extracted once with 100 ml diethylether.
  • Tris (8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-bis (1,3)dioxole-4-yl)methanol (1.26 g, 1.62 mmol (prepared by reaction of tris(2,2,6,6-tetramethylbenzo[l,2-d:4,5- d']bis(1,3)dioxol-4-yl)methanol (See Example 44) with nBuLi in DMF) ) was dissolved in dry MeOH (80 mL). To this solution was added MnO 2 (18.9 g, 217 mmol), NaCN (1.26 g, 25.7 mmol) and acetic acid (HOAc) (1.26 mL).
  • the reaction mixture was heated to 65 °C for 40 h and was then filtered through Celite and the filtrate was evaporated to dryness.
  • the residue was partitioned between CH 2 Cl 2 (100 mL) and water (40 mL).
  • the organic phase was washed with another 2x30 mL of water, the organic phase was separated, dried (Na 2 SO 4 ) and the solvent was evaporated to yield a yellow to brown residue, which was further pumped to dryness.
  • the residual foam was chromatographed on a column packed with SiO 2 , eluting with CH 2 Cl 2 /Et 2 O (4:1). The fractions containing pure product were collected and the solvent was evaporated to yield 1.1 g (77 %) of pure
  • aromatic C-O aromatic C-O
  • 118.2 alifatic O-C-O
  • 111.9 quart. C-subst. aromatic
  • 105.9 quart. p-C-subst. aromatic
  • 72.1 quart, alifatic C-OH
  • 24.6 CH 3
  • Trimethylsilyl chloride (68.1 mL, 539 mmol) and sodium iodide (81.0 g, 540 mmol) were mixed in acetonitrile (500 mL), and tris (2,2,6,6-tetramethylbenzo[1,2-d:
  • Tris (2,2,6,6-tetramethyl-benzo[1,2-d:4,5-d']bis (1,3)- dioxole-4-yl)methane (1.65 g, 0.244 mmol.
  • Example 17 was dissolved in dry diethyl ether (150 mL).
  • n-BuLi (5.86 mL, 2.5 M in toluene, 1.465 mmol) was added in two portions (2/3 and 1/3), and the temperature of the mixture was raised to 40 °C (the ether refluxed). After maintaining this temp, for 15-20 min, the mixture was poured onto CO 2 (s), and left overnight. Water (90 mL) was added to dissolve the solid residue.
  • Tris(2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-bis(1,3)- dioxole-4-yl)methane (3.00 g, 4.40 -mmol (Example 17)) was dissolved in ether (100 mL) and n-BuLi (10.8 mL, 27.0 mmol) was added. The mixture was refluxed for 20 min, and after cooling to room temperature
  • Tris (2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-bis(1,3)- dioxole-4-yl)methane (1.35 g, 2.0 mmol (Example 17)) was dissolved in dry THF (400 mL) under N 2 , and the temp was lowered to -40 °C and n-BuLi (4.86 mL, 12.2 mmol) was added and the temperature was allowed to rise gradually to 0°C. The mixture was cooled to -60 °C, and a
  • Acetic anhydride (AcO) 2 O (30 mL) was added to pyridine (35 mL).
  • Tris(8-hydroxymethyl-2,2,6,6-tetramethylbenzo [1,2-d:4,5-d']-bis(1,3)dioxole-4-yl)methanol (0.400 g, 0.51 mmol (Example 33) was added under stirring, which was maintained at room temperature for two days.
  • Tris(2,2,6,6-tetramethyl-benzo[1,2-d:4,5-d']-bis(1,3)-di oxole-4-yl) methane (2.0 g, 3.5 mmol (Example 17) was dissolved in dry ether (100 mL) at room temperature.
  • n-butyl lithium (6 mL) was added, and the reaction mixture was heated to reflux (15 min). At this temperature another portion of n-butyl lithium (2 mL) was added and the heating was
  • Tris(8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-bis (1,3)-dioxole-4-yl)methane (140 mg, 0.18 mmol.
  • Example 23 was dissolved in a mixture of dry DMSO (15 mL) and of dry ether (50 mL). NaH (5 mg, 0.19 mmol) and t-BuOK (catalytic amount) were added under N 2 -atmosphere. The color of the solution changed from yellow to deep green-blue. After 4h of stirring at room temperature under N 2 I 2 (46 mg, 0.18 mmol) was added, and after 2 min the reaction mixture was poured into a saturated
  • ESR 4 lines (internal ratio 1:3:3:1) with line widths of ca 70 mG.
  • Tris(8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-bis (1,3)dioxole-4-yl)methanol 200 mg, 0.20 mmol was dissolved in of dry THF (15 mL) and SOCl 2 (80 mg, 0.20 mmol) was added. After stirring at room temperature for 2 h the solvent was evaporated ( ⁇ 70 °C) and the residue was pumped dry overnight. The orange product
  • N 2 -atmosphere was added; first SnCl 2 (0.15 g, 0.80 mmol) and then Zn(Hg), (0.15 g, 2.20 mmol) (prepared by treating 120 g zinc powder with a mixture of 12g HgCl 2 , 6 mL cone. HCl and 150 mL of water for 5 min. and decanting off the liquid). Stirring was maintained for 0.5 h. The reaction mixture was applied to a column (1 cm diameter) consisting of 3 cm of SiO 2 at the bottom and 15 cm of Chelex 100 on top. Elution was performed with dry THF under N 2 -atmosphere. The eluent was evaporated to dryness, leaving a brown-black crystalline residue (0.19 g, 100%).
  • Tris(8-methoxycarbonyl-2,2,6,6-tetramethylbenzo[1,2-d:4, 5-d']-bis(1,3)dioxol-4-yl)methanol 240 mg.
  • Example 15 was dissolved in of dry THF (25 mL) and SOCl2 (38 mg, 23 'L) was added at room temperature. Stirring was maintained for 2.5 h. The solvent of the reaction mixture was then evaporated to dryness ( ⁇ 70 °C).
  • a radical content of ca 5% was estimated by ESR.
  • the Overhauser enhancement was 80.
  • n-butyllithium (4.25 mL, 10.6 mmol) was added.
  • the dry ice/acetone bath was exchanged with a water/ice bath.
  • the new cooling bath was removed after one hour and forty five minutes.
  • Cold (-78 °C) diethylcarbonate (0.363 mL, 3 mmol) in THF (10 mL) was cannulated into the reaction mixture over a period of 10 minutes.
  • the resulting mixture was kept at (-70) - (-78) °C for two hours, followed by a period of one hour and thirty minutes at approximately 0 °C (ice/water bath).
  • the mixture was then stirred till noon the following day without addition of ice, at which time the temperature inside the reaction flask was +16 °C.
  • the mixture was then stirred without external cooling for three more hours, poured into a half saturated sodium
  • Tris(8-mercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-b is (1,3)dioxol-4-yl)methanol (2.93 g, 50%, 1.86 mmol) was dissolved in dry DMF (100 mL) under argon. K 2 CO 3 (4 g) was added and the solution cooled to the freezing point. Ethylchloroacetate (5 mL, 46.7 mmol, Janssen 11822.85) was added, and the reaction mixture was stirred at room temperature overnight. Most of the DMF and excess ethylchloroacetate were removed by high vacuum distillation at 30-40 °C.
  • UV (Absorbt ion maxima/minima) 195 (p) , 229 (sh) , 302 (v) ,
  • ESR 7 lines, lw 30 mG, aH 60 mG.
  • Tris(8-ethoxycarbonylmethylthio-2,2,6,6,- tetramethylbenzo-[1,2-d:4,5-d']-bis(1,3)dioxole-4-yl) methyl (1.97 g, 1.91 mmol 90 % pure) was dissolved in a degassed (helium followed by argon) mixture of dioxane (Lab Scan C2512 HPLC quality) and water (200 mL (3:1)).
  • Sodium hydroxide (4.3 mL, 2 M, 8.58 mmol, He, Ar, 0 °C) was added and the hydrolysis performed in a ultrasound bath (Sonorex RK 2555). The reaction was followed by HPLC, RP18 column (Nucleosil 5 mm) with
  • the detector system consisted of a diode array UV detector - Varian 9065 polychrome). During the reaction the diester- and monoester radicals were observed as well as the tricarboxylic acid salts. The reaction mixture was frozen when the HPLC analysis showed pure tricarboxylic acid sodium salt (mixture of radical and carbinol) and subjected to freeze drying.
  • ESR H 2 O 0.3 mM, 200 G: 7 lines, Lw 27 mG, a 60 mG,
  • alkaline water was added (150 mL, 1 M, degassed with argon) followed by vigorous stirring in ten minutes. The phases were separated and the water phase was washed with diethylether (100 mL, degassed with argon). The water phase was acidified with HCl (5 M). The
  • diethylether 50 mL, argon
  • organic phases were combined, washed (sodium dihydrogen phosphate buffer, 30 mL), dried (MgSO 4 , 30 min) and evaporated to dryness.
  • Diethylether dry, argon was added to the brown oil to induce the crystallization. Upon the dissolution of the oil the title compound crystallized as porous yellow crystals. The product was isolated by filtration.
  • Tris(2,2,6,6-tetramethylbenzo([1,2-d:4,5-d']-bis(1,3)- dioxol-4-yl)methanol (6.35 g, 9.38 mmol) was dissolved in dry diethylether (200 mL) under argon and cooled to 0°C.
  • n-Butyllithium (22.5 mL, 56.30.10-3 mol) was added and the temperature was increased to induce reflux. The reaction mixture was refluxed for 25 minutes. After cooling to 0 °C, dry formaldehyde (gas, formed by
  • Tin(II) chloride (127 mg, 0.986 mmol) was added 10 minutes after the boron compound, and zinc (187 mg, 2.85 mmol) was added after another 15 minutes. One hour and fifteen minutes later the reaction mixture was green. The solution was evaporated, and subsequently filtered through a SiO 2 column with tetrahydrofuran as the eluent. The residue (80 mg, 0.099 mmol, 87% (containing some radical precur) was dissolved in tetrahydrofuran and the radical characterized by ESR and Overhauser
  • reaction mixture was evaporated and checked with 13 C NMR without removing the excess diethanol amine from the intermediary tris(8-di(hydroxyethyl)- aminocarbonylmethylthio-2,2,6,6-tetramethylbenzo[1,2-d: 4,5-d']-bis(1,3)dioxole-4-yl)methanol: [(CD 3 OD, 75 MHz) ⁇ : 171.34, 142.55, 139.97, 119.12, 112.99, 98.94, 60.73, 60.58, 52.97, 50.36, 36.84, 25.88, central COH at ca.
  • Tris(8-ethoxycarbonylmethylthio-2,2,6,6-tetramethylbenzo -[1,2-d:4,5-d']-bis(1,3)dioxole-4-yl)methanol (4.00 g, 3.819 mmol (Example 27)) was dissolved/suspended in a mixture of water and ethanol (200 mL, (1:1)) and cooled to approximately 5°C.
  • Sodium hydroxide (15.3 mL, 1.0 M, 15.3 mmol) was added and the reaction was followed by HPLC. The next day more sodium hydroxide (3.82 mL, 1.0 M, 3.82 mmol) and (7.64 mL, 1.0 M, 7.64 mmol) was added.
  • the ethanol was evaporated after complete conversion had been observed (HPLC).
  • the alkaline aqueous phase was extracted with heptane (2x100 mL) and then acidified with HCl (2.0 M) to pH 5.
  • the product was taken up in diethylether (2x100 mL). Upon further acidification of the aqueous phase (to pH 3), more precipitate was formed. This was also taken up in diethylether (2x100 mL).
  • the combined ether phases were extracted once with water (100 mL) and dried (Na 2 SO 4 ). Evaporation yielded 3.11 g (3.23 mmol, 85 %) of a white crystalline material. When the material was dried at very high vacuum and high temperature the substance turned blue, possibly due to the formation of an internal zwitter ion. Upon exposure to moist air the white color
  • reaction mixture was poured into a solution of NaOH (50 mL, IM) and extracted with diethyl ether (100 mL).
  • the aqueous phase was acidified with cone. HCl to pH 2 while stirring.
  • the product was isolated by extracting with diethyl ether (3x50 mL).
  • Tris(8-ethoxycarbonylmethylthio-2,2,6,6-tetramethylbenzo [1,2-d:4,5-d']-bis(1,3)dioxole-4-yl)methanol (1.06 g, 1.01 mmol (Example 27) was added to a solution of trimethyl silylchloride (0,767 mL, 6.07 mmol) and sodium iodide (0.91 g, 6.07 mmol) in acetonitrile (50 mL) and stirred for ten minutes. Saturated sodium thiosulfate (30 mL) was added, followed by diethylether (70 mL), and the mixture was stirred for 10 minutes.
  • the phases were separated and the organic phase was washed with water (30 mL).
  • the organic phase was diluted with more ether (100 mL), since crystals had started to form in the funnel.
  • the solution wds kept in the freezer over night after drying (MgSO 4 ) and filtration.
  • the crystals formed were removed (impurity) and the solution evaporated to dryness.
  • the product was purified by dissolving the substance at room temperature in diispropyl ether (E. Merck 118867, 30 mL), followed by bubbling with helium.
  • the flask was stoppered and put in the refrigerator for two and a half hours.
  • the product was collected by filtration (glass sinter no. 3), and the mother liquor was evaporated to approximately half the volume.
  • the total yield after collecting the second crop was 640 mg
  • Tris(8-mercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-b is (1,3)dioxole-4-yl)methanol (1.00 g, 1.27 mmol
  • Tris(8-mercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)dioxole-4-yl)methanol 1.000 g, 1.269 mmol Example 31 was added to a solution of acetonitrile (75 mL, argon bubbled) and potassium carbonate (6.0 g).
  • Tris(8-ethyloxycarbonylthio-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methanol (0.100 g, 0.099 mmol.
  • Example 45 was dissolved in THF (5 mL, sodium benzophenone ketyl) and SOCl 2 (0.073 mL, 0.998 mmol) was added. The mixture was stirred for 3 hours and then evaporated under argon.
  • Overhauser enhancements (THF, 548.9 MHz, 200 G) : 9 mW 12 enhancement, 18 mW 25 enhancement.
  • Tris(8-mercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)dioxole-4-yl)methanol 1.000 g, 1.268 mmol.
  • Example 31 pyridine (0.620 mL, 7.606 mmol) and N,N- dimethylamino-pyridine (catalytic amount) were added to degassed (argon bubbled) acetonitrile (50 mL) and cooled close to the freezing point.
  • 2,2-Dimethylpropanoic acid chloride 0.40 mL, 7.606 mmol
  • Tris(8-tertbutylcarbonylthio-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methanol (0.0957 g, 0.0919 mmol.
  • Example 47 was dissolved in THF (25 mL, argon atmosphere., potassium benzophenone ketyl dried), and BF 3 .OEt 2 (0.5 mL, 48% in diethyl ether, Fluka) was added. After stirring for 5 minutes SnCl 2 (0.1249 g, 0.659 mmol) was added followed by a gradual change in color to light brown.
  • Zinc (0.5 g, 7.646 mmol) was added 1.5 hours after the SnCl 2 . Two hours later the color had changed to green. A sample taken (after letting the Zn settle) with a gas tight syringe showed a large Overhauser enhancement.
  • the reaction mixture was poured onto a column consisting of three layers; top layer SiO 2 , intermediate layer SiO 2 and K 2 CO 3 1:1 and bottom layer SiO 2 .
  • the K 2 CO 3 binds the BF 3 .OEt 2 , which has to be removed to avoid destabilizing the corresponding cation radicals. Yield: 0.079 g
  • ESR (THF, 200 G) : Linewidth 109 mG, one unresolved line.
  • Overhauser enhancements (THF, 548.9 MHz, 200 G, conc. ⁇ 1 mM) : 9 mW 96 enhancement, 18 mW 114 enhancement.
  • Tris(8-mercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)dioxole-4-yl)methanol 1.000 g, 1.268 mmol, Example 31
  • acetyl chloride 0.540 mL, 7.605 mmol
  • K 2 CO 3 2.0 g, 1.447 mmol
  • Tris(8-methylcarbonylthio-2,2,6,6-tetramethylbenzo[1,2- d:4,5-d']bis(1,3)dioxole-4-yl)methanol (0.0915 g, 0.0999 mmol, Example 49) was dissolved in THF (25 mL, argon atmosphere, potassium benzophenone ketyl dried), and BF 3 .OEt 2 (0.5 mL, 48% in diethyl ether Fluka) was added. A temporary red color was seen when the drops were hitting the surface of the solution. After stirring for 5 minutes, SnCl 2 (0.1249 g, 0.659 mmol) was added
  • 1,2,4,5-Tetrahydroxybenzene (5.00 g, 35.00 mmol, Example 4) was dissolved in THF (200 mL) and cyclohexanone (13.0 mL, 140.00 mmol) was added in one portion. P 2 O 5 was then added in small portions under efficient stirring. After addition was completed the temperature was increased to 80 °C for 4 hours. One large ball was formed in the flask during this time. After cooling to room
  • Benzo[1,2-d:4,5-d']bis(1,3)dioxole-2,6- dispirocyclohexane (2.00 g, 6.60 mmol, Example 52) was dissolved in diethyl ether (80 ml, dried over Al 2 O 3 ) and cooled to -10 °C in an ice acetone bath.
  • n-Butyl lithium (3.70 mL, 2.5 M in hexane) was added with a syringe over a period of five minutes. The mixture was stirred at the same temperature for 1 hour and overnight at room temperature. Diethyl carbonate (0.28 mL, 2.4 mmol) was added at room temperature and the mixture immediately changed color to red-brown.
  • 2,5-Dihydroxy-1,4-benzoquinone (4.00 g, 28.55 mmol) was suspended in water (50 ml, distilled) followed by Na 2 S 2 O 4 (10.00 g, 57.47 mmol) and HCl (5.5 g, 55.75 mmol cone, soln.). The mixture was stirred 30 min. at room temperature
  • 2,2,6,6-Tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole (8.80 g, 40.00 mmol. Example 5) was dissolved in THF (100 mL) and cooled to -20 °C. n-Butyllithium (25.0 mL, 40.0 mmol, 1.6 M) was added and the temperature was adjusted to ambient temperature over a period of 30 minutes and then recooled to -20 °C.
  • Example 51 was dissolved in a CH 3 CN (50 mL) and cooled to 0 °C. CH 3 I (0.42 ml, 6.74 mmol) and K 2 CO 3 (4.0 g) were added. The resulting mixture was stirred at room temperature for 70 minutes. Before filtering away the
  • Tris(8-tertbutylcarbonylthio-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methane (0.205 g, 0.200 mmol, 97.3 %).
  • ESR 200 G, 548.9 MHz, three lines, THF: Linewidth 85 mG, a H 175 mG.
  • Tris(8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']bis- (1,3)dioxole-4-yl)methane (0.104 g, 0.134 mmol, Example 23) was dissolved in a mixture of DMSO (10 mL), and diethyl ether (30 mL). NaH (0.0037 g, 0.134 mmol, 80% in oil) and KOtBu (catalytic amount) were added and the resulting mixture was stirred under argon. Samples (about 50 mL) were taken with irregular intervals and quenched with DCl/D 2 O (10% DCl) under argon. After 2 hours and 15 min. the 1 H NMR measurements of the
  • the mixture was diluted with diethyl ether (50 mL) and washed with Na 2 S 2 O 3 (sat. 2x25 mL), dried (Na 2 SO 4 ) and evaporated yielding 0.030 g (40.8%).
  • the radical content was 60 % according to 1 H NMR (Evans method) and 64% by HPLC (Kromasil 10 mm, C8, 250 mm long, i.d. 4.6 mm, CH 3 CN:H 2 O 70:30 to 100:0 gradient 20 minutes, UV 254 nm detection).
  • the HPLC chromatogram of the tris(8-formyl-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methyl radical showed a peak at 5.93 s corresponding to the radical and a peak at 6.58 s corresponding to the starting material.
  • the HPLC separated materials also showed distinct UV spectra.
  • the white crystals were washed with diethyl ether (50 mL, sodium benzophenone ketyl) under argon, and the ether removed by filtration through the sinter. Weighing of the flask with the dry lithium salt indicated that there remained around 8 mmol lithium salt in the flask. THF (70 mL) was added to the salt, the mixture cooled to 0 °C, and diethyl carbonate (0.654 mL, 5.4 mmol) was cannulated into the solution and the mixture was left overnight to reach room temperature.
  • Tris(2-methoxycarbonylthien-4-yl)methane (0.218 g, 0.5 mmol. Example 66) was dissolved in dry THF (25 ml) under an argon atmosphere. Solid KOtBu (0.055 g, 0.5 mmol) was added, the solution was stirred for 30 min. and I 2 (0.127 g, 1.0 mmol) was added.
  • Tris(8-methylthio-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']-bis(1,3)dioxole-4-yl)methyl (0.163 g, 0.20 mmol. approximately 15 % radical content, Example 8) was dissolved in CH 2 Cl 2 (10 ml) under an argon atmosphere and 3-chloroperbenzoic acid (0.207 g, 1.20 mmol) was added. After stirring for 15 minutes, ESR spectroscopy of the reaction mixture showed a new radical.
  • ESR 6 lines with a H : 290 mG, linewidth: 113 mG.
  • Chelex-100 was treated with 14 g (of SnCl 2 .H 2 O, 116 mequiv.) in water (100 mL). The solid material was filtered and washed with water (100 mL) and EtOH (500 mL) and ether (100 mL) and was then dried in a
  • Example 4 was dispersed, in pyridine (100 mL) and diethyl ether (100 mL), and Me 3 SiCl (70 mL, 645 mmol) was slowly added (heat evolved). After 3 hours the pyridiniumchloride was filtered off and the solvents of the filtrate (red) were evaporated, leaving a red oil, which was dissolved in ether, more solid material was filtered off, and the solvents of the filtrate (red) were evaporated. The residue was dissolved in diethyl ether and extracted with water (2x50 mL).
  • Tris(8-nitromethylhydroxymethyl-2,2,6,6- tetramethylbenzo-[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methane (0.670 g, 0.710 mmol (Example 83)) was dissolved in Ac 2 O (30 mL) and NaOAc (2.00 g, 24.4 mmol) was added and the reaction mixture was refluxed for 0.5 h. The solution turned deep red. The solvent was
  • 3,4-Methylenedioxy-2,5-thiophenedicarboxylic acid diethylester (3.08 g, 11.3 mmol (Example 75)) was refluxed in EtOH/KOH (88 mL EtOH and 5.57 g, 11.3 mmol KOH) for 48 h.
  • EtOH/KOH 88 mL EtOH and 5.57 g, 11.3 mmol KOH
  • the reaction mixture was allowed to cool and the precipitate was filtered and the filter cake was triturated with cold 0.1 M HCl.
  • the basic filtrate from the first filtration was also triturated with 0.1 M HCl and the crystals from these acidifications were pooled, dried and later recrystallized from water/EtOH (1:1) and yielded 2.62 g (95%) of the desired mono-carboxylic acid.
  • Example 80 The product of Example 80 (0.100 g, 0.370 mmol) was dissolved in CH 2 Cl 2 and chilled to 0 °C and molecular sieves (3 ⁇ , dried at 350 °C in vacuum) were added before adding SOCl 2 (740 mmol). The reaction mixture was stirred at room temperature over night. Excess solvent and SOCl 2 were removed under reduced pressure and the residue was partitioned between 10% Na 2 CO 3 and CH 2 Cl 2 . The organic phase was separated, dried (Na 2 SO 4 ), filtered and the solvent was evaporated yielding 0.050 g (44%) of the desired product.
  • Tris(8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']bis- (1,3)dioxole-4-yl)methane (0.150 g, 0.197 mmol, Example 23) and nitromethane (0.36 g, 5.9 mmol) were mixed in dry dioxane (20 mL), and NaH (0.030 g, 0.197 mmol, 80 % in oil) was added at ambient temperature. After stirring overnight, the reaction was checked by TLC, and found to be completed. IR (film on NaCl) of the reaction mixture confirmed this, no CHO fragment coud be detected. Water (50 mL) and a few drops of HCl (2 M) were added.
  • the mixture was extracted with ether (3x50 mL). The organic extracts were washed with water (40 mL), dried (Na 2 SO 4 ) and the solvent was evaporated, leaving a crystalline yellow residue.
  • the product was chromatographed on a column of silica with CH 2 Cl 2 ,EtOAc 45:5 as eluent. The fractions containing pure product were pooled and the solvent was evaporated, yielding 0.150 g (81 %).
  • Tris(8-diethylaminocarbonyl-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis-(1,3)dioxole-4- yl)methane (0.076 g, 0.080 mmol (Example 87)) was dissolved in a mixture of of dry THF (40 mL, sodium benzophenone ketyl) and dry DMSO (10 mL, molecular sieves 4 ⁇ ) under N 2 .
  • KOtBu (0.009 g, 0.080 mmol) was added and the mixture stirred at room temperature for 4 hours.
  • Tris(benzo[1,2-d:4,5-d']bis(1,3)dioxole-4-yl)methanol (1.00 g, 1.90 mmol (Example 3) was mixed with dry THF (25 mL, sodium benzophenone ketyl) under Ar (g) and cooled to -78 °C.
  • n-BuLi (3.8 mL, 2.5 M solution in hexane) was added with a syringe. The cooling bath was removed and the resulting mixture was allowed to reach room temperature.
  • the mixture turned thick and pasty and THF (25 mL, sodium benzophenone ketyl) was added in order to facilitate stirring.
  • CH 3 SSCH 3 (1 mL) was added. The mixture became homogeneous (and dark) almost instantaneously.
  • the reaction mixture was poured on ice-water (200 mL) and extracted with CH 2 Cl 2 (3x100 mL). The organic phase was dried
  • Tris(8-methylthiobenzo[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methanol was converted to the corresponding radical with BF 3 .OEt 3 (cation formation) and CrCl 2 (reductant) as described in other Examples.
  • the ESR spectrum showed a linewidth of 120 mG in THF at a concentration of 1 mM.
  • the Overhauser enhancement was 10 at 5 W.
  • Tris(8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']bis- (1,3)dioxole-4-yl)methyl (0.065 g, 0.976 mmol (Example 64)), with a radical content of about 10%, and Na 2 S 2 O 5 (0.370 g, 1.95 mmol) were mixed in a 25 mL round flask under N 2 (g). Water (1.5 mL, He degassed 15 min.) and dioxane (1.5 mL, He degassed 15 min.) were added. After 15 minutes stirring most of the solid material had dissolved. HPLC analysis showed that the starting aldehyde was consumed after 45 minutes. An Overhauser experiment confirmed the presence of radical in the reaction mixture. Overhauser enhancement was 59 at 5W microwave power. ESR four lines, Linewidth 133 mG, a H 973 mG.
  • the bisulfite adduct was precipitated by the addition of dioxane and the precipitate was filtered and washed twice with dioxane. The product was dried under vacuum in room temperature overnight.

Abstract

The invention relates to the use of carbon stable free radicals as image enhancements agents in Overhauser MRI.

Description

TRIARYLMETHYL RADICALS AND THE USE OF INERT CARBON
FREE RADICALS IN MRI.
The present invention relates to the use of stable free radicals, in particular inert carbon radicals, as image enhancing agents in magnetic resonance imaging (MRI) as well as to contrast media containing such radicals and to the use of such radicals and their non- radical precursors in the manufacture of MRI contrast media.
MRI is a diagnostic technique that has become particularly attractive to physicians as it is non- invasive and does not involve exposing the patient under study to potentially harmful radiation, such as for example the X-radiation of conventional radiography.
This technique, however suffers from several serious drawbacks, including in particular the expense of manufacture and operation of the MRI apparatus, the relatively long scanning time required to produce an image of acceptable spatial resolution, and the problem of achieving contrast in the magnetic resonance (MR) images between tissue types having the same or closely similar imaging parameters, for example in order to cause a tissue abnormality to show up clearly in the images.
The expense of manufacture and operation of an MRI apparatus is closely associated with the strength of the magnetic field that the primary magnet in the apparatus is required to generate in order to produce images of acceptable spatial resolution in an acceptable time.
MR images are generated by manipulation of the MR signals detected from the sample, for example a human or animal body, placed in a magnetic field and exposed to pulses of radiation of a frequency (typically
radiofrequency (RF)) selected to excite MR transitions in selected non-zero spin nuclei (the "imaging nuclei", which are generally water protons in body fluids) in the sample.
The amplitude of the induced MR signals is
dependent upon various factors such as the strength of the magnetic field experienced by the sample, the temperature of the sample, the density of the imaging nuclei within the sample, the isotopic nature and chemical environment of the imaging nuclei and the local inhomogeneities in magnetic field experienced by the imaging nuclei.
Thus many techniques have been proposed for
enhancing MR image quality, for example by increasing MR signal amplitude or by increasing the difference in MR signal amplitude between different tissue types.
The imaging parameters (nuclear density, T1 and T2) for tissues of interest may be altered and many
proposals have been made for doing this by the
administration of magnetically responsive materials into patients under study (see for example EP-A-71564
(Schering), EP-A-133674 (Schering) and WO-A-85/04330 (Jacobsen)). Where such materials, generally referred to as MRI contrast agents, are paramagnetic they produce significant reduction in the T1 of the water protons in the body zones into which they are administered or at which they congregate, and where the materials are ferromagnetic or superparamagnetic (for example as suggested by Jacobsen) they produce a significant reduction in the T2 of the water protons. In either case the result is enhanced (positive or negative) contrast in the MR images of such zones.
The contrast enhancement achievable by such agents in conventional MRI is relatively limited and it is generally not such as to allow a reduction in the image acquisition period or in the field strength of the primary magnet.
Utilisation of the spin transition coupling
phenomenon known as dynamic nuclear polarisation or as the Overhauser effect to amplify the population
difference between the ground and excited spin states of the imaging nuclei by the excitation of a coupled ESR transition in a paramagnetic species present in the sample being imaged has been described by Hafslund
Nycomed Innovation AB in WO-A-88/10419.
This new technique for generating a MR image of the sample, which is hereinafter termed electron spin resonance enhanced magnetic resonance imaging (ESREMRI), or Overhauser MRI, involves exposing the sample to a first radiation of a frequency selected to excite nuclear spin transitions in selected nuclei in the sample (radiation which is generally of radiofrequency or thereabouts and thus for convenience will be referred to hereinafter as RF radiation) and also exposing the sample to a second radiation of a frequency selected to excite electron spin transitions coupled to nuclear spin transitions for at least some of the selected nuclei (radiation which is generally of microwave frequency or thereabouts and thus for convenience is referred to hereinafter as MW or UHF radiation), the MR images being generated from the resulting amplified MR signals (free induction decay signals) emitted by the sample.
The paramagnetic substance which possesses the ESR transition which couples with the NMR transition of the image nuclei may be naturally present within the imaging sample or more usually may be administered as an ESREMRI contrast agent.
In WO-A-88/10419 various ESREMRI contrast agents were proposed, for the most part these being nitroxide stable free radicals, although the use of chloranil semiquinone radical and of Fremy's salt was also
proposed.
In WO-A-90/00904 Hafslund Nycomed Innovation AB proposed the use of deuterated stable free radicals, in particular deuterated nitroxide stable free radicals, as ESREMRI contrast agents. Organic free radicals however frequently have properties which render them unsuitable for use as
ESREMRI contrast agents. Thus free radicals commonly are unstable in physiological conditions, or have very short half-lives leading to toxicity problems. A further drawback is the low relaxivity exhibited by many free radicals, which results in poor coupling of the electron and nuclear spin transitions and thus a poor enhancement of the magnetic resonance signal. A need therefore exists for improved free radical ESREMRI contrast agents.
The ESREMRI contrast agents so far proposed in the literature have all been "oxygen free radicals" that is to say radicals where the unpaired electron or electrons are associated with oxygen atoms.
We have now surprisingly found that carbon free radicals, i.e. radicals where the unpaired electron or electrons are primarily associated with carbon atoms are particularly attractive for use as ESREMRI contrast agents.
For such free radicals to be effective, they should be relatively long lived and to distinguish from free radicals which have a momentary existence, those usable as ESREMRI contrast agents will be referred to herein as being "inert" free radicals, that is having a half life of at least one minute at ambient temperature.
Viewed from one aspect the present invention thus provides the use of an inert carbon free radical for the manufacture of a contrast medium for use in ESREMRI.
Viewed from a further aspect, the invention also provides a method of magnetic resonance investigation of a sample, said method comprising introducing into said sample an inert carbon free radical, exposing said sample to a first radiation of a frequency selected to excite electron spin transitions in said free radical, exposing said sample to a second radiation of a
frequency selected to excite nuclear spin transitions in selected nuclei in said sample, detecting free induction decay signals from said sample, and, optionally,
generating an image or dynamic flow data from said detected signals.
Viewed from a still further aspect, the invention also provides a magnetic resonance imaging contrast medium comprising a physiologically tolerable inert carbon free radical together with at least one
pharmacologically acceptable carrier or excipient.
For in vivo imaging, the inert carbon free radical should of course preferably be a physiologically
tolerable radical , or one presented in a physiologically tolerable, e.g. encapsulated, form.
Inert carbon free radicals are well known and a renge of these has been described for example by
Ballester et al. (see JACS 93: 2215 (1971), J. Org. Chem. 47:259-64 and 4498 (1982), 48 3716 (1983), 53 1267-73 (1980), 54 4811-15 (1989), Accounts of Chemical Research 18: 380 (1985) and references therein); Fox et al. (see JACS 109, 7088-94); Gomberg, JACS 22, 757 (1900);
Neunhoffer Chem. Ber., 91, 1801 (1958); Maki, Chem.
Phys, 35, 761 (1963); Dunnebacke, Chem. Ber. 122 533 (1989); Jundeikis JACS 84 1132 (1961); Sinclair, JACS 90 5074 (1968); Bent, JACS 84 3250 (1932); Falle, Canad. J. Chem. 44 1387 (1966); Ziegler, Annalen 458 248 (1927); Allan, JCS (1936) 440; Acta (Chem. Scand. 16 1817
(1962); Theilacker, Annalen 594 214 (1955); Muller, Angew. Chem. 5 6 (1966); Schlenck, Annalen 372 1 (1910); Teilacker, Angew. Chem. 69 322 (1957); Sabacky, JACS 89 2054 (1967); Muller, Tetrakedron Lett 3877, (1967);
Marvel JACS 66 415 (1944); and Trapp, J. Chem. Phys 45 3472 (1966).
Preferred inert carbon free radicals for use according to the invention exhibit high stability to oxygen, to pH, for example in the range pH 5-9, and in aqueous solution, particularly stability up to a
concentration of 300 mM. Further desirable characteristics include reduced tendency to
dimerization, long half-life, preferably greater than 1 minute, particularly preferably greater than 1 hour and especially preferably 1 year, long relaxation times, both T1e and T2e preferably being greater than 1 μsec, high relaxivity, for example greater than 0.3 mM-1sec-1 and a small number of esr transition lines.
Particularly preferred inert carbon free radicals include the substituted methyl radicals, in particular triarylmethyl radicals where each of the three aromatic substituent groups may be the same or different and where two or three such groups may optionally be linked together. Particularly preferably the radical comprises optionally substituted six-membered carbocyclic or heterocyclic aromatic rings optionally carrying one or more fused carbocyclic or heterocyclic rings.
The possibility exists to optimize different characteristics, e.g. solubility, stability, line broadening, of the overall radical by appropriate combinations of different aryl substituents on the methyl carbon. Combinations, where two such aryl substituents, preferably identical, are selected to optimize stability and line broadening, and one aryl substituent is selected to optimize solubility are considered particularly interesting.
In order to optimize the above-mentioned desirable properties, a number of criteria need to be borne in mind in selecting or constructing triarylmethyl radicals for use according to the invention.
Thus, the aromatic rings of the triarylmethyl radical advantageously are substituted and the nuclear identities of nuclei in all substituents and their position within the molecule should be selected so as to minimise their effect (line splitting or broadening) on the esr transition.
In such cases, a six-membered aromatic ring is preferably substituted at the ortho and para positions. This is desirable in order to minimise dimerisation and oxygen attack on the molecule. The meta position is optionally substituted, preferably with a bulky
substituent, again to minimise attack by oxygen and at least one of the substituents should conveniently comprise a water solubilizing moiety. Such substituents preferably have no magnetic moment, or have a very low effective spin density. Alternatively, in order to minimise their effect on the esr transition, the
substituents should be bonded in such a manner that they are capable of free rotation.
Particularly preferred inert carbon free radicals include the triarylmethyl radicals of formula I
.C(Ar1)3 (I)
(where each group Ar1, which may be the same or
different, is preferably a substituted thienyl, phenyl, 4-pyridinyl, 3-pyridinyl, 2-pyridinyl, 5-pyrimidyl or 4- pyrimidyl group). Other preferred triarylmethyl
radicals include those of formula la
(Ar12)3C. (la) where each Ar12, which may be the same or different, comprises an optionally substituted 5-7 membered
carbocyclic or heterocyclic aromatic ring optionally carying one or more fused carbocyclic or heterocyclic rings, one or more such Ar12 groups preferably being a group Ar1 as defined herein.
Particularly preferably each group Ar1 represents a 6 membered carbon-attached carbocyclic or heterocyclic aromatic ring containing up to 2 non-adjacent ring nitrogens optionally substituted at the or any ortho carbon by a group R1 to R4, at the or any meta carbon by a group R2 or R3 and at any para carbon by a group
R1,R2,R3 or R4, with the proviso that no more than two ring carbons are unsubstituted, preferably only one ring carbon at most being unsubstituted;
each of R1 to R4, which may be the same or different, independently represents a group of formula -M, -XM,
-XAr2 or -Ar2; M represents a water solubilizing group, each group X, which may be the same or different, represents an oxygen or sulphur atom or a NH or CH2 group;
Ar2 represents a 5 to 10 membered aromatic ring
optionally substituted by a solubilizing group M;
or groups R1 and/or R4 on different Ar1 groups may
together represent bridging oxygen or sulphur atoms or
NR5 or CR5 2 groups, where R5 represents a hydrogen atom or an optionally hydroxylated, optionally aminated,
optionally alkoxylated, optionally carboxylated alkyl, oxo-alkyl, alkenyl or alkaryl group;
or groups R2 and R3 may also represent hydrogen atoms or alkyl groups;
or adjacent groups R1 , R2, R3 or R4, preferably groups at the ortho and meta portions, together with the two intervening carbon atoms may represent groups of formula
Figure imgf000010_0001
where R6 represents a hydrogen atom, a hydroxyl group, an optionally alkoxylated, optionally hydroxylated acyloxy or alkyl group or a solubilising group M; Z represents an oxygen or sulphur atom or a group NR5, CR7 2, or SiR7 2; each R7, which may be the same or different, represents a hydrogen atom, an alkyl, hydroxyalkyl, alkoxycarbonyl or carbamoyl group or two groups R7 together with the atom to which they are bound represent a carbonyl group or a 5 to 8 membered cycloalkylidene, mono- or di- oxacycloalkylidene, mono- or di-azacycloalkylidene or mono- or di-thiacycloalkylidene group optionally with the ring attachment carbon replaced by a silicon atom (preferably however in any spiro structure the ring linking atom will be bonded to no more than three heteroatoms) and R7 where it is other than hydrogen, is optionally substituted by a group R6;
or a salt thereof.
In the radicals of formula I, the groups Ar1 are preferably groups of formula
Figure imgf000011_0001
where each Y independently represents CH, or more preferably CM, C-XM, C-Ar2, C-XAr2 or a nitrogen atom.
Certain of the radicals of formula I are new and they, their salts and their non-radical precursors (i.e, compounds of formula (Ar12)3CX4 or (Ar1)3CX4 where X4 is a leaving group, e.g. hydrogen, hydroxyl, halogen,
carboxyl, CO2OCO.C(Ar12)3 or NNC(Ar12)3) form further aspects of the present invention.
In the inert carbon radicals of formula I, the solubilizing groups M may be any of the solubilizing groups conventionally used in diagnostic and
pharmaceutical products. Particularly preferred
solubilizing groups M include optionally hydroxylated, optionally alkoxylated alkyl or oxo-alkyl groups and groups of formulae R5, COOR5, OCOR5, CHO, CN, CH2S(O)R5, CONR5 2, NR5COR5, NR5 2, SO2NR5 2, OR5, PO3 2-, SOR5, SO2R5, SO3M1 , COOM1 (where M1 is one equivalent of a physiologically tolerable cation, for example an alkali or alkaline earth metal cation, an ammonium ion or an organic amine cation, for example a meglumine ion), -(O(CH2)n)mOR5 (where n is an integer having a value of from 1 to 3 and m is an integer having a value of from 1 to 5),
or CH2R8 (where R8 is a hydrophilic R5 group)
Figure imgf000012_0001
or SR10 where R10 is a group R5 or an alkyl group
optionally substituted by one or more, especially two or three groups COOR5, OCOR5, CHO, CN, CONR5 2, NR5COR5, NR5 2, SO2NR5 2, OR5, PO3 2-, SOR5, SO2R5, SO3M1, COOM1, or -
(O(CH2)n)mOR5.
Especially preferred as solubilizing groups M are groups of formula C(H)3-n(CH2OH)n, R9, COR9, SR9, SOR9,
SO2R9, CON(R9)2, NR9 2, NHR9 and CONHR9 [where R9 may represent a group
-CH2CH2OH, -CH2OH
-O-CH2CH2OH, -CH2OCH2CH2OH,
Figure imgf000013_0001
Figure imgf000013_0002
(although any R9 group attached to a sulphur, nitrogen or oxygen atom is preferably not hydroxylated at the α carbon)], and groups of formula SR 12 where R12 is a group CH2COOR13, CH(COOR13)2, CH2CONHR9, CH2CONR9 2,
CR5(COOR13)2, CH(CN)CO2R13, (CH2)nSO3-M1 , (CH2)nCOR1,
CH(COR9)CH2COR9 and CH(R5)COR9 where n, M1 and R5 are as earlier defined and R13 is a hydrogen atom, an alkyl group or a group M1 or R9.
Further especially preferred solubilising groups M or XM include groups of formula X' C((CH2)n COOR13)2R14, X'C((CH2)nCOOR13)3 and X'C((CH2)nCOOR13)R14 2, where R13 is as defined above, n is an integer from 1 to 3, X' is an oxygen or sulphur atom, and R14 is a hydroxyalkyl group such as a group R9 as earlier defined.
Other examples of preferred R1 groups include for example the following structures
-S-(CH2CH2O)n, R19 where n1 is 0, 1 or 2 and R19 is hydrogen or C1-4 alkyl
-S-(CH2)n,-CO-R23 where R23 is C1-4 alkyl (e.g.
methyl, ethyl or t-butyl), NR2 21 or OR21 and R21 is C1-4 alkyl
-COR22 where R22 is hydrogen,
hydroxyl, R23, or COOR21
-CH2O [CH2CH2O]n,CH3
-CH2OCOR21
Figure imgf000014_0002
and -CHX-CR1 2CR5 2-X where X is oxygen or sulphur.
Where M represents a group containing a moiety NR5 2, this may also represent an optionally substituted nitrogen-attached 5 to 7 membered heterocyclic ring optionally containing at least one further ring
heteroatom, e.g. N or O, for example a group of formula
Figure imgf000014_0001
In the inert carbon radicals of formula (I), any alkyl or alkenyl moiety conveniently will contain up to 6, especially up to 4, carbon atoms and any aryl moiety will preferably contain 5 to 7 ring atoms in the or any aromatic ring and especially preferably will comprise an aromatic ring with 0, 1 or 2 further aromatic rings fused directly or indirectly thereto.
Preferred structures for the aryl substituents on the carbon radical centre include those in which at least one of such substituents carries at least one, and preferably two, fused rings of formula
Figure imgf000015_0001
where X and Z are as defined before, especially rings of formulae
Figure imgf000015_0002
where X is oxygen or sulphur and R7 is hydrogen or optionally hydroxylated methyl.
Particularly preferred structures for the aryl groups Ar1 in the inert carbon free radicals of formula I include the following:
Figure imgf000015_0003
wherein X is oxygen or sulphur, Y is N, CCOOR5, CSR5, CM or C-XM and M, R5 and Z are as earlier defined.
Particularly preferred structures include those in which CR7 2 represents CH2, C(CH2OH)2 or C(CH3)2, X
represents an oxygen or sulphur atom and those of formula
Figure imgf000016_0001
where R1 is a group M or XM as hereinbefore defined and M2 represents a solubilising group M or a group SCH3, S(O)CH3, S(O2)CH3, SCH2CH2N(CH3)2, SCH2COOH, SCH2COOCH3, SCH2COOCH2CH3 and SC(H)3-n(CH2OH)n where n is an integer of from 1 to 3.
Especially preferred groups Ar1 include optionally substituted benzo [1,2-d:4,5-d']bis[1,3]dioxole, benzo[1,2-d:4,5-d']bis[1,3]dithiole, and benzo[1,2- d:4,5-d']bis[1,3]oxathiole groups.
Preferred inert carbon free radicals for use according to the invention include the following:
Figure imgf000016_0002
Especially preferred inert cation free radicals include
Figure imgf000017_0001
and water soluble derivatives thereof such as
Figure imgf000017_0002
(where each of R42, R43 and R44 are non-ionic solubilising groups e.g. hydroxyalkyl or alkoxyalkyl groups);
Figure imgf000017_0003
and water soluble derivatives thereof such as
Figure imgf000018_0001
(where R42, R43 and R44 are as defined above).
Inert free radicals which have relatively few transitions, e.g. less than 15, preferably less than 10, in their ESR spectra and radicals having narrow
linewidth ESR transitions, e.g. up to 500 mG, preferably less than 150 mG, especially less than 60 mG and
particularly less than 25mG, are especially preferred for use as ESREMRI contrast agents. (The linewidths referred to are conveniently the intrinsic linewidths (full width at half maximum in the absorption spectrum) at ambient conditions).
Whilst low numbers of ESR transition lines are generally preferred to obtain more effective coupling of the ESR and NMR transitions, we have found that
surprisingly good coupling, and therefore enhancement of the MR signal, may also be achieved with radicals showing a large number of ESR transitions.
Where the radicals have a multiplicity of ESR transitions, the hyperfine splitting constant is
preferably very small. In this connection radicals having as few as possible non-zero spin nuclei,
positioned as far away as possible from the paramagnetic centre are thus especially preferred.
Certain of the triarylmethyl free radicals of formula I are themselves novel and in a further aspect the present invention also provides novel inert carbon free radicals of formula I or salts thereof.
Most known triarylmethyl radicals have short relaxation times and half lives and are generally unstable, being oxygen-sensitive and particularly susceptible to dimerization, and thus would not
generally be considered for use as contrast agents.
Moreover known triaryl methyl radicals are water- insoluble and are therefore generally not suited for administration to the body. The choice of triaryl methyl radicals as ESREMRI contrast agents is therefore not an obvious one.
The novel triarylmethyl radicals of the invention include radicals which surprisingly are stable at physiological pH, have long half lives (at least one minute, and preferably at least one hour), long
relaxation times, and exhibit surprisingly good
relaxivity. Water-soluble triaryl methyl radicals are a particularly important aspect of the invention.
The triarylmethyl radicals may be coupled to further molecules for example to lipophilic moieties such as long chain fatty acids or to macromolecules, such as polymers, proteins, polysaccharides (e.g.
dextrans), polypeptides and polyethyleneimines. The macromolecule may be a tissue-specific biomolecule such as an antibody or a backbone polymer such as polylysine capable of carrying a number of independent radical groups which may itself be attached to a further
macromolecule. Coupling to lipophilic molecules or substitution of the radical with lipophilic groups is particularly useful since it may enhance the relaxivity of the radicals in certain systems such as blood. Such lipophilic and macromolecular derivatives of the radicals of formula I and salts thereof form a further aspect of the present invention.
The linkage of a compound of formula I to the further molecule may be effected by any of the
conventional methods such as the carbodiimide method, the mixed anhydride procedure of Krejcarek et al. (see Biochemical and Biophysical Research Communications 77: 581 (1977)), the cyclic anhydride method of Hnatowich et al. (see Science 220: 613 (1983) and elsewhere), the backbone conjugation techniques of Meares et al. (see Anal. Biochem. 142: 68 (1984) and elsewhere) and
Schering (see EP-A-331616 for example) and by the use of linker molecules as described for example by Nycomed in WO-A-89/06979.
In view of their surprisingly beneficial
properties, the novel triarylmethyl radicals of the invention may also be used as ESR spin labels in ESR imaging or in magnetometry.
The inert carbon free radicals may be prepared from their non-radical precursor compounds by conventional radical generation methods. Suitable non-radical precursor compounds include the corresponding triaryl methanes, triaryl methyl halides and triaryl methanols, and derivatives, e.g. ethers, of the triaryl methanols.
Thus in a further aspect the invention provides a process for the preparation of the novel triarylmethyl radicals of the invention which comprises subjecting a radical precursor therefor to a redical generation step and optionally subsequently modifying the substitution on the aryl moieties, e.g. by oxidation or reduction. By such modification for example sulphide substituents, (e.g. -SCH3 or -SCH2COOEt) may be oxidized to the corresponding sulphones so avoiding problems of acidic hydrogens prior to radical formulation. Similarly lipophilic substituents (such as -SCH2COOEt) may be reduced to corresponding hydrophilic substituents
(e.g. -SCH2CH2OH).
Thus by way of illustration the radical-precursor can be represented by formula XXXV
(Ar12)3CLv (Lv) (XXXV) where Lv is a group displaceable to produce a radical Formula XXXV embrace formulae such as
(Ar12)3COH (II)
(Ar12)3CHal (III)
(Ar12)3CH (IV)
(Ar12)3CCOOH (XXXI)
(Ar12)3C.CO.O.O.CO.C(Ar12)3 (XXXII)
(Ar12)3C.NN C(Ar12)3 (XXXIII) Where Hal represents halogen, e.g. Br or Cl).
Thus for example carbon free radicals may
conveniently be prepared from corresponding triaryl methyl halides by reduction with a metal catalyst, such as copper, zinc or silver, or by electrolytic reaction on an electrode or by photochemical reaction in the presence of a chlorine radical scavenger, e.g. an olefin. Alternatively, carbon free radicals may be prepared from the corresponding triaryl methanes by reaction with a base, e.g. in the presence of sodium hydride followed by a reaction with an oxidant, e.g. iodine in the presence of oxygen or a quinone such as chloranil, following for example the method described in US-A-3347941. Another method to prepare triarylmethyl radicals is to react triarylmethanes with other, less stable radicals such as tert-butoxyl radicals. The latter radicals are generated in situ via thermolysis or photolysis of an appropriate precursor, such as a peroxide or an azo compound. A further example of a method by which radical preparation may be effected is reaction of the corresponding triaryl methanols in the presence of an acid to form a carbonium ion followed by reduction to the free radical in the presence of a suitable reducing agent, such as metal ions e.g. Cr2+, Fe2+, or by electrochemical reduction. The carbon free radicals may also be generated by a comproportionation reaction between cations and anions of a corresponding radical precursor. In such a reaction an electron is exchanged between the anion and the cation, and two radicals are generated. Triarylmethyl radicals may thus be prepared by mixing together a triarylmethyl radical precursor cation with a corresponding anion.
Triarylmethyl radicals may also be prepared by
thermolysis or photolysis or a corresponding dimeric triarylmethyl structure, for example an
azobistriarylmethyl or a bis (triarylmethylcarboxylic acid) peroxide. An alternative method of preparation of triarylmethyl radicals is the electrochemical
decarboxylation of a triarylmethylcarboxylate.
While radicals with long half lives in aqueous solution, for example at least one hour, preferably ten days, more preferably fifty days and especially
preferably at least one year are clearly particularly desirable for use in in vivo imaging, shorter lived inert free radicals may still be utilised in imaging (e.g. of inanimate samples) and these may particularly conveniently be prepared immediately pre-administration.
The non-radical precursors may themselves be prepared by methods conventional in the art. Thus a process for the preparation of a triaryl methyl radical precursor may comprise one or more of the following steps:- a) (to prepare a triarylmethanol of Formula II
HO-C(Ar 12)3 (II) wherein Ar12 is as hereinbefore defined)
reacting a compound of formula XXIII
H-Ar12 (XXIII) with alkyl lithium (e.g. BuLi) and a compound of formula CO(OR")2 (where R" is an alkyl group, e.g. a C1-9 alkyl especially ethyl); b) (to prepare a triarylmethanol of Formula II
HO-C(Ar12)3 (II) wherein Ar12 is as hereinbefore defined) reacting an organometallic compound comprising a metal linked Ar12 moiety (e.g. Ar12Li or Ar12 MgHal) with a compound of formula XXV, XXVI or XXVII
R"OCOOR" (XXV)
Ar12COOR" (XXVI)
(Ar12)2CO (XXVII) where R" is as hereinbefore defined, especially methyl); c) (to prepare a triarylmethanol of Formula II
HO-C(Ar12)3 (II) wherein Ar12 is as hereinbefore defined) hydrolysing a compound of formula III Hal-C(Ar12)3 (II)
(where Hal and Ar12 are as hereinbefore defined); d) (to prepare a triarylmethanol of Formula II
HO-C(Ar12)3 (III) wherein Ar12 is as hereinbefore defined) reacting a compound of formula XXVII with a compound of formula Hal-Ar12; e) (to prepare a triarylmethyl halide of Formula III
HO-C(Ar12)3 (III) wherein Ar12 is as hereinbefore defined) halogenating a triarylmethane of formula IV
HC(Ar12)3 (IV)
(e.g. under illumination or by reaction with N- bromosuccinimide or thionyl chloride or by reaction with a tetrahalomethane, e.g. CCl4, in the presence of AlCl3) or halogenating a triarylmethanol of formula II; f) (to prepare a triarylmethane of formula IV)
reacting a compound of formula XXIII with a
trialkoxymethane of formula XXVIII
(R"O)3CH (XXVIII)
(where R" is as hereinbefore defined, especially methyl), e.g. in the presence of AlCl3; g) (to prepare a triarylmethane of formula IV)
hydrogenating or otherwise reducing a triarylmethyl halide of formula III or a triarylmethanol of formula II (e.g. using sodium borohydride or trimethylsilylchloride and potassium iodide; h) (to prepare a triarylmethane of formula IV)
reacting a compound of formula XXIII with a
compound of formula XXIX (Ar12) CHHal (XXIX)
Figure imgf000025_0001
(wherein n, is 0, 1 or 2 and n2 is 1, 2 or 3 and n1 +n2 is 3), e.g. in the presence of AlCl3; i) (to prepare a triarylmethane of formula IV)
reacting a compound of formula XXX
(Ar12)2CHLv (XXX)
(where Lv is a leaving group, e.g. OTs) with an organometallic compound comprising a metal linked Ar12 moiety (e.g. Ar12CuLi); j) (to prepare a triarylacetic acid of formula XXXI
(Ar12)3CCOOH (XXXI)
(where Ar12 is as hereinbefore defined)
reacting a triarylmethyl halide of formula III with carbon monoxide (e.g. in the presence of Co2(CO)8) on a triarylmethyl organometallic compound with carbon dioxide; k) (to prepare a compound of formula XXXII
(Ar12)3CCOOOCOC(Ar12)3 (XXXII)
(where Ar12 is as hereinbefore defined)
reacting a triarylacetic acid with thionyl chloride and a peroxide, e.g. H2O2; l) (to prepare a compound of formula XXXIII
(Ar12)3CN=NC(Ar12)3 (XXXIII)
(where Ar12 is as hereinbefore defined) oxidizing a triarylmethylamine halide of formula
XXXIV
(Ar12) 3CNHHal (XXXIV) e.g. with silveroxide; m) reacting a triarylmethyl radical precursor to
modify the substitution on one or more of the aryl moieties.
For process step (b), the starting ketone of formula XXVII may be prepared by oxidation, e.g. with CrO3, of the corresponding alcohol (Ar12)2CHOH (itself preparable by reaction of the monoaldehyde Ar12CHO with an Ar12 containing organometallic, e.g. Ar12 Li or
Ar12MgHal), or by reaction of such an organometallic with the corresponding carboxylic acid Ar12COOH, or by reaction of the acid chloride Ar12COCl with Ar12H, e.g. in the presence of AlCl3.
For process step (d), the starting material of formula XXXIV may be prepared by reaction of a
corresponding triarylmethyl carbanion with NH2Cl and subsequently with bromate.
The reduction of step (g) may be effected using borane or LiAlH4 and AlCl3.
Triaryl methyl halides may be prepared following the procedures described by Dünnebacke et al. in Chem. Ber. 122:533-535 (1989).
In synthesising substituted triaryl methyl
radicals, the substituents may be introduced onto individual Ar12 groups before they are trimerized to form the triaryl radical precursor compounds, or they may be introduced directly onto the triaryl precursor compound or the actual radical itself. It is also possible to effect the substitution and trimerization steps
simultaneously in a "one-pot" reaction.
The Ar12 groups may be prepared by following
reaction schemes such as those suggested below
Figure imgf000027_0001
(wherein R7' is a hydrogen atom or a group R7 as hereinbefore defined, optionally protected by a protecting group).
Figure imgf000027_0002
(wherein R7' is as defined above)
Figure imgf000028_0001
Figure imgf000029_0001
To introduce substituents onto the Ar12 groups such as solubilising groups M for example, reaction schemes such as the following may be used
( i )
Figure imgf000029_0002
Figure imgf000030_0001
Figure imgf000031_0001
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
wherein in each of schemes (i) to (xxiv) set out above R1' to R4 ' are optionally protected groups R1 to R4 and R5 is as hereinbefore defined. Particularly preferably, R1 ' and R2' and R3 ' and R4 ' may represent ring-forming groups -X-CR7'2-X-, e.g. OC(CH3)2O-.
Similar procedures may be used for the introduction of substitutents onto heterocyclic Ar12 groups.
The following are examples of schemes for "one-pot" synthesis of triaryl methyl radical precursors.
Figure imgf000038_0002
Figure imgf000039_0001
As indicated above, a particularly interesting group of radicals for use according to the invention includes compounds of Formula .C(Ar12)3, where one, two or three Ar12 groups comprises a central 5-6 membered carbocyclic or heterocyclic aromatic ring bearing two five-membered fused rings, each said fused ring
comprising two ring heteroatoms selected from oxygen and sulphur.
The "monomer" and "dimer" compounds, having this structure are particularly useful for the preparation of the radical precursors and thus in a further aspect the invention provides tricylic compound comprising a central 5-6 membered carbocyclic or heterocyclic
aromatic ring bearing two five-membered fused rings, each said fused ring comprising two ring heteroatoms selected from oxygen and suphur. Particularly preferred embodiments of such compounds are the compounds of formula XL
Figure imgf000040_0001
(where X and R7 are as hereinbefore defined, Y1 is a group CH, N, CCOOR5, CSR5, CM or CXM, R5 and M are as defined in claim 6 and R40 is a hydrogen atom, or a optionally substituted hydroxyl, methyl or formyl group or group
Figure imgf000040_0002
where Z''' is CHOH, C=O or CHHal and Hal is a halogen atom), or a salt thereof.
Particularly preferred compounds of formula XL include those wherein each X is oxygen, each R7 is optionally hydroxylated methyl and Y1 is other than N.
The invention also provides, in another aspect, process for the preparation of a compound of formula XL, said process comprising condensing a compound of formula XLI
Figure imgf000040_0003
(wherein R40' and Y'' are groups R40 or Y1 as defined in claim 23 or protected such groups, and X is as defined in claim 23) with a compound of formula (R7')2 CX (where R7' is a group R7 as defined in claim 23 or a protected R7 group) under oxidizing conditions and if necessary removing any protecting groups, optionally after
reduction (eg with Fe/HCl) of a compound of formula XLII
Figure imgf000041_0001
to yield the starting material of formula XLI.
For use in ESREMRI, the inert carbon free radicals are conveniently formulated into contrast media together with conventional pharmaceutical carriers or excipients. Contrast media manufactured or used according to this invention may contain, besides the inert free radicals (or the non-radical precursor where radical formation is to be effected immediately before administration), formulation aids such as are conventional for
therapeutic and diagnostic compositions in human or veterinary medicine. Thus the media may for example include solubilizing agents, emulsifiers, viscosity enhancers, buffers, etc. The media may be in forms suitable for parenteral (e.g. intravenous) or enteral (e.g. oral) application, for example for application directly into body cavities having external voidance ducts (such as the gastrointestinal tract, the bladder and the uterus), or for injection or infusion into the cardiovascular system. However solutions, suspensions and dispersions in physiological tolerable media will generally be preferred.
Free radicals which are relatively unstable or insoluble in the sample environment may be encapsulated, e.g. in gastric juice resistant capsules containing a medium in which they are stable. Alternatively, the radical may be presented as an encapsulated freeze dried powder in a soluble capsule. Such formulations might conveniently be dissolved shortly before in vivo use.
For use in in vivo diagnostic imaging, the medium, which preferably will be substantially isotonic, may conveniently be administered at a concentration
sufficient to yield a 1 micromolar to 10 mM
concentration of the free radical in the imaging zone; however the precise concentration and dosage will of course depend upon a range of factors such as toxicity, the organ targetting ability of the contrast agent, and the administration route. The optimum concentration for the free radical represents a balance between various factors. In general, optimum concentrations would in most cases lie in the range 0.1 to 100mM, especially 0.2 to 10mM, more especially 0.5 to 5mM. Compositions for intravenous administration would preferably contain the free radical in concentrations of 10 to 1000mM
especially 50 to 500 mM. For ionic materials, the concentration will particularly preferably be in the range 50 to 200mM, especially 130 to 170mM and for non- ionic materials 200 to 400mM, especially 290 to 330mM. For imaging of the urinary tract or the renal or biliary system however, compositions may perhaps be used having concentrations of for example 10 to 100mM for ionic or 20 to 200mM for non-ionic materials. Moreover for bolus injection the concentration may conveniently be 0.1 to 100mM, preferably 5 to 25mM, especially preferably 6 to 15mM.
The accompanying drawing, Figure 1, shows a
magnetic resonance image produced according to the invention. Specifically, there is shown a coronal slice through a rat following peroral administration of a contrast medium containing tris(2,2,6,6-tetramethyl sodium-8-carboxylate methylthiobenzo[1,2-d:4,5- d']bis(1,3)dioxole)methyl (the radical of Example 11). The gastrointestinal tract can be seen very clearly In Figure 1:
1. indicates the stomach;
2. indicates the intestines;
3. indicates the head end of the rat;
4. indicates the tail end of the rat;
5. indicates the right hand side of the rat;
6. indicates the left hand side of the rat.
The image was acquired under the following
conditions:
a) TR = 0.5 sec, UHF Irradiation Time = 0.38 sec. 256 excitations (256 x 256 matrix). Slice thickness 1 cm. Field of view 25 cm.90° flip angle (SR).
Single echo (gradient). TE = 30 ms. Single slice. 1. Average. b) The instrumental parameters were:
Proton frequency 417 kHz (H = 100 G) UHF frequency = 274 MHz. The UHF-resonator had a very low loaded Q ≤ 10 (200 g rat), and a volume of approximately 1L (diameter 10 cm). The applied UHF power was < 30 W of which only a small fraction was deposited in the animal (< 1/10). The proton coil had a diameter of 126 cm and thus a very low filling factor when loaded, with a rat (5 cm). The Q factor of this coil was high (> 1000), but loaded with both UHF-resonator and animal decreased to below 500. c) The signal/noise (S/N) ratio was approximately 100.
The perorlly applied volume of contrast medium was approximately 5ml and the concentration of radical was less than 05mM.
In the unenhanced image, where no contrast medium was administratered, the S/N ratio was -3 resulting in an image where no details could be distinguished from the background noise.
The present invention will now be further
illustrated by the following non-limiting Examples
(percentages, parts and ratios are by weight and
temperatures are in degrees Celsius unless otherwise stated).
Example 1
2.5-Dimercapto-1,4-dihydroxγbenzene
Ammonia was condensed (ca 200ml) into 150 ml of dry diethylether in a 3-necked flask, with external cooling. Then 9.0 g (0.0256 mole) of 2,5-dibenzylmercapto-p- benzoquinone was dissolved into the liquid. Sodium (5.9 g, 0.256 mole) cut into fine pieces was added portionwise with efficient stirring. After stirring for an additional 2.5 hours, abs. ethanol (20 ml) was added and the ammonia was evaporated. Water (170 ml) was added to the reaction product and it was extracted with 2 x 30 ml of ether. The aqueous phase was then
acidified to pH 1-2, with cone, hydrochloric acid, and extracted with 3 x 80 ml of ether. The ether extracts were collected, dried (Na2SO4), the solvent evaporated leaving a fluffy light brown glistening residue, 4.3 g (90%).
MS (Silated Product) : M/e 462 (42% M+) 447 (5% M+-15)
Example 2
2,2,6,6-Tetramethylbenzo[1.2-d:4.5-d']bis(1,3)dithiole
Figure imgf000044_0001
1,3,5,7-Tetrathia-S-indacene-2,6-dione (4.0 g, 0.016 mole, prepared according to Larsen and Bechgaard J. Org Chem 52 : 3287 (1987)) was suspended in 60 ml of a IM solution of sodium methoxide in methanol. Stirring was maintained for 1/2 hour at ambient temp, until a clear solution was formed. The reaction mixture was then evaporated to dryness and the residue acidified with 5 N hydrochloric acid to pH 1. The aqueous phase was extracted with 3 x 70 ml of methylene chloride. The organic phases were dried (Na2SO4), the solvent
evaporated leaving a light tan coloured crystalline residue. This was suspended in 50 ml of dry toluene, and 3 ml of acetone and 2.5 ml of fluoroboric acid etherate (HBF4. Et2O) were added. The mixture was stirred at ambient temperature for 5 hours then refluxed over night. The reaction mixture was then poured into 100 ml of cold saturated sodium hydrogen carbonate solution. The phases were separated and the organic phase was washed with 30 ml of water. The aqueous phases were back-extracted with 40 ml of methylene chloride. The organic phases were collected, dried (Na2SO4) and the solvent evaporated leaving a light yellow cryst. residue, 4.1 g (92%).
IR(film) : 2960,2920 CM-1,
1H-NMR (CDCl3) δ : 1.88 (CH3 12H), 7.02 (arom H, 2H) ppm MS: m/e 286 (14% M+)
Example 3
Tris(benzo[1.2-d:4.5-d']bis(1,3)dioxole-4-yl)methanol
Figure imgf000046_0001
3.2 g Benzo[1,2-d: 4,5-d']bis(1,3)dioxole prepared according to F. Dallacker et al. Liebigs Ann. Chem. 725, 99-105 (1969) (0.019 mole) was dissolved in 100 ml dry ether under Argon. After cooling in ice-acetone to - 15°C, 10 ml 2.5 M butyllithium in hexanes (Aldrich) was added from a syringe. The cooling bath was removed and the mixture was stirred for 2 hours. 0.8 ml
diethylcarbonate (0.0068 mole) was added with a slight increase in temperature and color change to yellow- brown. The mixture was stirred at room temperature overnight and then poured over 150 ml ice-water and extracted with 3 x 75 ml CH2Cl2. The organic phase was washed with 100 ml water, dried over MgSO4 and evaporated to dryness to yield 2.96 g (88%) m; 125 °C (unsharp). 1H-NMR (CDCl3) δ : 5.75 (CH2, 12H); 6.25 (Arom H, 3H) ppm MS: m/e 524 (100% M+)
The corresponding radical showed a linewidth of 500 mG in its ESR spectrum and an Overhauser enhancement of 8 at 5hr UHF power.
Example 4
1,2.4,5-Tetrahvdroxybenzene[1,2-d:4,5-d'Ibis(1,3)dioxole
14 g 2.5-dihydroxy-1,4-benzoquinone (0.10 mole) was suspended in 100 ml 96% ethanol. 0.1 g 10% Pd on C was added under N2 and reduced at 40 Psig in a Parr apparatus (in the usual manner) until 0.10 mole H2 was absorbed. The dark reaction mixture was filtered to remove the catalyst and evaporated to dryness to afford the product in quantitative yield.
Example 5
2.2,6,6-Tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole
Figure imgf000047_0001
18.6 g of the 1,2,4, 5-tetrahydroxybenzene prepared according to Example 4 (0.13 mole) and 70 ml acetone (58.6 g, 1.0 mole) was dissolved in 1 1 tetrahydrofuran. 168 g P2O5 (1.18 mole) was added to the vigorously stirred mixture in portions as fast as possible. The mixture was heated to reflux for 4 hours. After cooling to room temperature the solids were filtered with suction and washed with 0.5 L ether. The combined filtrates were treated with 10 g K2CO3 and stirred 1 hour, filtered and evaporated to dryness yielding a yellow-brown oily solid. The product was triturated with petroleum ether, decanted and evaporated to yield 13.8 g of the title compound (48%) as white-yellow crystals, mp = 122 °C, which can be recrystalized from a small amount of petroleum ether.
1H NMR (CDCl3) δ : 1.65 (CH3, 12H); 6.75 (Arom H, 2H) ppm 13C NMR δ : 25.49 (CH3); 92.75 (Arom CH); 117.81 (CMe2); 140.43 (Arom C) ppm
MS: m/e 222 (90% M+), 207 (100%, M+-15) Example 6
3-Methylthio-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)dioxole
Figure imgf000048_0001
1.1 g of 2,2,6,6,-tetramethylbenzo(1,2-d:4,5- d']bis (1,3) dioxole prepared according to Example 5
(0.005 mole) was dissolved in 25 ml dry ether under argon and treated with 2.2 ml 2.5 M butyllithium in hexane, at room temperature. After 1 hour 0.52 g dimethyldisulfide (0.0055 mole) was added and the mixture stirred overnight at room temp. The reaction mixture was then poured into 50 ml ice-water. The phases were separated and the water phase extracted with 50 ml ether. The combined organic phase was washed with 50 ml 2 M NaOH, dried over MgSO4 and evaporated to yield 1.1 g (82%) as white crystals, mp = 108°C, which can be recrystallized from a small amount of methanol.
1H NMR (CDCl3) δ : 1.67 (CH3; 12H); 2.45 (-SCH2, 3H) 6.26 (Arom CH, 1H)
Example 7
Tris(8-Methylthio-2,2,6,6-tetramethylbenzo[1,2-d:4.5- d']bis(1.3)dioxole)methanol
Figure imgf000049_0001
6.2 g 3-methylthio-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis (1,3) -dioxole prepared according to Example 6
(0.0235 mole) was dissolved in 150 ml dry ether under argon. The solution was cooled in an ice-methanol bath, while 10 ml 2.5 M butyllithium in hexane (0.025 mole) was added and then left with stirring at room
temperature for one hour. 0.95 ml diethylcarbonate
(0.0078 mole) was added.
After 18 hours the reaction mixture was poured over 200 ml ice-water and the product extracted with 3 x 75 ml
CH2Cl2. The organic phase was washed with 100 ml H2O, dried over MgSO4 and evafporated to dryness, yielding ca
5 g yellow solid. The product was triturated with a little cold petroleum ether and filtered to yield 2.1 g of the title compound (32%) as yellow crystals, mp >
260 °C.
1H NMR (CDCl3) δ : 1.51 (CH3, 36H); 2.40 (SCH3, 9H); 4.20
(OH,1H) ppm
13C-NMR δ : 17 . 28 ; 25.48 ; 72 . 56 ; 99 . 87 , 111. 97 138 . 71 ;
140.97 .
MS: m/e 830 (80% M+), 714 (100% M+-116)
Example 8
Tris(8-methylthio-2,2,6,6-tetramethylbenzo[1,2-d:4.5- d']-bis(1,3)dioxole)methyl
Figure imgf000050_0001
250 mg Tris-(3-methylthio-2,2,6,6-tetramethylbenzo[1,2- d:4,5-d']bis(1,3)dioxole)methanol (0.3 mmol. Example 7) was dissolved in 50 ml dry THF (Al2O3, super I, basic) under Argon. 0.5 g CrCl2 and then 0.5 ml BF3 etherate was added to the vigorously stirred mixture. After 15 minutes the reaction mixture was poured over 50 ml 4 M NaOH. The organic phase was separated and filtered through a short column of SiO2 and eluted with dry ether. The dark violet solution was evaporated to dryness yielding 176 mg (71%) of the title compound as a black powder. A solution of this material in tetrahydrofuran was shown to contain 41% radical according to the method of Evans (J. Chem. Soc. 2003 (1959)).
MS: m/e 814 (60% M+-1)
Example 9
Tris(8-ethoxycarbonylmethylthio-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1.3)dioxole)methanol
Figure imgf000051_0001
2.25g (0.010 mole) of the benzobisdioxole of Example 5 in 50 ml tetrahydrofuran (THF, HPLC-grade) was cooled to -80° in an dry ice-acetone bath. 4.4 ml (1.1 eqv) 2.5 M n-butyl lithium was added and the mixture allowed to come to ambient temperature. After about 15 minutes 0.35g of sulphur (S8) was added in one portion. After about 20 minutes the sulphur had reacted and the
brownish solution was cooled to -80°C and treated with 4.4 mL 2.5 M n-butyl lithium. The cooling bath was removed and the temperature allowed to rise again to ambient temperature. After about 20 minutes a cloudy suspension was obtained. 0.4 mL diethylcarbonate was added.
After 1 hour, 5.5 ml (0.05 mole) of chloroacetic acid ethylester was added in one portion (slight heat formation). The reaction mixture become very dark and homogeneous. TLC in CHCl3 showed that a "trimer" was formed along with dimeric ketones (and other products). After another ½ hour the reaction mixture was poured into 200 mL ice-water and extracted with 3 x 75 mL diethyl ether. The organic phase was washed with 2 x 50 mL H2O, dried over MgSO4 and evaporated to dryness yielding an orange oil it was separated on silica with CHCl3-diethyl ether as eluent.
Evaporation of the solvent yielded 1.46g orange oil (very viscous) yield: 42%. The product was verified using 1H NMR, 13C NMR and mass spectrometry.
1HNMR (CDCl3) δ : 1.22 (t) (CH3,9H); 1.50 (CH3,36H), 3.57 (CH2,6H); 4.1 (CH2,6H) ppm
13CNMR δ : 14.10; 25.44; 35.49; 61.22; 96.64; 112.45, 117.77, 138.67, 141.25, 169.016 ppm
MS m/e 1407 (10%, M+1), 1031 (30% M+-15)
Example 10
Tris(8-ethoxycarbonylmethγlthio-2,2,6,6- tetramethylbenzo[1,2-d:4.5-d']bis(1.3)dioxole)methyl
Figure imgf000052_0001
250 mg of tris (8-ethoxycarbonylmethylthio-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole)methanol prepared according to Example 9 was dissolved in about 100 mL THF (HPLC-grade) and placed in a 250 mL
separating funnel. A rapid stream of argon was bubbled through the solution. 200 mg CrCl2 was added followed by 0.4 mL BF3-diethylether. After 5 minutes 75 mL
diethylether was added and then the mixture was
extracted with 2 x 75 ml H2O and 1 x 75 ml 2M NaOH. The dark organic phase was filtered through 5cm SiO2, eluted with diethylether and evaporated to dryness in vacuo affording a black-brown oil that slowly solidified on addition of 5 ml methanol 177 mg black crystals were obtained, and washed with petroleum ether.
Radical content: 60% (NMR - Evans method)
ESR 0.2 mM in Toluene: 7 lines ACH2: 66 Milli Gauss linewidth : 33 Milli Gauss Example 11
Tris(2,2,6,6-tetramethyl sodium-8-carboxγlatemethylthiobenzo[1,2-d:4,5-d']bis(1,3)dioxole)methyl
Figure imgf000053_0001
70mg of tris (8-ethoxycarbonylmethylthio-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole)methyl prepared according to Example 10 in 2mL methanol, 120 μL NaOH/H2O (0.019 g NaOH) were sonicated for 0.5 hr. A test sample (few drops) was diluted in H2O and
diethylether was added. No color appeared in the etheric phase. The hydrolysis mixture was evaporated to dryness yielding 53 mg of the title product.
Example 12
Tris(8-methoxycarbonylmethylthio-2,2,6,6,- tetramethylbenzo[1,2-d:4,5-d']bis(1.3)dioxole)methanol
Figure imgf000054_0001
11.38g of the benzobisdioxole of Example 5 (0.051 mole) was dissolved in 250 ml HPLC grade tetrahydrofuran under argon and cooled to -45°C in dry ice. 26.2 mL n-butyl lithium (0.055 mole) 2.1 M, was added from a syringe over about 1 minute. The temperature rose to -30°C, the cooling bath was removed and the mixture was left with stirring for 30 min. It was cooled to -30° and 1.75g S8 was added in one portion. The cooling bath was removed and after 35 minutes the temperature had risen to 0°C and all the sulphur had reacted. The mixture was cooled to -40° and 26.2 ml n-butyl lithium was added in one portion. The cooling bath was removed and a slightly colored suspension was formed just above 0°C. After 1 hour the temperature has risen to 15°C and a white suspension had formed, which was then cooled to -20°C and 2 mL diethylcarbonate was added. The mixture changed color from yellow through green to brown and the cooling bath was removed. After 1 hour the temperature had risen to -20°C, was again cooled to -10°C and 10 mL chloro-acetic acid methyl ether was added (exothermic). The cooling bath was removed and the mixture become homogeneous and very dark. After ½ hour the reaction mixture was poured into ice-water (500 ml) and 20 mL acetic acid added. 300 mL diethyl ether was added and the phases were separated. The water phase was
extracted with additional diethyl ether. The organic phase was stirred for 15 minutes with 10g K2CO3(anhydrous), decanted and washed with two lots of
200 mL H2O, dried over MgSO4 and evaporated. It was then separated on a "TLC-SiO2"-column with
CHCl3/CH2Cl2/diethylether. Fraction 3 (the diethyletherphase) contained 9.6g of the product (57%). It was crystallized from cyclohexane to yield 2.5g yellow crystalline powder.
1H NMR (CDCl3) δ : 1.485 (CH3, 36H); 3.65 (OCH3; 9H); 3.54
(CH2 6H)ppm
13C NMR: 25.25, 35.31, 52.23; 72.41; 96.43, 112.42,
117.71, 138.57; 141.22; 169.43.
MS M/e 1004 (70% M+); 988 (50% M+-16)
Example 13
Tris(8-methoxγcarbonylmethylthio-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole)methyl
Figure imgf000055_0001
1.0g of tris(8-methoxycarbonylmethylthio-2,2,6,6,- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole)methanol prepared according to Example 12 was dissolved in 150 mL THF (HPLC-grade) in a separating funnel. 1.0g CrCl2 (anhydrous) was added and a rapid stream of argon was passed through the solution. 2mL BF3/diethylether was added followed by diethylether after 10 min. Inorganic salts were extracted with H2O and 2M NaOH. The organic phase was filtered through a short column of SiO2 and exaporated to a brown-black oil. It was taken up in about 20 mL methanol and precipitated with a half volume of H2O, filtered and dried in vacuum to yield 0.78g of a black brown powder.
Example 14
Tris(8-mercapto-2,2,6.6-tetramethylbenzo[1,2-d:4.5- d:4,5-d']bis(1,3)dioxole)methanol
Figure imgf000056_0001
4.5g of the benzobisdioxole of Example 5 were dissolved (under N2) in about 100ml THF (HPLC-grade) and cooled to -78°C in dry-ice acetone bath, 85ml 2.5m butyllithium (BuLi) (in hexane) was added. A transient color change to red was observed with the first drops of BuLi, but almost immediately the color changed to very pale
yellow. The cooling-bath was removed. After 20 minutes the reaction mixture was temporarily coooled and 0.64g S8 (powder) was added in one portion. The cooling bath was removed and the color changed to light yellow as the particles of sulphur reacted just below 0°C. The
reaction mixture was left to stand with stirring at ambient temperature for an additional 30 minutes. After cooling to -78°C, 2.5ml BuLi 2.5m) was added. After stirring for 1 hour at room temperature a white, thin, slurry had formed. It was cooled to 78°C and 0.81 ml diethylcarbonate was added slowly. The mixture was left to stir at ambient temperature and the white suspension thickened and changed colour from yellow to brown. After 1.5 hours the reaction mixture was poured into 100 ml diethylether with about 30g NaH2PO4 saturated with N2. The phases were separated and the H2O-phase was extracted once with 100 ml diethylether. The combined organic phase was washed once with H2O with about 15g NaH2PO4, dried over MgSO4, filtered and evaporated in vacuo to yield 5.0 g voluminous semi solid. The product was taken up in approximately 20 ml diethylether and slowly precipitated with heptane, filtered off and dried in vac. to afford 4.55g yellow powder. It was purified on TLC-silica 60M (Merck). 1g material was dissolved in 20 ml diethylether applied to a flash column (400 ml SiO2 in diethylether-heptane (7:3) and eluted with diethylether until the first yellow band appeared, yielding 0.20 g of a nearly colorless yellow crystalline solid.
1H NMR (CDCl3) δ : 1.49 (CH3), 3.25 (SH), 4.10 (OH)
13C NMR δ : 25.48, 72.33, 93.55, 110.66, 117.51, 138.26 and 138.54.
Example 15
Tris(8-methoxycarbonyl-2.2.6,6-tetramethylbenzo[1,2-d:4, 5-d']bis(1,3)dioxole-4-yl)methanol
Figure imgf000057_0001
Tris (8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-bis (1,3)dioxole-4-yl)methanol (1.26 g, 1.62 mmol (prepared by reaction of tris(2,2,6,6-tetramethylbenzo[l,2-d:4,5- d']bis(1,3)dioxol-4-yl)methanol (See Example 44) with nBuLi in DMF) ) was dissolved in dry MeOH (80 mL). To this solution was added MnO2 (18.9 g, 217 mmol), NaCN (1.26 g, 25.7 mmol) and acetic acid (HOAc) (1.26 mL). The reaction mixture was heated to 65 °C for 40 h and was then filtered through Celite and the filtrate was evaporated to dryness. The residue was partitioned between CH2Cl2 (100 mL) and water (40 mL). The organic phase was washed with another 2x30 mL of water, the organic phase was separated, dried (Na2SO4) and the solvent was evaporated to yield a yellow to brown residue, which was further pumped to dryness. The residual foam was chromatographed on a column packed with SiO2, eluting with CH2Cl2/Et2O (4:1). The fractions containing pure product were collected and the solvent was evaporated to yield 1.1 g (77 %) of pure
tris (8-methoxycarbonyl-2,2,6,6- tetramethylbenzo
[1,2-d:4,5-d']bis(1,3)dioxole-4-yl)methanol.
1H NMR (CDCl3, 300 MHz) δ: 1.44 (CH3, 36H, s), 3.78 (0CH3, 9H, s), 4.24 (OH, 1H, s).
13C NMR (CDCl3, 75 MHz) δ : 163.4 (C=O), 140.5 139.2
(aromatic C-O), 118.3 (alifatic O-C-O), 115.0 (quart. C-subst. aromatic), 99.1 (quart. p-C-subst. aromatic), 72.6 (quart, alifatic C-OH), 51.9 (OCH3), 25.5 (CH3) .
MS (Thermospray) : M++23 (Na) 888, 889.
Example 16
Tris (8-methoxycarbonyl-2.2.6,6-tetramethylbenzo[1,2-d:4, 5-d']bis(1,3)dioxole-4-yl)methanol
Figure imgf000058_0001
The ester of Example 15, tris(8-methoxycarbonyl-2,2,6,6- tetramethyl-benzo[1,2-d:4,5-d']bis (1,3) dioxole-4-yl) methanol (0.30 g, 0.34 mmol) was dissolved in MeOH (10 mL), and NaOH (0.041 g, 1.02 mmol) dissolved in MeOH/H2O (2.32 M NaOH solution) was added until pH reached 7. In total 0.44 mL of the basic solution was used. The MeOH was evaporated in vacuum due to solubility problems and THF (3.5 mL) was added. The reaction mixture cleared with this treatment. After 12 h the reaction mixture was turbid and a precipitate had formed. This
precipitate dissolved with the addition of water (10 mL). The THF was evaporated under reduced pressure and water (10 mL) was added and the aqueous phase was extracted with ether (10 mL). The organic phase was separated and the aqueous phase was acidified (pH 3.5) with 2M HCl. A yellow precipitate was formed and the aqueous phase was extracted with ether (3x20 mL) and CH2Cl2 (30 mL). The organic phases were collected, dried (Na2SO4) and the solvent was evaporated to yield the product tris (8-carboxy-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d'] bis(1,3)dioxole-4-yl)methanol as a slightly tanned residue (0.25 g, 87%). The product contained a small impurity (appreciated to about 2% at the same extinction) according to HPLC (C18, ion pair (tetrabutyl-ammonium acetate) chromatography, CH3CN:H2O) with UV (254 nm) detection.
1H NMR (D2O, 300 MHz) δ : 1.26 (CH3, 36H, s).
13C NMR (D2O, 300 MHz) δ : 169.6 (C=O), 138.9 138.8
(aromatic C-O), 118.2 (alifatic O-C-O), 111.9 (quart. C-subst. aromatic), 105.9 (quart. p-C-subst. aromatic), 72.1 (quart, alifatic C-OH), 24.6 (CH3).
IR (KBr, cm-1) : 3450 (OH-stretching broad), 1670 (C=O stretching s). Example 17
Tris (2 , 2 , 6 , 6-tetramethyl-benzo [ 1 , 2-d : 4 , 5-d ' ] bis ( 1 , 3 ) - dioxole-4-yl) methane
Figure imgf000060_0001
Trimethylsilyl chloride (68.1 mL, 539 mmol) and sodium iodide (81.0 g, 540 mmol) were mixed in acetonitrile (500 mL), and tris (2,2,6,6-tetramethylbenzo[1,2-d:
4,5-d']-bis(1,3)dioxole-4-yl)methanol (62.4 g, 90.2 mmol, Example 44) and was added with efficient stirring at room temperature. The reaction flask was surrounded with aluminum foil to prevent light to enter. After stirring for 24 h, the reaction mixture was poured into 2 L of a Na2S2O3 solution (70g of Na2S2O3 x 5 H2O in 2L of water). A yellow precipitate was formed, filtered off and was left to dry on the. filter under suction (2 h). The product was triturated with i-PrOH twice, filtered and washed with cold diisopropyl ether (15 mL) to yield 54.1 g (88%) of the product
tris(2,2,6,6-tetramethyl-benzo[1,2-d:4,5-d']bis
(1,3)dioxole-4-yl)methane.
1H NMR (CDCl3, 300 MHz) 5: 1.47 (CH3, 36H, s), 5.42 (CH, 1H, q, J=0.37 Hz), 6.20 (aromatic H, 3H, d, J=0.37 Hz). 13C NMR (CDCl3, 75 MHz) δ : 139.5 139.8 (aromatic C-O), 116.7 (alifatic O-C-O), 107.6 (quart, aromatic), 90.7 (aromatic C-H), 30.7 (C-H), 25.3 (CH3).
S (El): M+-16 (676, 100%), M+-15 (678, 40%), 338.5 (70%). Example 18
Tris(8-carboxyl-2,2,6,6-tetramethyl-benzo[1,2-d:4,5-d']- bis(1,3)dioxole-4-yl)methane and bis(8-carboxyl-2,2,6,6- tetramethyl-benzo [1,2-d:4,5-d']-bis(1,3)dioxole-4-yl)- (2,2,6,6-tetramethyl-benzo[1,2-d:4,5-d']-bis(1,3)dioxole -4-yl)methane
Figure imgf000061_0001
Tris (2,2,6,6-tetramethyl-benzo[1,2-d:4,5-d']bis (1,3)- dioxole-4-yl)methane (1.65 g, 0.244 mmol. Example 17) was dissolved in dry diethyl ether (150 mL). n-BuLi (5.86 mL, 2.5 M in toluene, 1.465 mmol) was added in two portions (2/3 and 1/3), and the temperature of the mixture was raised to 40 °C (the ether refluxed). After maintaining this temp, for 15-20 min, the mixture was poured onto CO2(s), and left overnight. Water (90 mL) was added to dissolve the solid residue. The aqueous phase was washed with ether (50 mL). The aqueous phase was then acidified with 2M HCl to pH 1-2, and the tan coloured precipitate which formed was filtered off, washed with of water (7 mL) and dried. RP-TLC (SiO2 RP18: glassplates) in MeOH:H2O (4:1) showed mainly two spots, (diacid and triacid with Rf=0.51 and 0.81, respectively). The product tris(8-carboxyl- 2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-bis (1,3)
dioxole-4-yl)methane was not separated from the mixture (1.43 + 0.10 = 1.53 g (raw material of acids)) but was used without further purification in esterification or amidation reactions. The products of these reactions can be separated by chromatography.
Example 19
Tris(8-methoxycarbonyl-2,2,6.6-tetramethyl-benzo[1,2-d: 4,5- d']-bis(1,3)dioxole-4-yl)methane and bis(8- methoxycarbonyl-2,2,6,6-tetramethyl-benzo[1,2-d:4,5- d']-bis(1,3)dioxole-4-yl)-(2,2,6,6-tetramethyl-benzo
[1,2-d:4,5-d']-bis(1,3)dioxole-4-yl)methane
Figure imgf000062_0001
A mixture of the acids tris(8-carboxy-2,2,6,6- tetramethyl- benzo[1,2-d:4,5-d']-bis(1,3)dioxole-4-yl) methane and bis (8-carboxy-2,2,6,6-tetramethyl-benzo[1,2- d:4,5-d']-bis(1,3)-dioxole-4-yl)-(2,2,6,6- tetramethyl-benzo[1,2-d:4,5-d']-bis(1,3)dioxole-4-yl)met hane (3.0 g, 0.36 mmol, Example 18) were dissolved in dry DMF (70 mL) and Cs2CO3 (9.8 g, 30 mmol) was added. The mixture was heated to 70 °C for 1.5 h and was then cooled to room temperature and CH3I (6.74 mL, 108 mmol) was added with efficient stirring at 35 °C for 40 h, and the reaction mixture was filtered and the solvent (DMF) evaporated at reduced pressure. The residue was
partitioned between CH2Cl2 (200 mL) and water (70 mL). The organic phase was extracted with another portion of water (70 mL). The aqueous phases were extracted back with of CH2Cl2 (70 mL). The organic phases were
extracted with a solution of saturated NaHCO3, dried (Na2SO4) and the solvent evaporated, leaving a light brown crystalline residue (3.05 g), which was
chromatographed on a semi preparative reversed phase column (30 cm i.d., packed with 10μm Kromasil, C8), eluting with CN:H2O (75:25).
Yield of tris (8-methoxycarbonyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-bis(1,3)dioxole-4-yl)methane 1.70 g (55%).
1H NMR (CDCl3, 300 MHZ) δ : 1.53 (s, CH3, 36H, 3.87 (s, OCH3, 9H), 5.42 (s, CH, 1H).
13C NMR (CDCl3, 75 MHz) δ : 163.8 (C = 0) 140.1, 140.0 (aromatic C-O), 118.4 (aliphatic O-C-O), 110.3 (quart, arom. C), 98.5 (p-substituted quart, aromatic), 51.8 (OCH3), 31.3 (C-H), 25.5 (CH3).
MS (Thermospray: M++23 (Na) 873.
Yield of bis(8-methoxycarbonyl-2,2,6,6,-tetramethyl- benzo[1,2-d:4,5-d']-bis(1,3)dioxole-4-yl)-(2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']-bis(1,3)dioxole-4- yl)methane = 0.60 g (20%).
1H NMR (CDCl3, 300 MHz) δ : 1.47 (s, CH3, 12H, 1.53 (s, CH3, 24H), 3.87 (s, OCH3, 6H) 5.42 (s, CH, 1H), 6.21 (s, aromatic H, 1H).
Ms (Thermospray): M++23 (Na) 815.
Example 20
Tris(8-methoxycarbonyl-2,2,6,6-tetramethylbenzo[ 1,2-d:4, 5-d']-bisd,3)-dioxole-4-yl)methane and bis(8-methoxy- carbonyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']- bis(1,3)-dioxole-4-yl)-(2,2,6,6-tetramethylbenzo[1,2-d: 4,5-d']-bis(1,3)-dioxole-4-yl)methane
e
Figure imgf000063_0001
Tris(2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-bis(1,3)- dioxole-4-yl)methane (3.00 g, 4.40 -mmol (Example 17)) was dissolved in ether (100 mL) and n-BuLi (10.8 mL, 27.0 mmol) was added. The mixture was refluxed for 20 min, and after cooling to room temperature
dimethylcarbonate (5.60 mL, 67.0 mmol) was added. The mixture turned dark brown, and the reaction mixture was stirred over night at room temperature. Water (40 mL) was added and the phases were separated. The aqueous phase was extracted with another portion of ether (50 mL). The organic phases were pooled, dried and
filtered, and the solvent evaporated leaving a semisolid brown residue. This was chromatographed on a SiO2 column (0.040-0.063 mm), eluting first with
petroleum-ether/ether (1:4) and then with ethyl acetate (EtOAc). The diester bis (8- methoxycarbonyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']- bis(1,3) dioxole-4-yl)-(2-2,6-6-tetramethylbenzo
[1,2-d:4,5-d']-bis(1,3)dioxole-4-yl)methane (1.27 g, 33.1%) and the triester tris(8-methoxycarbonyl-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']-bis(1,3)dioxole-4-yl) methane (0.37 g, 11.0 %) were isolated. For
spectroscopic data see Expmple 19.
Example 21
Tris(8-ethoxycarbonyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5 -d']-bis(1,3)dioxole-4-yl)methane
Figure imgf000065_0001
Tris (2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-bis(1,3)- dioxole-4-yl)methane (1.35 g, 2.0 mmol (Example 17)) was dissolved in dry THF (400 mL) under N2, and the temp was lowered to -40 °C and n-BuLi (4.86 mL, 12.2 mmol) was added and the temperature was allowed to rise gradually to 0°C. The mixture was cooled to -60 °C, and a
solution of ethylchloroformate (4.0, 36.7 mmol) in THF (50 mL) was added. The reaction mixture was left overnight and worked up as described under Example 20 above. The chromatography gave (0.41 g, 24%) of
tris(8-ethoxycarbonyl-2,2,6,6-tetramethylbenzo
[1,2-d:4,5-d']-bis(1,3)dioxole-4-yl)methane.
1H NMR (CDCl3, 300 MHz) δ : 1.35 (t, CH3, 9H), 1.52 (s, CH3, 36H), 4.34 (q, CH2, 6H), 5.41 (s, CH, 1H).
13C NMR (CDCl3, 75 MHz) δ : 163.4 (C = O), 140.1, 140.0 (aromatic C-O), 118.3 (aliphatic O-C-O), 110.2 (quart, aromatic C), 98.8 (quart. C-substituted aromatic), 60.7 (CH2), 31.3 (C-H), 25.5 (CH3), 14.2 (CH3).
Example 22
Tris(8-methoxycarbonyl-2.2.6,6-tetramethylbenzo[1,2-d:4, 5-d']bis(1,3)dioxole-4-yl)methanol
Figure imgf000066_0001
Acetic anhydride (AcO)2O (30 mL) was added to pyridine (35 mL). Tris(8-hydroxymethyl-2,2,6,6-tetramethylbenzo [1,2-d:4,5-d']-bis(1,3)dioxole-4-yl)methanol (0.400 g, 0.51 mmol (Example 33) was added under stirring, which was maintained at room temperature for two days.
Pyridine and excess anhydride were evaporated (oil-pump) at 40-50°C to a syrup, which was taken up in 70 mL of CH2Cl2. The organic phase was washed with water (30 mL), 0.5 M HCl (40 mL), water (50 mL) and NaHCO3 (saturated, 30 mL). The organic phase was separated, dried and the solvent was evaporated, leaving a syrup, which
crystallized after standing for ca 1 h and the product tris(8- methylcarbonyloxymethyl-2,2,6,6-tetramethyl-benzo[1,2-d: 4,5-d']-bis(1,3)dioxole-4-yl)methanol was isolated
(0.460 g, 100%).
1H NMR (300 MHz, CDCl3) δ : 1.48 (s. CH3, 36H), 2.05 (s, CH3CO, 9H), 5.25 (s, CH2, 6H), 4.19 (s, OH, 1H)
Ms (Thermospray) : M++23 (Na) 931.
Example 23
Tris(8-formyl-2.2.6,6-tetramethγlbenzo[1,2-d:4,5-d']-bis (1,3)dioxole-4-yl)methane and bis(8-formyl-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']-bis(1,3)dioxole-4-yl)- (2,2,6,6-tetramethylbenzo[1,2-d:4.5-d']-bis(1.3)dioxole- 4-yl)methane
Figure imgf000067_0001
Tris(2,2,6,6-tetramethyl-benzo[1,2-d:4,5-d']-bis(1,3)-di oxole-4-yl) methane (2.0 g, 3.5 mmol (Example 17)) was dissolved in dry ether (100 mL) at room temperature.
Under an inert atmosphere n-butyl lithium (6 mL) was added, and the reaction mixture was heated to reflux (15 min). At this temperature another portion of n-butyl lithium (2 mL) was added and the heating was
interrupted. After 5 min DMF (2.7 mL, 35 mmol) was carefully added and the reaction mixture was left stirring at room temperature overnight. Water (100 mL) and glacial acetic acid (1.5 mL) were added to the reaction mixture and the phases were separated. The aqueous phase was extracted with water (2x50 mL), and dried over a mixture of Na2SO4 and K2CO3. After filtering through a bed of SiO2 the solvent was evaporated leaving a yellow to red crystalline residue, which was
chromatographed on a column of SiO2 with CH2Cl2/ether (4:1) as eluent, yielding pure dialdehyde
bis (8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:
4 ,5-d']-bis(1,3)-dioxol-4-yl)-(2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']-bis(1,3)-dioxol-4-yl)meth ane 0.610 g (20%) and trialdehyde tris(8-formyl- 2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-bis(1,3)- dioxol-4-yl)methane 1.23 g (51%).
Bis (8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']- bis(1,3)di3xole-4-yl)-(2,2,6,6-tetramethylbenzo
[1,2-d:4,5-d']-bis(1,3)dioxol-4-yl)methane: 1H NMR (300 MHz CDCl3) δ : 1.50 (s, CH3, 12H) 1.55 (s, CH3
24H) 5.42 (s, C-H, 1H) 6.24 (s, aromatic H, 1H) 10.06
(s, CHO, 2H).
13C NMR (75 MHZ, CDCl3) d: 185.59, 140.19, 140.15, 139.67,
139.59, 119.46, 117.15, 113.10, 105.36, 105.21, 91.40,
31.43, 25.52, 25.36.
MS (Thermospray): M++23 (Na) 770.
Tris(8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-bis
(1,3)-dioxole-4-yl)methane:
1H NMR (300 MHz, CDCl3) δ : 1.56 (s. CH3, 36H) 5.44 (s.
C-H, 1H) 10.07 (s. CHO, 3H).
13C NMR (75 MHz, CDCl3) δ: 185.5 (C=O) 140.3 140.1 (arom
C-O) 119.7 (alif. O-C-O) 111.9 (quart, arom C) 105.4
(p-sub. quart, arom C) 31.7 (C-H) 25.6 (CH3) .
IR (KBr, cm-1): 1700 (s. C=O) 2980 (m, C-H str) 1040 (s.
Ar-O-C).
MS (Thermospray): M++23 (Na) 783.0.
Example 24
Tris(8-formyl-2.2,6.6-tetramethylbenzo[1.2-d:4,5-d']-bis (1,3)-dioxole-4-yl)methyl
Figure imgf000068_0001
Tris(8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-bis (1,3)-dioxole-4-yl)methane (140 mg, 0.18 mmol. Example 23) was dissolved in a mixture of dry DMSO (15 mL) and of dry ether (50 mL). NaH (5 mg, 0.19 mmol) and t-BuOK (catalytic amount) were added under N2-atmosphere. The color of the solution changed from yellow to deep green-blue. After 4h of stirring at room temperature under N2 I2 (46 mg, 0.18 mmol) was added, and after 2 min the reaction mixture was poured into a saturated
solution of Na2S2O3 (100 mL). The organic phase was separated, dried (Na2SO4) and the solvent was evaporated leaving a black crystalline residue weighing 0.120 g (88
%).
MS (Thermospray): M++23 (Na) 782.0.
Radical content (NMR method) >50%.
ESR: 4 lines (internal ratio 1:3:3:1) with line widths of ca 70 mG.
Overhauser enhancements: 9mW: 13 18mW: 25 5mW: 152 5mW:
254 after dilution to 10 mM.
Example 25
Tris(8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-bis (1,3)dioxol-4-yl)methyl
Figure imgf000069_0001
Tris(8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-bis (1,3)dioxole-4-yl)methanol (200 mg, 0.20 mmol) was dissolved in of dry THF (15 mL) and SOCl2 (80 mg, 0.20 mmol) was added. After stirring at room temperature for 2 h the solvent was evaporated (<70 °C) and the residue was pumped dry overnight. The orange product
tris(8-formyl-2,2,6,6-tetramethyl-benzo[1,2-d:4,5-d']- bis(1,3)-dioxol-4-yl)methylchloride was dissolvee in of dry THF (15 mL) and BCl3 (0.26 mL, IM in CH2Cl2) was added at room temperature and the solution immediately turned black. After 0.5 h of stirring under
N2-atmosphere was added; first SnCl2 (0.15 g, 0.80 mmol) and then Zn(Hg), (0.15 g, 2.20 mmol) (prepared by treating 120 g zinc powder with a mixture of 12g HgCl2, 6 mL cone. HCl and 150 mL of water for 5 min. and decanting off the liquid). Stirring was maintained for 0.5 h. The reaction mixture was applied to a column (1 cm diameter) consisting of 3 cm of SiO2 at the bottom and 15 cm of Chelex 100 on top. Elution was performed with dry THF under N2-atmosphere. The eluent was evaporated to dryness, leaving a brown-black crystalline residue (0.19 g, 100%).
Radical content was ca 27% according to HPLC (ion pair, tetrabutylammoniumacetate, SiO2 Cl8, CH3CN/H2O (75:25)). ESR spectrum of 4 peaks (int ratio 1:3:3:1) with 70 mG linewidth.
Example 26
Tris(8-methoxycarbonyl-2,2,6,6-tetramethylbenzo[1,2-d:4, 5-d']-bis(1.3)dioxole-4-yl)methyl
Figure imgf000070_0001
Tris(8-methoxycarbonyl-2,2,6,6-tetramethylbenzo[1,2-d:4, 5-d']-bis(1,3)dioxol-4-yl)methanol (240 mg. Example 15) was dissolved in of dry THF (25 mL) and SOCl2 (38 mg, 23 'L) was added at room temperature. Stirring was maintained for 2.5 h. The solvent of the reaction mixture was then evaporated to dryness (<70 °C). After pump drying over night tris(8-methoxycarbonyl-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']-bis(1,3)dioxole-4-yl) methylchloride was dissolved in of dry THF (25 mL) and, in turn SnCl2 (0.10 g, 0.53 mmol) and then Zn(Hg) (see Example 25) (0.10 g, 1.52 mmol) were added under N2. The solution turned black and was filtered through a column (1 cm diameter) of 15 cm Chelex 100 (top) and 3 cm of SiO2 (bottom), under N2 with THF as eluent. The solvent was evaporated leaving a black crystalline residue
(0.20 g).
ESR spectrum showed 10 lines with linewidths = 48 mG. A radical content of ca 5% was estimated by ESR.
At 75 mW, the Overhauser enhancement was 80.
Example 27
Tris(8-ethoxycarbonylmethylthio-2,2,6,6-tetramethylbenzo [1,2- d:4.5-d']-bis(1.3)dioxole-4-yl) methanol
Figure imgf000071_0001
2,2,6,6-Tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole (2.22 g, 10 mmol (Example 5)) was dissolved in dry tetrahydrofuran (dried using sodium benzophenone ketyl) and cooled to -78 °C under argon. n-Butyllithium (4.25 mL, 2.5 M in hexane, 10.6 mmol) was added. The cooling bath was removed 35 minutes later and the mixture stirred for 40 minutes, when dry sulfur (S8, 0.320 g, 1.25 mmol) was added in one portion. The sulfur had dissolved one hour and fifteen minutes later. The reaction mixture was then recooled to -78 °C and
n-butyllithium (4.25 mL, 10.6 mmol) was added. The dry ice/acetone bath was exchanged with a water/ice bath. The new cooling bath was removed after one hour and forty five minutes. Cold (-78 °C) diethylcarbonate (0.363 mL, 3 mmol) in THF (10 mL) was cannulated into the reaction mixture over a period of 10 minutes. The resulting mixture was kept at (-70) - (-78) °C for two hours, followed by a period of one hour and thirty minutes at approximately 0 °C (ice/water bath). The mixture was then stirred till noon the following day without addition of ice, at which time the temperature inside the reaction flask was +16 °C. The mixture was then stirred without external cooling for three more hours, poured into a half saturated sodium
dihydrogenphosphate buffer (100 mL) and extracted with diethylether (4x100 mL). The organic phase was washed with the same buffer (50 mL) and dried (MgSO4). This yielded 2.93 g of product, which by 1H NMR (300 MHz, CDCl3) was shown to contain approximately 50% of
tris(8-mercapto-
2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-bis
(1,3)dioxol-4-yl)methanol. The was used immediately in the next step.
Tris(8-mercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-b is (1,3)dioxol-4-yl)methanol (2.93 g, 50%, 1.86 mmol) was dissolved in dry DMF (100 mL) under argon. K2CO3 (4 g) was added and the solution cooled to the freezing point. Ethylchloroacetate (5 mL, 46.7 mmol, Janssen 11822.85) was added, and the reaction mixture was stirred at room temperature overnight. Most of the DMF and excess ethylchloroacetate were removed by high vacuum distillation at 30-40 °C. The residue was mixed with saturated sodium dihydrogenphosphate buffer (100 mL) and extracted with diethyl ether (4x150 mL). The etheral phase was washed with phosphate buffer (2x50 mL) and water (50 mL), dried (MgSO4) and evaporated.
Purification was achieved through two flash
chromatography (E. Merck 0.040-0.063 mm SiO2)
separations with n-heptane: ethyl acetate (1:1),
followed by straight phase (E.Merck 20-45 mm CH2Cl2:EtOAc 9:1) and reversed phase (Prep-pak Cl8, MeOH:H2O, 8:2, 15% CH2Cl2 in application volume) HPLC chromatography, and finally recrystallization from diisopropyl ether. Yield (1.57 g, 15%, 1.5 mmol).
UV (maxima/minima): 220 (p), 249 (v), 259 (p), 297 (v), 344 (p). Other spectroscopic data; see Example 9.
Example 28
Tris (8-ethoxycarbonylmethylthio-2 , 2 , 6 , 6 , - tetramethylbenzo ( [1 , 2-d: 4.5-d ' ] -bis ( 1.3 )
dioxole-4-yl) methyl
Figure imgf000073_0001
Tris(8-ethoxycarbonylmethylthio-2,2,6,6,- tetramethylbenzo( [1,2-d:4,5-d']-bis(1,3)dioxole-4-yl) methanol (2.00 g 1.91 mmol) (prepared as described in Example 27) was dissolved in dry (sodium
benzophenone ketyl) degassed (Ar) THF (1.0 L) in a separatory funnel (2.0 L). A rapid stream of argon was bubbled through the solution. Borontrifluoroethyl etherate (2.88 mL 48% Fluka 15720) was added with a syringe. The clear solution turned immediately dark blue, indicating formation of the corresponding cation. Tin(II) chloride (2.90 g 15.3 mmol E.Merck 818150) was added. The color changed from blue to colorless to geen in a couple of minutes, and the resulting mixture was bubbled with argon for 10 minutes, when Zinc (2.50 g, 38.2 mmol Janssen 19.834.46) (activated by treatment with 1 M hydrochloric acid followed by water, ethanol and diethylether washings and high vacum drying) was added. The argon bubbling was continued for another 20 minutes, when more zinc (2.5 g) was added. 45 Minutes later the last amount of zinc (3.0 g) was added, followed by borontrifluoroethyl etherate (1.44 mL). The reaction was continously monitored by HPLC. The
substrate and the radical separated on an analytical RP18 column (Nucleosil 5 mm) with acetonitrile:water (75:25) containing the ion pair tetrabutylammonium acetate (5 mM) (pH 6.7). The detector system consisted of a diode array UV detector (Varian 9065 polychrome). The radical was distinguished from the substrate by the UV spectra (see below). The reaction was stopped when the radical content reached a maximum (~90% by UV, not considering different extinction coefficients). The volume of the reaction mixture was reduced to about 700 mL during the reaction period. The reaction mixture was diluted with dry (sodium benzophenone ketyl)
diethylether (1.0 L) and extracted with dry, oxygen free sodium hydroxide (2x100 mL, 2 M, 0 °C, He). The organic phase was filtered through a SiO2 column (40 cm long, I.D. 5 cm, E. Merck 9385 0.0040-0.063 mm). The column was preconditioned with dry oxygen free diethylether before the filtration. The last portion of the radical was eluted with pure diethylether (sodium benzophenone ketyl, Ar). The radical was obtained as black/green crystals after evaporation under argon. Yield (1.87 g, 1.814 mmol, 95%). MS (Thermospray) : M++23 (Na) 1052 .
UV (Absorbt ion maxima/minima) : 195 (p) , 229 (sh) , 302 (v) ,
339 (p) , 348 (v) .
ESR (THF): 7 lines, lw 30 mG, aH 60 mG.
Overhauser (THF less than 1 mM cone., 200 G) : freq.
548.9 MHz, 9 mW 78 enhancement, 18 mW 116 enhancement.
Example 29
Tris(2,2,6,6-tetramethyl sodium-8-carboxylatomethylthiobenzo[1,2-d:4,5-d']-bis(1,3)dioxole- 4-yl)methyl
Figure imgf000075_0001
Tris(8-ethoxycarbonylmethylthio-2,2,6,6,- tetramethylbenzo-[1,2-d:4,5-d']-bis(1,3)dioxole-4-yl) methyl (1.97 g, 1.91 mmol 90 % pure) was dissolved in a degassed (helium followed by argon) mixture of dioxane (Lab Scan C2512 HPLC quality) and water (200 mL (3:1)). Sodium hydroxide (4.3 mL, 2 M, 8.58 mmol, He, Ar, 0 °C) was added and the hydrolysis performed in a ultrasound bath (Sonorex RK 2555). The reaction was followed by HPLC, RP18 column (Nucleosil 5 mm) with
acetonitrile:water (75:25) containing tetrabutylammonium acetate (5 mM, pH 6.7). The detector system consisted of a diode array UV detector - Varian 9065 polychrome). During the reaction the diester- and monoester radicals were observed as well as the tricarboxylic acid salts. The reaction mixture was frozen when the HPLC analysis showed pure tricarboxylic acid sodium salt (mixture of radical and carbinol) and subjected to freeze drying.
Yield (2.07 g, 100% 1.90 mmol) of a black/brown, fluffy material, containing excess NaOH.
Radical content: 50% (NMR - Evans method).
ESR (H2O 0.3 mM, 200 G) : 7 lines, Lw 27 mG, a 60 mG,
200G, Freq. 548.9 MHz.
Overhauser: (H2O 0.3mM, 200 G) : Freq. 548.9 MHz, 9 mW 63 enhancement, 18 mW 81 enhancement.
Example 30
8-Mercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-bis (1,3)dioxole
Figure imgf000076_0001
2,2,6,6-Tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole (30.0 g, 135 mmol (Example 5)) was dissolved in dry (sodium benzophenoneketyl) diethylether (250 mL), and heated to reflux. n-Butyllithium (50 mL, 2.68 M in toluene, 134 mmol) was added and the reflux continued one hour. The flask was cooled to -78 °C and sulfur (4.297 g, 134 mmol) added. The cooling bath was
exchanged with an ice/water cooling bath and the
reaction mixture was stirred for one hour before
alkaline water was added (150 mL, 1 M, degassed with argon) followed by vigorous stirring in ten minutes. The phases were separated and the water phase was washed with diethylether (100 mL, degassed with argon). The water phase was acidified with HCl (5 M). The
precipitated crystals were taken up in diethylether (degassed argon), dried (MgSO4) and evaporated to
dryness. The pure crystals are stable for weeks under argon in the freezer. Yield: 24.86 g (72.5 %).
1H NMR (CDCl3, 300 MHz) δ : 1.65, 3.28, 6.13.
13C NMR (CDCl3, 75 MHz) δ : 139.87, 138.33, 118.31, 94.99, 90.23, 25.54.
Example 31
Tris(8-mercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']- bis(1.3)dioxole-4-yl)methanol
Figure imgf000077_0001
8-Mercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-bis(1, 3)dioxole (24.9 g, 97.9 mmol (Example 30)) was dissolved in dry diethylether (200 mL) in a three necked
round-bottomed flask, equipped with a sintered glass filter (no. 4) at one of the outlets. The reaction mixture was cooled to (-78) °C and n-butyllithium (36.5 mL, 97.9 mmol, in toluene) was added. The dry
ice/acetone bath was exchanged with a water/ice bath. The new cooling bath was removed after one hour. The solvent, and most of the soluble impurities were removed from the lithium salt by filtration through the sintered glass filter. The whole filtration took about ten minutes. The salt was washed to the bottom of the flask with dry diethylether (30 mL). Tetrahydrofuran (250 mL, sodium benzophenone ketyl dried) was added and the solution was cooled to (-78 °C). n-Butyl lithium (36.5 mL, 97.9 mmol, in toluene) was added. After a period of ten minutes, the temperature was gradually raised to 0 °C with a water/ice bath. The mixture was stirred with this cooling for one hour and twenty minutes, followed by a period of thirty minutes at room temperature.
After recooling to (-78) °C, diethylcarbonate (3.63 mL, 30 mmol) in tetrahydrofuran (20 mL) was added to the reaction mixture over a period of one minute. The temperature was raised gradually with the help of a water/ice bath. The reaction was followed by taking samples (quench of small samples in sodium
dihydrogenphosphate buffer under argon, evaporating organic phase) and running 1H NMR. The trimerisation was complete after four hours. The mixture was quenched with sodium dihydrogenphosphate buffer (saturated, 130 mL), stirred twenty minutes and the phases were
separated. The water phase was extracted with
diethylether (50 mL, argon) and the organic phases were combined, washed (sodium dihydrogen phosphate buffer, 30 mL), dried (MgSO4, 30 min) and evaporated to dryness. Diethylether (dry, argon) was added to the brown oil to induce the crystallization. Upon the dissolution of the oil the title compound crystallized as porous yellow crystals. The product was isolated by filtration.
Yield: 10.0 g (12.7 mmol, 39 %).
1H NMR (CDCl3, 300 MHz) δ: 1.49, 3.25, 4.10.
13C NMR (CDCl3, 75 MHz) δ: 138.54, 138.26, 117.51,
110.16, 93.55, 72.33, 25.53.
MS (Thermospray): M++23 (Na) 811.
Crystallization of the mother liquor gave (1H NMR) 0.8 g of dimeric (ketone) product. (See Example 51). Example 32
Tris(8-ethoxycarbonγlmethylthio-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-bis(1,3)dioxole-4-yl)methanol
The title compound was made with pure tris (8-mercapto- 2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-bis(1,3)dioxole- 4-yl)methanol (from Example 31) (2.10 g 2.67 mmol) and ethylchloroacetate (16.0 mmol), using a procedure analogous to that described in Example 27. Yield 1.93 g (98%).
1H NMR (CDCl3, 300 MHz) δ: 4.12, 3.54, 1.51, 1.24.
13C NMR (CDCl3, 75 MHz) δ: 169.00, 141.22, 138.64,
117.75, 112.40, 96.62, 72.48, 61.20, 35.47, 25.42,
14.08.
Example 33
Tris(8-hydroxymethyl-2,2,6,6-tetramethylbenzo[1,2-d:4.5- d']-bis(1,3)-dioxol-4-yl)methanol
Figure imgf000079_0002
Tris(2,2,6,6-tetramethylbenzo([1,2-d:4,5-d']-bis(1,3)- dioxol-4-yl)methanol (6.35 g, 9.38 mmol) was dissolved in dry diethylether (200 mL) under argon and cooled to 0°C. n-Butyllithium (22.5 mL, 56.30.10-3 mol) was added and the temperature was increased to induce reflux. The reaction mixture was refluxed for 25 minutes. After cooling to 0 °C, dry formaldehyde (gas, formed by
sublimation) (4.0 g, 133 mmol) was added and the
resulting mixture was stirred over night while the
temperature gradually was increased to room temperature. After quenching with sodium dihydrogenphosphate buffer (200 mL; saturated), extraction with diethylether (5x250 mL), drying (MgSO4) and evaporation, the product was isolated by column chromatography (E. Merck 0.040-0.063 mm SiO2, 6.27 cm, CH2Cl2:EtOAc 3:2 (2.0 L), CH2Cl2:EtOAc (1:1) (2.0 L), CH2Cl2:EtOAc (2:3) (2.0 L). Yield 0.239 g (0.305 mmol (3.3 %) .
1H NMR (300 MHz, CDCl3) δ: 4.59 (s, CH2, 6H), 1.23 (s, CH3, 36H), OH not seen.
13C NMR (75 MHz, CDCl3) δ: 138.70, 139.38, 117.23,
105.88, 72.51, 56.66, 25.48.
Example 34
Tris(8-methoxycarbonyl-2.2.6,6-tetramethylbenzo[1,2-d:4,5- d' ](1,3)dioxole-4-yl)methanol
Figure imgf000080_0001
Tris (8-hydroxymethyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d'](1,3)dioxole-4-yl) methanol (0.105 g, 0.134 mmol
(Example 33)) and a catalytic amount of
tetrabutylammoniumhydrogen sulfate were added to a
preformed solution of dimethylsulfate (0.2 mL) and
sodium hydroxide (50%, 1.0 mL) in CH2Cl2 (2 mL). The resulting solution was stirred at ambient temperature for 48 hours. The mixture was evaporated and the
resulting oil chromatographed on silica
(CH2Cl2: diethylether (5:1)). The major product was not completely pure according to TLC, but upon dissolution in CDCl3 the impurities did not dissolve. Evaporation of the filtered solution yielded 94 mg (0.114 mmol, 85 %) of pure title compound.
1H NMR (300 MHz, CDCl3) δ: 4.40 (s, CH2, 6H), 3.30 (s, CH3, 9H), 1.47 (s, CH3, 36H), OH not seen.
13C NMR (75 MHz, CDCl3) δ: 139.64, 138.58, 116.97,
112.37, 102.65, 72.61, 63.49, 57.16, 25.46.
Example 35
Tris(8-methoxycarbonyl-2.2.6,6-tetramethylbenzo[1,2-d :4,5- 5-d']bis(1,3)dioxole-4-yl)methyl
Figure imgf000081_0001
Tris(8-methoxymethyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)dioxole-4-yl)methanol ( 94.0 mg, 0.114 mmol (Example 34)) and thionyl chloride (40 mL, 0.57 mmol) were stirred in tetrahydrofuran (2 mL) (sodium
benzophenone ketyl dried) for 45 minutes and evaporated. The residue was dissolved in fresh tetrahydrofuran (10 mL) and boron trichloride (330 mL, 1 M in CH2Cl2). The color of the solution turned light brown.
Tin(II) chloride (127 mg, 0.986 mmol) was added 10 minutes after the boron compound, and zinc (187 mg, 2.85 mmol) was added after another 15 minutes. One hour and fifteen minutes later the reaction mixture was green. The solution was evaporated, and subsequently filtered through a SiO2 column with tetrahydrofuran as the eluent. The residue (80 mg, 0.099 mmol, 87% (containing some radical precur) was dissolved in tetrahydrofuran and the radical characterized by ESR and Overhauser
enhancements:
ESR (200 G) : Linewidth 1.5 G (70 overlapping lines).
Overhauser enhancements (548.9 MHz, 200 G) : 5 W 60 enhancements.
Example 36
Tris (8-hydroxyethylthio-2 , 2 , 6 , 6-tetramethylbenzo [ 1 , 2-d: 4 , 5- d ' ] -bis (1 , 3) dioxole-4-yl) methanol
Figure imgf000082_0001
H LiAlH4 (15.2 mg, 0.40 mmol) was added to a solution of tris(8-ethoxycarbonylmethylthio-2,2,6,6-tetramethylbenzo -[1,2-d:4,5-d']-bis(1,3)dioxole-4-yl) methanol (10.5 mg 0.10 mmol (Example 27)) in diethyl ether (10 mL) under nitrogen at 20 °C. The reaction was followed by HPLC (reversed phase Cl8, acetonitrile:water (3:1), 5 mM tetrabutylammonium acetate). The mixture was quenched with ethylacetate when no more substrate was seen by HPLC. Dilute sulfuric acid was then added until pH 6-7. The ether phase was separated, and the water phase was extracted with diethyl ether. The combined etheric phases were dried (MgSO4) and evaporated, yielding 0.0901 g (97.8 %, 0.0978 mmol) of a yellowish oil, which gradually crystallized upon standing.
1H NMR (300 MHz, Acetone d6) δ: 1.49 (s, CH3, 36H), 2.51 (bs, OH, 3H), 2.59 (t, CH2, 6H), 4.38 (s, OH 1H).
13C NMR (75 MHz, Acetone d6) δ: 141.96, 138.93, 117.80, 112.52, 98.06, 72.50, 60.98, 36.25, 25.18.
MS (Thermospray): M++23 (Na) 943, M+-18 902.
Example 37
Tris (8-hydroxyethylthio-2 , 2 , 6 , 6-tetramethylbenzo [ 1 , 2-d: 4 .5- d ' ] -bis (1 , 3 ) dioxole-4-yl) methyl
Figure imgf000083_0001
LiAlH4 (95.8 mg, 2.52 mmol) was added to a solution of tris (8-ethoxycarbonylmethylthio-2,2,6,6-tetramethylbenzo -[1,2-δ:4,5-d']-bis(1,3)dioxole-4-yl)methyl (1.30 g, 1.26 mmol, 50% radical content (Example 28)) in
diethylether (50 mL) under nitrogen at 20 °C. The reaction was followed by HPLC (reversed phase Cl8, acetonitrile:water (3:1), 5 mM tetrabutylammonium acetate). The mixture was quenched with ethylacetate when no more substrate was seen according to HPLC.
Dilute sulfuric acid was then added until pH 6-7. The ether phase was separated, and the water phase extracted with diethylether (2x100 mL). The combined etheric phases were dried (Na2SO4) and evaporated, yielding 0.96 g (84%, 1.06 mmol) of a yellowish oil. The product was characterized by ESR and Overhauser measurements. HPLC chromatography in combination with diode array detection and UV spectral analysis showed a radical content of about 6-7 % after evaporation overnight.
Example 38
Tris(8-di(methylcarbonyloxyethyl)aminocarbonylmethylthio -2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-bis(1,3)
dioxole-4-yl) methanol
Figure imgf000084_0001
Tris(8-ethoxycarbonylmethylthio-2,2,6,6,- tetramethylbenzo-([1,2-d:4,5-d']-bis(1,3)dioxole-4-yl) methanol (0.4675 g, 0.446 mmol (Example 27)) and
diethanolamine (0.939 g, 8.93 mmol) were mixed and aminolysis was performed in toluene at reflux
temperature under nitrogen for thirty six hours. At this time HPLC analysis (reversed phase Cl8,
acetonitrile: water (3:1), 5 mM tetrabutylammonium acetate, 254 nm UV detection) showed complete
consumption of the starting material. The crude
reaction mixture was evaporated and checked with 13C NMR without removing the excess diethanol amine from the intermediary tris(8-di(hydroxyethyl)- aminocarbonylmethylthio-2,2,6,6-tetramethylbenzo[1,2-d: 4,5-d']-bis(1,3)dioxole-4-yl)methanol: [(CD3OD, 75 MHz) δ: 171.34, 142.55, 139.97, 119.12, 112.99, 98.94, 60.73, 60.58, 52.97, 50.36, 36.84, 25.88, central COH at ca. 72 ppm was not seen.] and redissolved in a mixture of pyridine (7.0 mL) and acetic anhydride (5.0 mL) and stirred over night at room temperature. TLC analysis (SiO2, methanol : ethylacetate (3:7)) showed formation of a more lipophilic product. This product was purified by two consecutive chromatographic separations on SiO2 (E. Merck 0.040-0.063 mm). The first column was eluted with n-heptane: ethylacetate (1:1) and ethylacetate: ethanol (1:1). The second column was eluted with
ethylacetate/n-butanol (95:5). The solvents were evaporated and the last amounts of butanol was removed by high vacuum evaporation under a period of forty eight hours. Yield 0.151 g (23%, 0.102 mmol) (about 20% more substance in the impure fractions).
1H NMR (CDCl3, 300 MHz) δ: 4.23 (t, CH2, 6H), 4.15 (t, CH2, 6H), 3.74 (s, CH2, 6H), 3.70 (t, CH2, 6H), 3.54 (t, CH2, 6H), 2.02 (s, CH3, 18H), 1.49 (s, CH3, 36H).
13C NMR (CDCl3, 75 MHz) δ: 170.63, 170.37, 168.40,
141.30, 138.60, 117.72, 112.38, 96.38, 72.45, 61.85, 61.83 , 47.78, 45.52, 35.43, 25.39,20.78, 20.66, (61.85 and 61.83 are nonequivalent possibly due to resticted rotation arising from the amide).
MS (Thermospray): M++23 (Na) 1495, 1496, 1497 and 1498 (scale not calibrated).
Example 39
Tris (8-carboxylmethylthio-2.2.6.6-tetramethγlbenzo- [ 1 , 2- d: 4.5-d ' ] -bis (1.3) dioxole-4-yl)methanol
Figure imgf000086_0001
Tris(8-ethoxycarbonylmethylthio-2,2,6,6-tetramethylbenzo -[1,2-d:4,5-d']-bis(1,3)dioxole-4-yl)methanol (4.00 g, 3.819 mmol (Example 27)) was dissolved/suspended in a mixture of water and ethanol (200 mL, (1:1)) and cooled to approximately 5°C. Sodium hydroxide (15.3 mL, 1.0 M, 15.3 mmol) was added and the reaction was followed by HPLC. The next day more sodium hydroxide (3.82 mL, 1.0 M, 3.82 mmol) and (7.64 mL, 1.0 M, 7.64 mmol) was added. The ethanol was evaporated after complete conversion had been observed (HPLC). The alkaline aqueous phase was extracted with heptane (2x100 mL) and then acidified with HCl (2.0 M) to pH 5. The product was taken up in diethylether (2x100 mL). Upon further acidification of the aqueous phase (to pH 3), more precipitate was formed. This was also taken up in diethylether (2x100 mL). The combined ether phases were extracted once with water (100 mL) and dried (Na2SO4). Evaporation yielded 3.11 g (3.23 mmol, 85 %) of a white crystalline material. When the material was dried at very high vacuum and high temperature the substance turned blue, possibly due to the formation of an internal zwitter ion. Upon exposure to moist air the white color
returns.
1H NMR (300 MHz, DMSOd6) δ: 12.55 (bs, COOH, 3H), 3.59
(s, CH2, 6H), 3.31 (bs, OH, 3H), 1.44 (s, CH3, 36H).
13C NMR (75 MHz, DMSOd6) δ: 170.04, 140.18, 138.17,
117.17, 111.83, 97.13, 71.47, 34.70, 24.98.
MS (Electrospray): Calc. 962.17, found 962.17.
Titration with sodium hydroxide (0.01 M) gave a purity
(% of molecules with three carboxylic acids) of 99.7 % +/- 1.9 % (SD).
Example 40
8-Hydroxy-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-(1,3)- dioxole
Figure imgf000087_0001
2,2,6,6-Tetramethylbenzo[1,2-d:4,5-d']-(1,3)dioxole (5.00 g, 22.5 mmol (Example 5)) was dissolved in diethyl ether (150 mL, sodium benzophenone ketyl) under argon. n-Butyl lithium (10.0 mL, 25 mmol, 2.5 M in toluene) was added at room temperature followed by methyl magnesium bromide (4.25 mL, 13 mmol, 3.0 M in diethyl ether, Aldrich). the resulting mixture was stirred at room temperature for 1 h. Oxygen was bubbled through the solution over a period of 2 hours, while cooling with a cold water bath. The reaction mixture was poured into a solution of NaOH (50 mL, IM) and extracted with diethyl ether (100 mL). The aqueous phase was acidified with cone. HCl to pH 2 while stirring. The product was isolated by extracting with diethyl ether (3x50 mL).
The ether was dried (Na2SO4) and evaporated yielding 1.50 g (6.3 mmol, 28 %) of 8-hydroxy-2,2,6,6- tetramethyl-benzo[1,2-d:4,5-d'] bis(1,3)dioxole.
1H NMR (300 MHz, DMSOd6) δ: 6.00 (s, aromatic H, 1H), 1.66 (s, CH3, 12H).
MS (Thermospray) : M++23 (Na+) 261
Example 41
8-Methoxy-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-(1,3)- dioxole
Figure imgf000088_0001
8-Hydroxy-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-(1,3)- dioxole (1.00 g, 4.20 mmol (Example 40)) was dissolved in CH2Cl2 (30 mL) and dimethyl sulfate (0.6 mL, 6.30 mmol), tetrabutyl-ammonium hydrogensulfate (catalytic amount) and sodium hydroxide (1.0 mL, 40 %) were added. The resulting mixture was stirred at room temperature for 24 hours. The phases were separated and the aqueous phase was extracted with diethyl ether (2 x 50 mL). The combined organic solution was extracted with ammonia (25 mL, 25%) and water (50 mL), dried (Na2SO4) and
evaporated. Yield 0.9g (83%) of a yellow oil.
1H NMR (CDCl3, 300 MHz) δ: 6.05 (s, CH, 1H), 4.02 (s,
CH3, 3H), 1.65 (s, CH3, 12H).
MS (Thermospray) : M++23 (Na+) 275.
Example 42
Tris (8-ethoxycarbonylmethγlthio-2 , 2 , 6 , 6-tetramethylbenzo [1 , 2-d: 4 .5-d ' ] -bis (1 , 3) dioxole-4-yl) methane
Figure imgf000089_0001
Tris(8-ethoxycarbonylmethylthio-2,2,6,6-tetramethylbenzo [1,2-d:4,5-d']-bis(1,3)dioxole-4-yl)methanol (1.06 g, 1.01 mmol (Example 27)) was added to a solution of trimethyl silylchloride (0,767 mL, 6.07 mmol) and sodium iodide (0.91 g, 6.07 mmol) in acetonitrile (50 mL) and stirred for ten minutes. Saturated sodium thiosulfate (30 mL) was added, followed by diethylether (70 mL), and the mixture was stirred for 10 minutes. The phases were separated and the organic phase was washed with water (30 mL). The organic phase was diluted with more ether (100 mL), since crystals had started to form in the funnel. The solution wds kept in the freezer over night after drying (MgSO4) and filtration. The crystals formed were removed (impurity) and the solution evaporated to dryness. The product was purified by dissolving the substance at room temperature in diispropyl ether (E. Merck 118867, 30 mL), followed by bubbling with helium.
The flask was stoppered and put in the refrigerator for two and a half hours. The product was collected by filtration (glass sinter no. 3), and the mother liquor was evaporated to approximately half the volume. The total yield after collecting the second crop was 640 mg
(0.621 mmol, 61%).
1H NMR (300 MHz, CDCl3) δ: 1.23 (t), 1.51 (s), 3.55 (s),
4.11 (q), 5.34 (s).
13C NMR (75 MHz, CDCl3) δ: 169.09, 140.810, 139.50,
117.81, 107.65, 95.37, 61.18, 35.71, 30.70, 25.38,
14.11.
MS (Thermospray): M++23 (Na) 1053.
Example 43
Tris(8-dimethylaminocarbonylthio-2,2,6,6- tetramethylbenzo[1,2-d:4.5-d']bis (,13)dioxole- 4-yl)methanol
Figure imgf000090_0001
Tris(8-mercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']-b is (1,3)dioxole-4-yl)methanol (1.00 g, 1.27 mmol
(Example 31)) was added to an oxygen free (argon
bubbling five min.) solution of K2CO3 (5.00 g) and dimethylcarbamoyl chloride (Fluka 39871, 0.367 mL, 4.0 mmol). A sample taken after forty five minutes, and controlled by 1H NMR, showed complete consumption of the substrate. The solution was filtered and evaporated. The crude product was 93% pure according to HPLC (C8, CH3CN:H2O, (3:1), 254 nm).
The substance was dissolved in diethylether (30 mL, dry, sodium benzophenone ketyl) and ultrasonicated for five minutes, followed by rotation at 35 °C for five minutes on a rotavapor at normal pressure. Cooling in the freezer for thirty minutes gave greyish crystals. Yield 0.580 g (0.579 mmol, 45.6%).
1H NMR (300 MHz, CDCl3) δ: 1.54 (s), 3.3 (bd), 4.20 (bs). 13C NMR (75 MHZ, CDCl3) δ: 163.02, 142.80, 138.78,
118.05, 113.52, 92.07, 72.63, 37.01, 25.45.
MS (Thermospray): M++23 (Na) 1024.
Example 44
Tris(2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']bis(1,3)- dioxole-4-yl)methanol
Figure imgf000091_0001
2,2,6,6-Tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole (17.570 g, 79.0 mmol (Example 5)) was dissolved in THF (300 mL, sodium benzophenone ketyl) and cooled to -20 °C with an ethanol/dry ice bath while maintaining an argon atmosphere. n-Butyl lithium (37.8 mL, 2.5 M in hexane, 95.0 mmol) was added with a syringe, and the resulting mixture was allowed to reach room temperature. The mixture was recooled to -20 °C and dimethyl carbonate (2.37 g, 2.20 mL, 26.0: mmol) was added. The cooling bath was removed and the reaction mixture was stirred at room temperature for 3.5 hours. The mixture was then poured onto ice/water containing HOAc (2%) and extracted with diethyl ether (2 x 300 ml). The organic phase was washed with water (2 x 100 mL) and dried (Na2SO4). The solvent was evaporated and the product triturated with petroleum ether. Yield 13.56 g (74.4 %)
1H NMR (CDCl3, 300 MHz) δ: 6.26 (S, arom. H, 3H), 1.48
(s, CH3, 36H), 4.28 (s, OH, 1H) .
13C NMR (CDCl3, 75 MHz) δ: 140.10, 139.00, 116.71,
112.57, 91.64, 72.69, 25.38.
MS (Thermospray): M++23 (Na) 715.
Example 45
Tris(8-ethyloxycarbonylthio-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methanol
Figure imgf000092_0001
Tris(8-mercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)dioxole-4-yl)methanol (1.000 g, 1.269 mmol Example 31) was added to a solution of acetonitrile (75 mL, argon bubbled) and potassium carbonate (6.0 g).
ClCOOEt (0.725 mL, 8.00 mmol) was added and the resulting mixture was vigourously stirred for 30 minutes. An NMR sample showed complete conversion at this time. The mixture was filtered and evaporated. The pure product was obtained by chromatography on a silica column eluting with ethyl acetate:heptane 1:1. Yield 1.26 g (98.7%).
1H NMR (CDCl3, 300 MHz) δ: 4.26 (q, CH2, 6H), 4.21 (s,
COH, 1H), 1.54 (s, CH3, 36H), 1.30 (t, CH3, 9H).
13C NMR (CDCl3, 75 MHz) δ: 166.18, 142.30, 138.80, 118.35
113.70, 91.26, 72.51, 64.09, 25.42, 14.22.
MS (Thermospray): M++23 (Na) 1027.
Example 46
Tris(8-ethyloxycarbonylthio-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4-yl)methyl
Figure imgf000093_0001
Tris(8-ethyloxycarbonylthio-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methanol (0.100 g, 0.099 mmol. Example 45) was dissolved in THF (5 mL, sodium benzophenone ketyl) and SOCl2 (0.073 mL, 0.998 mmol) was added. The mixture was stirred for 3 hours and then evaporated under argon.
More THF (3x50 mL, sodium benzophenone ketyl) was added and evaporated after each addition. The residue was dissolved in THF (50 mL, sodium benzophenone ketyl) and BCl3 (955 mL, 0.998 mmol, 1 M soln. in CH2Cl2) and stirred for 15 minutes, when SnCl2 (0.189 g, 0.999 mmol) was added. The mixture was stirred for 10 minutes and zinc (0.653 g, 9.985 mmol, specially activated by p. a. HCl (2 M), water, ethanol, ether, high vacuum drying 250 °C the same day)) was added. The reaction mixture was worked up after 3 hours stirring, by diluting with dry, oxygen-free diethyl ether (300 mL), extracting with NaOH
(2x50 mL, 2 M, oxygen free) and filtering the solution through a silica column, eluting with ether. Yield
0.058 g, (0.0594 mmol 60%).
ESR (THF, 200 G) : Linewidth 109 mG (one wide line containing 70 resonances).
Overhauser enhancements (THF, 548.9 MHz, 200 G) : 9 mW 12 enhancement, 18 mW 25 enhancement.
Example 47
Tris(8-tertbutylcarbonylthio-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methanol
Figure imgf000094_0001
Tris(8-mercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)dioxole-4-yl)methanol (1.000 g, 1.268 mmol. Example 31), pyridine (0.620 mL, 7.606 mmol) and N,N- dimethylamino-pyridine (catalytic amount) were added to degassed (argon bubbled) acetonitrile (50 mL) and cooled close to the freezing point. 2,2-Dimethylpropanoic acid chloride (0.940 mL, 7.606 mmol) was added with a
syringe, and the reaction mixture was allowed to reach room temperature over a period of 4 hours. The solvent was evaporated and the residue was dissolved in diethyl ether (200 mL). The ether was extracted with NaH2PO4 (50 mL, sat.), HCl (50 mL, 1 M), NaH2PO4 (50 mL, sat.) and NaCl (50 mL, sat.) and dried (Na2SO3). Yield after filtration and evaporation: 1.00 g (0.9604 mmol, 75.7
%). The compound was taken to analyical purity by dissolving in diisopropyl ether (80 mL) at room
temperature with the help of ultrasound. Cooling in the refrigerator for 30 minutes gave 0.29 g (0.2785 mmol,
22.0 %) of the pure compound.
1H NMR (CDCl3, 300 MHz) δ: 4.21 (s, CH, 1H), 1.53 (s, CH3,
36H), 1.30 (s, CH3, 36H).
13C NMR (CDCl3, 75 MHz) δ: 200.00, 142.05, 138.87,
118.01,
MS (Thermospray): M++23 (Na) 1063.
Example 48
Tris(8-tertbutylcarbonylthio-2, 2 ,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1.3)dioxole-4- yl)methyl
Figure imgf000095_0001
Tris(8-tertbutylcarbonylthio-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methanol (0.0957 g, 0.0919 mmol. Example 47) was dissolved in THF (25 mL, argon atmosphere., potassium benzophenone ketyl dried), and BF3.OEt2 (0.5 mL, 48% in diethyl ether, Fluka) was added. After stirring for 5 minutes SnCl2 (0.1249 g, 0.659 mmol) was added followed by a gradual change in color to light brown. Zinc (0.5 g, 7.646 mmol) was added 1.5 hours after the SnCl2. Two hours later the color had changed to green. A sample taken (after letting the Zn settle) with a gas tight syringe showed a large Overhauser enhancement. The reaction mixture was poured onto a column consisting of three layers; top layer SiO2, intermediate layer SiO2 and K2CO3 1:1 and bottom layer SiO2. The K2CO3 binds the BF3.OEt2, which has to be removed to avoid destabilizing the corresponding cation radicals. Yield: 0.079 g
(0.07713 mmol, 83.9 %).
ESR (THF, 200 G) : Linewidth 109 mG, one unresolved line. Overhauser enhancements (THF, 548.9 MHz, 200 G, conc.< 1 mM) : 9 mW 96 enhancement, 18 mW 114 enhancement.
Example 49
Tris (8-methylcarbonylthio-2 , 2 , 6 , 6-tetramethylbenzo [ 1 , 2- d: 4 , 5-d ' ]bis (1 , 3 ) dioxole-4-yl) methanol
Figure imgf000096_0001
Tris(8-mercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)dioxole-4-yl)methanol (1.000 g, 1.268 mmol, Example 31), acetyl chloride (0.540 mL, 7.605 mmol) and K2CO3 (2.0 g, 1.447 mmol) were added to CH3CN (25 mL, degassed with argon). An NMR sample showed complete reaction after 90 minutes. The solvent was evaporated and the product was purified by flash chromatography (SiO2, 230-400 mesh, i.d.35 mm, 40cm length) followed by crystallization in diisopropyl ether (50 mL). The product was dissolved at room temperature with the help of ultrasound. The product was collected after 2 hours in the freezer. Yield: 0.61 g (0.667 mmol, 52.6%)
1H NMR (CDCl3, 300 MHz) δ: 2.42 (s, CH3, 9H), 1.55 (s,
CH3, 36H).
13C NMR (CDCl3, 75 MHz) δ: 190.58, 141.81, 138.86,
118.32, 113.55, 91.44, 72.50, 29.97, 25.42.
MS (Thermospray): M++23 (Na) 937.
Example 50
Tris(8-methylcarbonylthio-2,2,6,6-tetramethylbenzo[1,2- d:4,5-d']bis(1.3)dioxole-4-yl)methyl
Figure imgf000097_0001
Tris(8-methylcarbonylthio-2,2,6,6-tetramethylbenzo[1,2- d:4,5-d']bis(1,3)dioxole-4-yl)methanol (0.0915 g, 0.0999 mmol, Example 49) was dissolved in THF (25 mL, argon atmosphere, potassium benzophenone ketyl dried), and BF3.OEt2 (0.5 mL, 48% in diethyl ether Fluka) was added. A temporary red color was seen when the drops were hitting the surface of the solution. After stirring for 5 minutes, SnCl2 (0.1249 g, 0.659 mmol) was added
followed by a gradual change in color to light brown. Zinc (0.500 g, 7.646 mmol, prepared as described above) was added 1.5 hours after the SnCl2. Two hours later the color had changed to green. A sample taken (after letting the Zn settle) with a gas tight syringe showed an enormous Overhauser enhancement. The reaction mixture was poured onto a column consisting of three layers: top layer SiO2, intermediate layer SiO2 and K2CO3 1:1 and bottom layer SiO2. The K2CO3 binds the BF3.OEt2, which has to be removed to avoid destabilizing the corresponding cation radicals. Yield: 0.0720 g (0.0802 mmol, 80.3 %, unknown radical content).
ESR (THF, 200 G) : One line;Linewidth 117 mG.
Overhauser enhancements (THF, 548.9 MHz, 200 G, <1 mM):11 mW 89 enhancement, 18 mW 110 enhancement.
Example 51
Bis(8-mercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)dioxole-4-yl)ketone
Figure imgf000098_0001
The title compound was isolated as a by-product in the reaction between diethyl carbonate and the lithium salt of 8-mercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)dioxole, see Example 31.
1H NMR (CDCl3, 300 MHz) δ: 3.46 (s, SH, 2H) , 1.63 (s,
CH3, 24H) .
13C NMR (CDCl3, 75 MHz) δ: 183.42, 138.96, 137.90,
119.55, 106.84, 100.36, 15.24.
MS (Thermospray): M++23 (Na) 557. Example 52
Benzo[1,2-d:4,5-d']bis(1,3)dioxole-2,6- dispirocyclohexane
Figure imgf000099_0001
1,2,4,5-Tetrahydroxybenzene (5.00 g, 35.00 mmol, Example 4) was dissolved in THF (200 mL) and cyclohexanone (13.0 mL, 140.00 mmol) was added in one portion. P2O5 was then added in small portions under efficient stirring. After addition was completed the temperature was increased to 80 °C for 4 hours. One large ball was formed in the flask during this time. After cooling to room
temperature the ball was broken up and the reaction mixture was poured on a mixture of ice (210 g) and NaOH (250 mL, 2 M). Ether (100 mL) was added and the phases separated. The aqueous was extracted with ether (2x50 mL). The combined organic phase was dried (Na2SO4), filtered and evaporated. The product was dissolved in MeOH (20 mL), heated, filtered, cooled and the product was collected by filtration. Yield 1.70 g (16%).
1H NMR (CDCl3, 300 MHz) δ: 6.35 (s, CH arom., 2H), 1.87 (t, CH2, 8H), 1.69 (t, CH2, 8H), 1.47 (m, CH2, 4H).
13C NMR (CDCl3, 75 MHz) δ: 140.37, 118.54, 92.80, 34.84, 24.57, 23.13. Example 53
Tris(benzo[1,2-d:4,5-d']bis(1,3)dioxole-2,6-dispirocyclohexane)methanol
Figure imgf000100_0001
Benzo[1,2-d:4,5-d']bis(1,3)dioxole-2,6- dispirocyclohexane (2.00 g, 6.60 mmol, Example 52) was dissolved in diethyl ether (80 ml, dried over Al2O3) and cooled to -10 °C in an ice acetone bath. n-Butyl lithium (3.70 mL, 2.5 M in hexane) was added with a syringe over a period of five minutes. The mixture was stirred at the same temperature for 1 hour and overnight at room temperature. Diethyl carbonate (0.28 mL, 2.4 mmol) was added at room temperature and the mixture immediately changed color to red-brown. After stirring for 1 hour it was poured on ice/water (100 mL). The organic phase was separated and the waterphase extracted with CH2Cl2 (100 mL). To facilitate the phase separation HCl (20 mL, 1 M) was added. The combined organic phase was dried (MgSO4), filtered and evaporated. Yield 1.90 g (31%).
13C NMR (CDCl3, 75 MHz): 140.1, 138.9, 117.5, 91.5, 72.5, 34.6, 24.6, 22.9. Example 54
1 , 2 , 4 , 5-Tetrahydroxybenzene
Figure imgf000101_0001
2,5-Dihydroxy-1,4-benzoquinone (4.00 g, 28.55 mmol) was suspended in water (50 ml, distilled) followed by Na2S2O4 (10.00 g, 57.47 mmol) and HCl (5.5 g, 55.75 mmol cone, soln.). The mixture was stirred 30 min. at room
temperature and evaporated to dryness. The residue was washed with THF (40 ml) and filtered. The THF was evaporated yielding 2.00 g (14.07 mmol, 49.3 %) of the title substance.
1H NMR (DMSO6, 300 MHz) δ: 7.59 (bs, OH, 4H),6.23 (s, CH, 2H).
13 C NMR (DMSOd6, 75 MHz) δ: 136,96, 104.65,
Example 55
1,2,4,5-Tetrahydroxybenzene
Figure imgf000101_0002
2,5-Dihydroxy-1,4-benzoquinone (10.00 g, 71.43 mmol) was suspended in water (200 ml, distilled) followed by HCl (6 mL, 142.86 mmol, cone). Iron (4.00 g, 71.43 mmol, powder) was added and the mixture was stirred 30 minutes at room temperature. The solution was filtered and the solution evaporated to dryness. The product was
isolated as a grey brown powder containing some iron complexes. Yield 14.80 g. The product is used as such in the reaction with acetone and P2O5 (Example 5) with no negative effects.
1H NMR (DMSOd6, 300 MHz) δ: 6.9-3.0 (broad, OH, 4H), 6.21 (broad s, CH, 2H).
13C NMR (DMSOd6, 75 MHz) δ: 136,96, 104.65.
Example 56
Tris(2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']bis(1,3)- dioxole-4-yl)methanol
Figure imgf000102_0001
2,2,6,6-Tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole (8.80 g, 40.00 mmol. Example 5) was dissolved in THF (100 mL) and cooled to -20 °C. n-Butyllithium (25.0 mL, 40.0 mmol, 1.6 M) was added and the temperature was adjusted to ambient temperature over a period of 30 minutes and then recooled to -20 °C. Bis(2,2,6,6- tetramethylbenzo-[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)ketone (18.80 g, 39.83 mmol, Example 57) was added and the temperature was once more adjusted to room temperature and the mixture was stirred for 18 hours. The mixture was then poured on water/AcOH (100 mL, 2 % AcOH) and extracted with diethyl ether (2x100 mL). The organic phase was washed with water (2x100 ml) and dried (Na2SO4). The solvent was evaporated and the product was washed with petroleum ether (20 mL, 40-60 °C). Yield 10.80 g (64.1%). Spectral data see example 44.
Example 57
Bis(2.2,6.6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)dioxole-4-yl)ketone
Figure imgf000103_0001
2,2,6,6-Tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole (400.0 g, 1.80 mol. Example 5) was dissolved in THF (6 L, dried, perhaps incompletely) and cooled to -20 °C with a cryostat while maintaining a nitrogen atmosphere. n-Butyl lithium (1350 mL, 1.6 M in hexane, 2.16 mol) was added with a dropping funnel, and the resulting mixture was allowed to reach room temperature. The mixture was recooled to -20 °C and dimethyl carbonate (47.0 mL, 0.56 mol) was added. The cryostat was turned off and the reaction mixture was allowed to reach room temperature over night while stirring. Water (3.0 L, containing 2 % HOAc) was added to the reaction mixture, and the
resulting solution was extracted with diethyl ether (2 x 3.0 1). The organic phase was washed with water (2 x 1.0 L) and dried (Na2SO4, K2CO3). The solvent was evaporated and the product triturated with petroleum ether (boiling range 40-60 °C). Yield after separation by recrystallisation in MeOH/H2O: 50.0 g (106.0 mmol,
18.9 % relative to dimethyl carbonate).
1H NMR (CDCl3, 300 MHz) δ: 6.42 (s, CH aromatic, 2H),
1.60 (s, CH3, 24H).
13C NMR (CDCl3 , 75 MHz ) δ : 184 . 55 (C=O) , 140. 51 , 139 . 43 ,
118.86, 109.13, 95.89, 25.56.
MS (Thermospray): M++23 493.
Example 58
Mono-(2.2,6,6-tetramethylbenzo[1,2-d:4,5-d']- bis(1,3)dioxole-4-yl)-mono(phenyl)-mono(pyridin-4- yl)methanol
Figure imgf000104_0001
2,2,6,6-Tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole (3.030 g, 13.60 mmol. Example 5) was dissolved in THF (50 mL, sodium benzophenon ketyl) under N2. The mixture was cooled to -78 °C. n-Butyllithium (5.10 mL, 13.6 mmol, 2.68 M in toluene) was added with a syringe during 5 minutes. 15 Minutes later the dry ice acetone cooling bath was excanged with a ice water bath and the reaction mixture was stirred for 1 hour. The mixture was
recooled to -78 °C and phenyl pyridyl ketone (2.50 g, 13.60 mmol) dissolved in THF (10 mL, Na benzophenone ketyl) was added dropwise. One hour later the cooling bath was exchanged with a ice/water bath and the
reaction was allowed to reach room temperature and stirred for 3 days. The THF was washed with NaH2O4 (2x50 mL, 1.25 M), dried (Na2SO4) and evaporated yielding 5.10 g crude product. Analytically pure compound was
obtained by dissolving the crude product in a mixture of hot CH3CN and THF and crystallizing. Yield 0.826 g,(2.04 mmol 15%).
1H NMR (CDCl3, 300 MHz) d 8.52 (m, CH pyridine, 2H, AA' in AA'XX'spin system), 7.26 (m, CH pyridin, 2H, XX' in
AA'XX'spin system), 6.31 (s, CH, 1H), 4.61 (s, OH, 1H), 1.47 (s, CH3, 6H), 1.40 (s, CH3, 6H).
13C NMR (CDCl3, 75 MHz) δ: 153.90, 149.16, 143.79,
140.83, 137.41, 127.85, 127.80, 127.53, 122.92, 118.17, 113.41, 110.08, 92.67, 79.28, 25.21, 25.10 (two
resonances at 25 ppm due to nonequivalence of methyl groups).
MS (Thermospray): M++1 406.
Example 59
Bis(8-methylthio-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1.3)dioxole-4-yl)ketone
Figure imgf000105_0001
Bis-(8-Mercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis-(1,3)dioxole-4-yl)ketone (0.6000 g, 1.1236 mmol
Example 51) was dissolved in a CH3CN (50 mL) and cooled to 0 °C. CH3I (0.42 ml, 6.74 mmol) and K2CO3 (4.0 g) were added. The resulting mixture was stirred at room temperature for 70 minutes. Before filtering away the
K2CO3, diethyl ether (50 ml) was added to ensure that all of the product was in solution. Filtration and
evaporation yielded a quantiatative amount (0.630 g, 100
%) of the pure title compound.
1H NMR (CDCl3, 300 MHz) δ: 2.42 (s, CH3, 6H), 1.55 (s,
CH3, 24H).
13C NMR (CDCl3, 75 MHz) δ: 183.30, 140.15, 138.68,
118.94, 107.68, 105.49, 26.57, 25.34, 16.12.
MS (Thermospray) M++23 (Na) 585, M++ 39 (Ka) 601.
Example 60
Bis(8-Methylmercapto-2,2,6,6-tetramethylbenzo
[1,2-d:4,5-d']bis(1.3)dioxole-4-yl)-mono(2- methylmercapto-pyrimidin-5-yl)methanol
Figure imgf000106_0001
5-Bromo-2-methylthio-pyrimidine (0.250 g, 1.2195 mmol) was dissolved in THF (50 mL, sodium benzophenone ketyl) and cooled to -105 °C. n-Butyl lithium (0.455 ml in toluene, 1.2195 mL) was added and the temperature was increased to -75 °C for 15 minutes and thereafter reduced to -105 °C. Bis(8-methylthio-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']-bis(1,3)dioxole-4- yl)ketone (0.63146 g, 1.1236 mmol, Example 59) was added in solid form and the temperature was gradually
increased to room temperature (removal of cooling bath). The mixture was stirred overnight, NaCl (15 mL, sat.) and diethyl ether (40 mL) were added and the phases separated after 5 minutes stirring. The organic phase was dried (MgSO4) and evaporated yielding 0.59 crude product. Pure product was obtained by crystallization in diethyl ether followed by a second crystallization in diisopropyl ether. Yield 0.115 g (0.1669 mmol, 14.9%). 1H NMR (CDCl3, 300 MHz) δ: 8.53 (s, 2H), 4.54 (1H, s), 2.55 (s, 3H), 2.41 (s, 6H), 1.49 (s, 24H).
13C NMR (CDCl3, 75 MHz) δ: 171.12, 156.42, 141.21,
137.54, 131.33, 118.26, 110.75, 101.18, 73.90, 25.38, 25.29.
MS (Thermospray) M++23 (Na) 711.
Example 61
Tris (8-methγlcarbonylthio-2 , 2 , 6 , 6-tetramethylbenzo[ 1 , 2- d: 4 .5-d ' ]bis (1. 3 ) dioxole-4-yl) methane
Figure imgf000107_0001
Nal (0.15972 g, 1.1256 mmol) and trimethylsilyl chloride (0.142 mL, 1.1256 mmol) were stirred in acetonitrile (50 mL). Tris (8-methylcarbonylthio-2,2,6,6- tetramethylbenzo-[1,2-d:4,5-d']bis(1,3)dioxole-4- yl) methanol (0.1286 g, 0.1407 mmol, Example 49) was added in solid form and the color of the solution became brownish. Na2S2O4 (20 mL, sat.) was added after 60 minutes and the mixture was stirred 5 minutes before separation of the phases. The aqueous phase was
extracted with diethyl ether (50 mL), and the combined organic phase was dried (MgSO4) and evaporated, yielding 0.105 g (0.1168 mmol, 83 %) of the title compound.
1H NMR (CDCl3, 300 MHz) δ: 5.42 (s, CH, 1H), 2.40 (s, CH3, 9H), 1.53 (S, CH3, 36H).
13C NMR (CDCl3, 75 MHz) δ: 191.16, 141.20, 139.66,
118.35, 108.81, 90.39, 31.01, 29.88, 25.34.
MS (Thermospray) M++23 (Na) 921.
Example 62
Tris(8-tertbutylcarbonylthio-2,2,6,6- tetramethylbenzo[1,2-d:6,5-d']bis(1.3)dioxole-4- yl)methane
Figure imgf000108_0001
Nal (0.185 g, 1.2342 mmol) and trimethylsilyl chloride (0.156 mL, 1.2336 mmol) were stirred in acetonitrile (50 mL). Tris(8-tertbutylcarbonylthio-2,2,6,6- tetramethylbenzo-[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methanol (0.220 g, 0.2056 mmol. Example 47) was added in solid form and the color of the solution became brownish. Na2S2O4 (20 mL, sat.) was added after 60 minutes and the mixture was stirred 5 minutes before separation of the phases. The aqueous phase was
extracted with diethyl ether (50 mL), and the combined organic phase was dried (MgSO4) and evaporated, yielding 0.105 g (0.1168 mmol, 83 %) of the title compound.
Tris(8-tertbutylcarbonylthio-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methane (0.205 g, 0.200 mmol, 97.3 %).
1H NMR (CDCl3, 300 MHz) δ: 5.42 (s, CH, 1H), 1.51 (s, CH3, 36H), 1.29 (S, CH3, 27H).
13C NMR (CDCl3, 75 MHz) δ: 200.51, 141.45, 139.68,
117.99, 108.59, 90.78, 46.90, 31.03, 27.17, 25.34.
MS (Thermospray) M++23 (Na) 1047.
Example 63
Bis(8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)dioxole-4-yl)-mono(2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1.3)dioxole-4- yl)methyl
Figure imgf000109_0001
Bis(8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)dioxole-4-yl)-mono(2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methane (0.100 g, 0.136 mmol) (from Example 23) was dissolved in a mixture of THF (40 mL, Al2O3) and DMSO (10 mL, mol. sieves.). tBuOK (0.0168 g, 0.150 mmol) was added and the resulting mixture was heated to 75 °C for 1 hour. The solution was dark green/black at this time. I2 (0.038 g, 0.150 mmol) was added and a sample was taken after 1 minute and an Overhauser enhancement experiment was done; a 19 times enhancement was measured at 5 W irradiation (200 G, 548.9 MHz, THF). After dilution with ether (100 mL), extraction with Na2S2O3 (sat.40 mL), drying (Na2SO4) and evaporation, an Overhauser
enhancement of 50 at 5 W irradiation was obtained.
ESR (200 G, 548.9 MHz, three lines, THF): Linewidth 85 mG, aH 175 mG.
Example 64
Tris(8-formyl-2,2,6,6-tetramethylbenzori,2-d:4,5-d']bis- (1.3)dioxole-4-yl)methyl
Figure imgf000110_0001
Tris(8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']bis- (1,3)dioxole-4-yl)methane (0.104 g, 0.134 mmol, Example 23) was dissolved in a mixture of DMSO (10 mL), and diethyl ether (30 mL). NaH (0.0037 g, 0.134 mmol, 80% in oil) and KOtBu (catalytic amount) were added and the resulting mixture was stirred under argon. Samples (about 50 mL) were taken with irregular intervals and quenched with DCl/D2O (10% DCl) under argon. After 2 hours and 15 min. the 1H NMR measurements of the
evaporated diethyl ether extact from the quench showed 37 % deuteration (anion formation). 18 Hours after the start the deuteration level was 70 %. The calculated amount left in the flask was 78 mg at this time. I2 (0.056 g, 2 equivalents) was added and the reaction mixture was worked up after 2 minutes reaction time.
The mixture was diluted with diethyl ether (50 mL) and washed with Na2S2O3 (sat. 2x25 mL), dried (Na2SO4) and evaporated yielding 0.030 g (40.8%). The radical content was 60 % according to 1H NMR (Evans method) and 64% by HPLC (Kromasil 10 mm, C8, 250 mm long, i.d. 4.6 mm, CH3CN:H2O 70:30 to 100:0 gradient 20 minutes, UV 254 nm detection).
Overhauser enhancements (200 G, 548.9 MHz, 5.9 mM in THF): 9 mW 51, 18 mW 88, 5W 251.
The HPLC chromatogram of the tris(8-formyl-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methyl radical showed a peak at 5.93 s corresponding to the radical and a peak at 6.58 s corresponding to the starting material. The HPLC separated materials also showed distinct UV spectra.
Example 65
8-Mercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']bis- (1,3)dioxole-4-yl)carboxylic acid ethylester
Figure imgf000111_0001
2,2,6,6-Tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole (4.00 g, 18.00 mmol, Example 5) was dissolved in diethyl ether (50 mL, sodium benzophenone ketyl), n-butyl lithium (7.56 mL, 18.90 mmol, 2.5 M in hexane) was added and the resulting solution was refluxed 30 minutes.
More diethyl ether (30 mL) was added and the mixture was cooled to -70 °C and S8 (0.5759 g, 17.96 mmol) was added and the temperature was increased to 0 °C. THF (100 mL) was added 2 hours after increasing the temperature and the mixture was recooled to -70 °C. n-Butyl lithium (8.64 mL, 18.0 mmol) was added and the temperature was increased to 0 °C. One hour and forty five minutes later the slurry was filtered through a glass sinter (no. 4) at one of the three necks of the reaction flask. The white crystals (lithium salt) were washed with diethyl ether (50 mL, sodium benzophenone ketyl) under argon, and the ether removed by filtration through the sinter. Weighing of the flask with the dry lithium salt indicated that there remained around 8 mmol lithium salt in the flask. THF (70 mL) was added to the salt, the mixture cooled to 0 °C, and diethyl carbonate (0.654 mL, 5.4 mmol) was cannulated into the solution and the mixture was left overnight to reach room temperature. The mixture was diluted with ether (300 mL), extracted with NaH2PO4 buffer (2x50 mL, sat.), dried (MgSO4) and evaporated yielding the title compound, 1.60 g (4.90 mmol, 90.7 % relative to diethyl carbonate).
1H NMR (CDCl3, 300 MHz) δ: 4.36 (k, CH2, 2H), 1.70 (s, CH3, 12H), 1.35 (t, CH3, 3H).
MS (El) M+ 326, 280, 224. Example 66
Tris(2-methoxycarbonylthien-4-yl)methane
Figure imgf000113_0001
Dry powdered AlCl3 (47.12 g, 0.353 mol) was placed in a three-necked flask and a mixture of thiophene-2- carboxylic acid methyl ester (20.0 g, 0.141 mol) and chloroform (47.8 g, 32.3 ml, 0.40 mol) was added rapidly but dropwise. After heating at reflux temperature for 1.5 h, the mixture was hydrolyzed with 50 % aqueous HCl (100 ml). Extraction with CH2Cl2 (3x150 ml) followed by drying of the combined organic phases (MgSO4) and evaporation gave the crude product as a red solid.
Filtering through a short silica column using petroleum ether/EtOAc as the eluant, followed by evaporation gave the title compound as a light yellow solid. Yield: 17.9 g (88 %).
1H NMR (CDCl3, 300 MHz) δ: 7.56 (CH, 3H, d, J=1.6 Hz), 7.12 (CH, 3H, m), 5.50 (CH, 1H, s), 3.84 (OCH3, s, 9H). 13C NMR (CDCl3, 75 MHz) δ: 162.31 (C=O), 143.79 (quart. C-CO2Me), 134.56 (quart. C-CH), 133.59 (thienyl CH), 129.03 (thienyl CH), 52.08 (OCH3). Example 67
Tris(2-methoxycarbonylthien-4-yl)methyl
Figure imgf000114_0001
Tris(2-methoxycarbonylthien-4-yl)methane (0.218 g, 0.5 mmol. Example 66) was dissolved in dry THF (25 ml) under an argon atmosphere. Solid KOtBu (0.055 g, 0.5 mmol) was added, the solution was stirred for 30 min. and I2 (0.127 g, 1.0 mmol) was added.
The Overhauser effect was measured directly on this solution and found to be 4 at 5 W.
Example 68
Tris(8-methylsulfonyl-2,2,6,6-tetramethylbenzo[1,2- d:4,5-d']-bis(1,3)dioxole-4-yl)methyl
Figure imgf000114_0002
Tris(8-methylthio-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']-bis(1,3)dioxole-4-yl)methyl (0.163 g, 0.20 mmol. approximately 15 % radical content, Example 8) was dissolved in CH2Cl2 (10 ml) under an argon atmosphere and 3-chloroperbenzoic acid (0.207 g, 1.20 mmol) was added. After stirring for 15 minutes, ESR spectroscopy of the reaction mixture showed a new radical.
ESR: 6 lines with aH: 290 mG, linewidth: 113 mG.
Overhauser enhancement: 5 at 5W.
Example 69
Bis(8-methyloxycarbonyl-2,2,6,6-tetramethylbenzo[1,2- d:4,5-d']bis(1,3)dioxole-4-yl)-mono(8-cyano-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methanol
Figure imgf000115_0001
The title compound was isolated as a byproduct in the synthesis of tris(8-methoxycarbonyl-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methanol (Example 15) in a yield of about 5 %.
1H NMR (CDCl3, 300 MHz) δ: 3.84 (s,, 6H), 1.50 (s, CH3,
36 H).
13C NMR (CDCl3, 75 MHz) δ: 163.43, 141.70, 140.57,
139.29, 139.07, 119.92, 118.50, 116.34, 114.52, 11.58,
99.30, 78.49, 72.51, 51.89, 25.54, 25.48.
MS (El) M+ 833.
IR (KBr, cm-1): 3000 (CH), 2240 (CN), 1760 (CO). Example 70
Bis (2 , 2 , 6 , 6-tetramethγlbenzo [ 1 , 2-d: 4 , 5- d']bis(1,3)dioxole-4-yl)-mono(1.2,3-trimethoxy-5- phenyl)methanol
Figure imgf000116_0001
2,2,6,6-Tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole (2.22 g, 10.0 mmol (Example 5)) was dissolved in THF (50 mL, sodium benzophenone ketyl) and cooled to -20 °C. n- Butyl lithium (4.80 mL, 12.0 mmol, 2.5 M in toluene) was added and the temperature increased to ambient
temperature. The mixture was recooled to -20 °C and 3,4,5-trimethoxybenzoic acid methyl esther (1.13 g, 5.0 mmol) dissolved in THF(10 mL) was added and the
resulting mixture was stirred at ambient temperature overnight. The solution was poured onto acidic water (2 % AcOH, 50 mL) and extracted with diethyl ether (2x50 mL). The organic phase was washed with water (2x50 mL), dried (Na2SO4) and evaporated yielding 3.10 g (4.7 mmol, 97 %) of the title compound.
1H NMR (CDCl3, 300 MHz) δ: 6.75 (s, arom. H, 2H), 6.28 (s, arom. H, 2H), 3.83 (s, OCH3, 3H), 3.76 (s, OCH3, 6H), 1.44 (s, CH3, 24H).
13C NMR (CDCl3, 75 MHz) δ: 152.29, 140.33, 138.81,
138.25, 137.56, 117.07, 113.58, 105.52, 92.06, 76.77, 60.86, 56.16, 25.30, 25.19.
MS (Thermospray) : M++23 (Na) 661. Example 71
Tris(8-ethoxycarbonylmethylthio-2,2,6,6- tetraroethylbenzo[1,2-d:4.5-d']bis(1,3)dioxole-4- yl)methyl
Figure imgf000117_0001
Tris(8-ethoxycarbonylmethylthio-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methanol (0.050 g, 0.048 mmol (Example 27)),was dissolved in dry THF (20 mL). Under Ar (g) BF3.OEt (0.020 mL, 0.080 mmol) was added, and an intense blue color developed (formation of carbocation). After 1 h was added a complex of Chelex-100 and SnCl2 + i.e. Chelex-100- Sn2 + [0.50 g, 0.05 mequiv. of Sn2+; (Preparation of the Chelex-100-Sn+-complex: 20 g (58 mequiv. of Na+) of
Chelex-100 was treated with 14 g (of SnCl2.H2O, 116 mequiv.) in water (100 mL). The solid material was filtered and washed with water (100 mL) and EtOH (500 mL) and ether (100 mL) and was then dried in a
desiccator at 0.1 torr, yielding the dry complex (25 g).)], followed 15 min later by Zn dust (0.030 g, 0.450 mmol). The reaction mixture started to change to a brown color. The reaction mixtured was directly filtered through a 3 cm (i.d. 1 cm) glass column filled with SiO2 (Merck, 0.043-0.060 mm) eluting with diethyl ether. The eluate was dried (Na2SO4), filtered and the solvent was evaporated, yielding a black crystalline mass (0.048 g,95.8 % ).
Overhauser enhancement: 89 at 9 mW in THF at 1.84 mM, (concetration estimated by NMR -Evans method).
ESR spectrum: 7 lines, Linewidth 31 mG, aH = 62 mG
Example 72
1,2,4,5-Tetratrimethylsilyloxybenzene
Figure imgf000118_0001
1,2,4,5-Tetrahydroxybenzene (14.20 g, 100.0 mmol
(Example 4)) was dispersed, in pyridine (100 mL) and diethyl ether (100 mL), and Me3SiCl (70 mL, 645 mmol) was slowly added (heat evolved). After 3 hours the pyridiniumchloride was filtered off and the solvents of the filtrate (red) were evaporated, leaving a red oil, which was dissolved in ether, more solid material was filtered off, and the solvents of the filtrate (red) were evaporated. The residue was dissolved in diethyl ether and extracted with water (2x50 mL). The organic layer was separated, dried (Na2SO4), filtered and the solvent was evaporated and the residual crystalline material was washed with cold MeOH, leaving white crystals (needles), which were dried in vacuum (4.6 g, 10%) melting at 112 °C.
GC/MS showed M+ 430 (100%)
1H NMR (CDCl3, 300 MHz) δ: 6.32 (s, CH, 2H), 0.20 (s,
Si(CH3)3 36H).
13C NMR (CDCl3, 75 MHZ) δ: 140.17, 113.63, 000.15.
Example 73
Tris(8-nitroethenyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)dioxole-4-yl)methane
Figure imgf000119_0001
Tris(8-nitromethylhydroxymethyl-2,2,6,6- tetramethylbenzo-[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methane (0.670 g, 0.710 mmol (Example 83)) was dissolved in Ac2O (30 mL) and NaOAc (2.00 g, 24.4 mmol) was added and the reaction mixture was refluxed for 0.5 h. The solution turned deep red. The solvent was
evaporated and the residue was partitioned between ether (100 mL) and water (50 mL). The organic layer was separated, dried (Na2SO4), filtered and the solvent was evaporated yielding a deep red crystalline residue (0.62 g, 98%). The 1H NMR and 13C NMR spectra were in identical to those recorded for the same product, given in Example 82. Example 74
3,4-Dihydroxy-2.5-thiophenyl dicarboxylic acid
diethylester
Figure imgf000120_0001
Sodium (27.8 g, 1.21 mol) was dissolved cautiously in refluxing absolute EtOH (1300 mL) and a mixture of bis (ethoxycarbonylmethyl) sulfide (108.0 g, 0.540 mol) and diethyl oxalate (81.8 g, 0.540 mol) was added dropwise. The reaction mixture was refluxed for 1 hour, allowed to cool, filtered and acidified. The new precipitate was filtered and dried (80 °C) in vacuum. Recrystallization from EtOH:EtOAC (1:1) (450 mL) gave two crops of the thiophene; 93.2 g (67%).
13C NMR (DMSOd6, 75 MHz) δ: 161.93, 150.15, 107.92, 60.80, 14.11. Example 75
3-4-Methylenedioxy-2,5-thiophenedicarboxylic acid
diethylester
Figure imgf000121_0001
3,4-Dihydroxy-2,5-thiophenyl dicarboxylic acid
diethylester (68.4 g, 300 mmol (Example 74)),
bromochl or ome thane, K2CO3 (40.0 g) and Na2S2O4 (4 spoons) were mixed in DMSO (315 mL) and refluxed for 24 h. The reaction mixture was filtered, cooled and filtered again. The solvent was evaporated, leaving a solid residue which was dissolved in CH2Cl2 and filtered. The filtrate was washed with water, 10% NaHCO3 and water. The organic layer was separated, dried (Na2SO4), filtered and the solvent was evaporated, yielding a crystalline residue, which was recrystallized from absolute EtOH (800 mL; the filtration performed while the solvent was hot), yielding the desired product 3,4- methylenedioxy-2,5-thiophenedicarboxylic acid
diethylester (11.8 g, 15%), melting at 124 °C.
13C NMR (DMSOd6, 75 MHz) δ: 160.13, 151.51, 113.36,
104.20, 61.87, 14.46. Example 76
3,4-Methylenedioxy-2,5-thiophenedicarboxylic acid monoethylester
Figure imgf000122_0001
3,4-Methylenedioxy-2,5-thiophenedicarboxylic acid diethylester (3.08 g, 11.3 mmol (Example 75)) was refluxed in EtOH/KOH (88 mL EtOH and 5.57 g, 11.3 mmol KOH) for 48 h. The reaction mixture was allowed to cool and the precipitate was filtered and the filter cake was triturated with cold 0.1 M HCl. The basic filtrate from the first filtration was also triturated with 0.1 M HCl and the crystals from these acidifications were pooled, dried and later recrystallized from water/EtOH (1:1) and yielded 2.62 g (95%) of the desired mono-carboxylic acid.
13C NMR (DMSOd6, 75 MHz) δ: 161.11, 159.83, 151.07,
150.64, 112.65, 105.43, 103.39, 61.35, 14.07.
Example 77
3,4-Methylenedioxy-2-bromo-5-ethoxycarbonyl thiophene
Figure imgf000122_0002
(See Chem. Ber. 108 (1975) p.576). 3,4-Methylenedioxy-2,5-thiophenedicarboxylic acid monoethylester (5.00 g, 20.5 mmol (Example 76)) was dissolved in water (115 mL) and the solution was made alkaline to pH 11 with K2CO3 . The solution was filtered and warmed to 50 °C before Br2 (1.8 mL) was added during a period of 1 h. Crystals precipitated, the precipitate was filtered off and the filter cake was washed with water and dried, yielding 2.3 g (34%) of the desired product, melting at 93 °C.
13C NMR (DMSOd6, 75 MHz) δ: 160.11, 150.32, 147.09, 110.75, 102.96, 85.64, 6.45, 14.33.
Example 78
3,4-Methylenedioxy-2-bromo-5-carboxy thiophene
Figure imgf000123_0001
NaOH (10 %) and MeOH were mixed in the proportion 1:1 (80 mL) and added to 3,4-methylenedioxy-2-bromo-5- ethoxycarbonyl thiophene (1.91 g, 7.00 mmol (Example 77)), and the reaction mixture was heated to 60-70 ºC and kept there for 2h. After cooling, the reaction mixture was filtered and the MeOH of the filtrate was evaporated and water was added. Acidification with 10% HCl precipitated the free acid 3,4-methylenedioxy-2- bromo-5-carboxy thiophene, which was filtered and dried in a desiccator (P2O5), yielding 1.41 g (82%).
MS (El 70 ev) : M+ 324 and 322 of the TMS derivative. Example 79
3 ,4-Methylenedioxy-2-bromo-thiophene-5-carboxylic acid chloride
Figure imgf000124_0001
3,4-Methylenedioxy-2-bromo-5-carboxy thiophene (9.64 g, 38.4 mmol (Example 78)) was dissolved in dry DMF (0.73 mL) and SOCl2 (38 mL) was added and the reaction mixture was refluxed for 5 hours. Excess SOCl2 was removed by distillation under reduced pressure, yielding 9.75 g (94%) of the acid chloride, which was used in the next reaction (see Example 80) without further purification.
Example 80
Figure imgf000124_0002
The crude 3,4-methylenedioxy-2-bromo-thiophene-5- carboxylic acid chloride from Example 79 (0.398 mmol) was dissolved in CH2Cl2 (1.0 mL) and slowly added dropwise to a mixture of 2-amino-2-methyl-1-propanol (0.478 mmol) and 4 , 4-dimethylamino pyridine (0.059 g, 0.478 mmol) in CH2Cl2 (1.0 mL) at 0 °C. After 12 h at room temperature water (2 mL) was added and the organic phase was separated and washed with two more portions of water (2x2 mL). The organic phase was dried by passing it through a small pipette packed with ground CaCl2 and evaporated yielding 0.1286 g (85 %).
GC/MS on the TMS derivative showed (M+-TMS+H) at m/e 321/323 (containing Br).
Example 81
Figure imgf000125_0001
The product of Example 80 (0.100 g, 0.370 mmol) was dissolved in CH2Cl2 and chilled to 0 °C and molecular sieves (3 Å, dried at 350 °C in vacuum) were added before adding SOCl2 (740 mmol). The reaction mixture was stirred at room temperature over night. Excess solvent and SOCl2 were removed under reduced pressure and the residue was partitioned between 10% Na2CO3 and CH2Cl2. The organic phase was separated, dried (Na2SO4), filtered and the solvent was evaporated yielding 0.050 g (44%) of the desired product.
GC/MS on the TMS derivative showed M+ at 303/305
(containing Br).
Example 82
Tris (8-nitroethenyl-2 , 2 , 6 , 6-tetramethylbenzo [ 1 , 2-d: 4 , 5- d' ]bis (1 , 3) dioxole-4-yl) methane
Figure imgf000126_0001
Tris(8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']bis-
(1,3)dioxole-4-yl)methan (0.45 g, 0.59 mmol, (Example
23)), nitromethane (20 mL, 290 mmol) and ammonium acetate (0.12 g, 1.56 mmol) were mixed and heated to 100
°C for 6.5 h. After cooling, water (70 mL) was added, followed by ether (100 mL). The organic phase was separated, dried (Na2SO4) and the solvents evaporated, leaving a dark-red oil, which solidified after pump drying, yielding 0.38 g (72%) of the product.
1H NMR (CDCl3, 300 MHz) δ: 7.98 (d, CH-NO2, 1H, JHH 11 Hz)
7.80 (d, CH, 1H, JHH 11 Hz), 5.41 (s, CH, 1H), 1.54 (s,
CH3, 36H).
13C NMR (CDCl3, 300 MHz) d:137.10, 136.86, 136.01,
126.29, 116.63, 107.32, 95.42, 68.89, 22.78.
MS (El): M++1 891 (40 %), M+ 890 (75 %), 818 (100 %).
Example 83
Tris(8-nitromethylhvdroxymethyl-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis- (1,3)dioxole-4- yl)methane
Figure imgf000126_0002
Tris(8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']bis- (1,3)dioxole-4-yl)methane (0.150 g, 0.197 mmol, Example 23) and nitromethane (0.36 g, 5.9 mmol) were mixed in dry dioxane (20 mL), and NaH (0.030 g, 0.197 mmol, 80 % in oil) was added at ambient temperature. After stirring overnight, the reaction was checked by TLC, and found to be completed. IR (film on NaCl) of the reaction mixture confirmed this, no CHO fragment coud be detected. Water (50 mL) and a few drops of HCl (2 M) were added. The mixture was extracted with ether (3x50 mL). The organic extracts were washed with water (40 mL), dried (Na2SO4) and the solvent was evaporated, leaving a crystalline yellow residue. The product was chromatographed on a column of silica with CH2Cl2,EtOAc 45:5 as eluent. The fractions containing pure product were pooled and the solvent was evaporated, yielding 0.150 g (81 %).
1H NMR (CDCl3, 300 MHz) δ: 5.40-5.50 (m, CH-O, 1H), 5.36 (s, CH, 1H), 4.79-4.86 (m, CH-NO2, 1H), 4.61-4.66 (m, CH2- NO2, 1H), 3.07 (s, OH, 1H), 1.50 (s, CH3) .
13C NMR (CDCl3, 75 MHz) δ: 139.87, 137.08, 118.38,
118.21, 78.80, 64.94, 30.58, 25.36 and 25.30 (CH3, two resonances due to assymmetry).
Example 84
Tris(8-diethylaminocarbonyl-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis-(1.3)dioxole-4- yl)methyl
Figure imgf000127_0001
Tris(8-diethylaminocarbonyl-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis-(1,3)dioxole-4- yl)methane (0.076 g, 0.080 mmol (Example 87)) was dissolved in a mixture of of dry THF (40 mL, sodium benzophenone ketyl) and dry DMSO (10 mL, molecular sieves 4Å ) under N2. KOtBu (0.009 g, 0.080 mmol) was added and the mixture stirred at room temperature for 4 hours.
n-BuLi (0.1 mL, 2.5 M in toluene, 0.25 mmol) was added, and the colour of the reaction mixture changed to dark red, after which I2 (0.041 g, 0.16 mmol) was added. A sample of this solution was investigated by ESR
spectroscopy, indicating a radical content of < 5% Overhauser enhancement 2-10 at 2W.
Example 85
Tris(8-methylthiobenzo[1,2-d:4.5-d']bis(1.3)dioxole-4- yl)methanol and tris(8-methylthiobenzo[1,2-d:4,5- d']bis(1,3)dioxole-4-yl)methyl
Figure imgf000128_0001
Tris(benzo[1,2-d:4,5-d']bis(1,3)dioxole-4-yl)methanol (1.00 g, 1.90 mmol (Example 3) was mixed with dry THF (25 mL, sodium benzophenone ketyl) under Ar (g) and cooled to -78 °C. n-BuLi (3.8 mL, 2.5 M solution in hexane) was added with a syringe. The cooling bath was removed and the resulting mixture was allowed to reach room temperature. The mixture turned thick and pasty and THF (25 mL, sodium benzophenone ketyl) was added in order to facilitate stirring. After 1 day CH3SSCH3 (1 mL) was added. The mixture became homogeneous (and dark) almost instantaneously. After 2 hours, the reaction mixture was poured on ice-water (200 mL) and extracted with CH2Cl2 (3x100 mL). The organic phase was dried
(MgSO4) and filtered and the solvent was evaporated to give a dark brown syrup, which was dissolved in CHCl3, filtered through SiO2 and evaporated to a new syrup. The brown syrup was chromatographed on SiO2 with Et2O as eluent. (The sample was applied to the column in a mixture of Et2O/CH2Cl2). Yield 1.05 g, 84 %.
MS (El 70 ev): M++ 662, 646, 616, 570.
Tris(8-methylthiobenzo[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methanol was converted to the corresponding radical with BF3.OEt3 (cation formation) and CrCl2 (reductant) as described in other Examples. The ESR spectrum showed a linewidth of 120 mG in THF at a concentration of 1 mM. The Overhauser enhancement was 10 at 5 W.
Example 86
2 , 6-Disilicium-2 , 2 , 6 , 6-tetra-tert-buty4lbenzo [ 1 , 2-d : 4 , 5-d ' ] 'bis (1.3 ) dioxole
Figure imgf000129_0001
1,2,4,5-Tetrahydroxybenzene (0.284 g, 2.0 mmol (Example 4)) and imidazole (0.81 g, 12.0 mmol) were dissolved in dry DMF (15 ml) and di-t-butyldichlorosilane (1.28 g, 6.0 mmol) was added dropwise with stirring. The
solution was stirred for 15 h, diethyl ether (50
ml, sodium benzophenone ketyl) was added. The organic phase was washed with HCl (2x25 ml, 5 %), NaOH 2x25 ml, IM), water (25 ml), dried and evorporated, yielding 0.50 g of a solid yellow residue. Recrystallization from diisopropyl ether gave 0.330 g (39%) pure, slightly yellow compound.
1H NMR (CDCl3, 300 MHz) δ: 6.12 (s, CH, 2H), 1.05 (s, bu, 36H).
MS (El, 70 ev, GLC inlet) m/e: 425 (3), 424 (12), 423 (36), 422 (100), 383 (14), 382 (31)
Example 87
Tris(8-diethylaminocarbonyl-2.2.6,6- tetramethylbenzo[1,2-d:4,5-d']'bis(1.3)dioxole-4- yl)methane and bis(8-diethylaminocarbonyl-2,2,6,6,- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4-yl)- mono(2,2,6,6-tetramethyl-benzo[1,2-d:4.5- d']bis(1,3)dioxole-4-yl)methane
Figure imgf000130_0001
A crude mixture of tris(8-carboxyl-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methane and bis(8-carboxyl-2,2,6,6-tetramethylbenzo- [1,2-d:4,5-d']bis(1,3)dioxole-4-yl)mono(2,2,6,6,- tetramethylbenzo[1,2-d:5-d']bis(1,3)dioxole-4- yl)methane (1.00 g, from Example 18) was dissolved in dry THF (10 mL) at room temperature, SOCl2 (0.61 mL, 8.4 mmol) was added, and stirring was continued for 2.5 hours. The solvent and excess SOCl2 was evaporated under reduced pressure, leaving a brown crystalline residue, which was dried on a vacuum pump (<1 torr) for 10 h.
This residue was dissolved in dry THF (5 mL), and Et2NH (1.50 g, 21.0 mmol) was added and stirred for 12 hours. The reaction mixture was partitioned between ether (75 mL) and water (50 mL). The organic phase was separated, dried (Na2SO4), filtered and the solvent was evaporated leaving a brown crystalline residue. Chromatograhpic (RP8, 10 μm, 20x250 mm, CH3CN:H2O 75:25) separation, yielded 0.100g (0.098 mmol, 14%) of tris (8- diethylaminocarbonyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)dioxole-4-yl)methane and 0.150 g (160 mmol, 37%) of bis(8-diethylaminocarbonyl-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4-yl)- mono (2,2,6,6-tetramethyl-benzo[1,2-d:4,5-d']bis- (1,3)dioxole-4-yl)methane. The yields are calculated for two steps (including the reaction in Example 18). Tris(8-diethylaminocarbonyl-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methane:
1H NMR (300 MHZ. CDCl3) δ: 1.06-1.12 (t, CH3. 3H), 1.17- 1.24 (t, CH3. 3H), 1.52 (s, CH3, 36H), 3.26-3.37 (q, CH2, 2N), 3.51-3.60 (q, CH2. 2H), 5.41 (s, CH, 1H).
Bis(8-diethylaminocarbonyl-2,2,6,6-tetramethylbenzo [1,2- d:4,5-d']bis(1,3)dioxole-4-yl)-mono(2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bos(1,3)dioxole-4- yl)methane
1H NMR (300 MHz. CDCl3) δ: 1.06-1.12 (t, CH3. 3H), 1.17- 1.24 (t, CH3. 3H), 1.52 (s, CH3, 24H), 1.54 (s, CH3, 12H), 3.26-3.37 (q, CH2. 2H), 3.51-3.60 (qs, CH2, 2H), 5. 41 (s , CH, 1H) , 6. 21 (s , aromatic H , 1H) .
Example 88
Tris(8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4.5-d']bis- (1,3)dioxole-4-yl)methyl bisulfite adduct
Figure imgf000132_0001
Tris(8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']bis- (1,3)dioxole-4-yl)methyl (0.065 g, 0.976 mmol (Example 64)), with a radical content of about 10%, and Na2S2O5 (0.370 g, 1.95 mmol) were mixed in a 25 mL round flask under N2(g). Water (1.5 mL, He degassed 15 min.) and dioxane (1.5 mL, He degassed 15 min.) were added. After 15 minutes stirring most of the solid material had dissolved. HPLC analysis showed that the starting aldehyde was consumed after 45 minutes. An Overhauser experiment confirmed the presence of radical in the reaction mixture. Overhauser enhancement was 59 at 5W microwave power. ESR four lines, Linewidth 133 mG, aH 973 mG.
The bisulfite adduct was precipitated by the addition of dioxane and the precipitate was filtered and washed twice with dioxane. The product was dried under vacuum in room temperature overnight.
Example 89
Tris(8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']bis- (1,3)dioxole-4-yl)methane bisulfite adduct
Figure imgf000133_0001
This reaction was performed with tris(8-formyl-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis-(1,3)dioxole-4- yl)methane (0.050 g, 0.066 mmol (Example 23)), and
Na2S2O5 (0.285 g, 1.5 mmol) analogous to the formation of the bisulfite adduct of tris(8-formyl-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis-(1,3)dioxole-4- yl)methyl radical as detailed above in Example 88, yielding 0.140 g (the theoretical yield is 0.070 g) of crystals containing NaHSO3.
1H NMR (300 MHZ, D2O) δ: 1.4 (d, CH3, 36H), 5.2 (s, CH, 1H), 5.3 (S, CH-OH, 3H).
13C NMR (75 MHz, D2O) d: 24.4 (d, CH3), 28.0 (s, CH), 102 (s), 107 (s), 119 (s), 138 (s), 140 (s), 164 (s)
Example 90
Tris (4-carboxy-2 , 3 , 5 , 6-tetrachlorophen-1-yl) methyl y
Figure imgf000133_0002
Tris(4-carboxy-2,3,5,6-tetrachlorophen-1-yl)methane (0.690 g, 0.87 mmol) [(1R (KBr, cm-1) 3450 (O-H str.), 2920 (C-H str), 1720 (C=O str.), 1550, 1420 (C-C in chlorinated aryls). 1H NMR (CD3OD, 300 MHz) δ: 8.00 (s, CH, 1H), 13C NMR (CD3OD, 75 MHz)) δ: 164.35, 132.40,
132.26, 133.00. 132.00, 56.88.] was mixed with NaOH (s) (0.090g, 3.6 mmol) in DMSO (10 mL) and stirred for 24 hours in the dark. I2 (0.110 g, 0.43 mmol) was dissolved in ether (40 mL) and this solution was added and the resulting mixture was stirred for 15 minutes. The reaction mixture was poured on saturated NaHCO3 (100 mL). The phases were separated and the aqueous phase (pH 2) was acidified to pH 1-2 (cone. HCl). The acidic aqueous phase was extracted with ether (2x100 mL). The ether phase were combined, dried (Na2SO4), filtered and the solvent was evaporated yielding a tan semi-crystalline residue of 0.250 g (36 %).
ESR (200 G) : One line, Linewidth 570 mG.
Overhauser enhancements (0.2 M in H2O, 200 G, 548.9 MHz) 2-10 at 2w microwave power.
Example 91
Tris (4-trichloromethyl-2 , 3 , 5 , 6-tetrachlorophen-1- yl) methyl
Figure imgf000134_0001
Tris(4-trichloromethyl-2,3,5,6-tetrachlorophen-1- yl)methane was converted to the corresponding radical as described in Example 90. ESR (200 G) : One line, Linewidth 1500 mG.
Overhauser enhancements (200 G, 548.9 MHz) 2-10 at 2W microwave power.
Example 92
Tris(2,3,5,6-tetrachloro-4-methylphen-1-yl)methyl
Figure imgf000135_0001
Tris(2,3,5,6-tetrachloro-4-methylphen-1-yl)methane was converted to the corresponding radical as described in
Example 90.
ESR (200 G) : One line, Linewidth 3200 mG.
Overhauser enhancements (200 G, 548.9 MHz) 2-10 at 2W microwave power.
Example 93
(Phenyl) - (pyrid-4-yl) - (thien-2-yl)methanol
Figure imgf000135_0002
Thiophene (1.150 g, 13.60 mmol) was dissolved in diethyl ether (50 mL, sodium benzophenone ketyl) under argon, n- Butyl lithium (5.10 mL, 13.60 mmol) was added quickly with a syringe under evolution of heat. The resulting mixture was stirred for 1 hour and 15 minutes at room temperature. After cooling to -75°C, benzoylpyridine (2.50 g, 13.6 mmol) dissolved in THF (10 mL) was added over a period of 10 minutes and the resulting mixture was stirred for 60 hours at room temperature. The resulting thick yellow suspension was diluted with THF (100 mL) and NaH2PO4 buffer (1.25 M, 100 mL) was added. The organic layer was separated and washed with more NaH2PO4 buffer (2x30 mL, 1.25 M), dried (Na2SO4) and evaporated yielding 3.24 g of crude material.
Chromatography (flash, TLC gel 125 g, CH2Cl2: diethyl ether 4:6) yielded 1.83 g (6.85 mmol, 50%) of the title compound.
1H NMR (DMSO d6, 300 MHz) δ: 8.49 (m, H), 7.49-7.47 (q, 1H), 7.35-7.24 (m, 7H), 6.97-6.95 (q, 1H), 6.70-6.68 (q, 1H).
13C NMR (DMSO d6, 75 MHz) δ: 155.63, 151.55, 149.29, 146.14, 127.85, 127.42, 127.00, 126.48, 126.44, 125.96, 121.89, 77.97.
MS (El 70 eV) : M++1 268, 190.
Example 94
(m-Chlorophenyl) - (phenyl) -pyrid-4-yl ) methanol m
Figure imgf000136_0001
m-Chlorobromobenzene (2.60 g, 13.60 mmol) was dissolved in THF (50 mL, sodium benzophenone ketyl) under argon. The solution was cooled to -78°C and s-butyl lithium (9.7 mL, 13.60 mmol in cyelohexane/isopentane) was added over a period of 10 niinutes. The resulting mixture was stirred for 1 hour at -78°C. Benzoylpyridine (2.50 g, 13.6 mmol) dissolved in THF (10 mL) was added over a period of 5 minutes and the resulting mixture was stirred for 60 hours at room temperature. The resulting yellow solution was hydrolysed with NaH2PO4 buffer (1.25 M, 40 mL). The organic layer was separated and washed with more NaH2PO4 buffer (30 mL, 1.25 M), dried (Na2SO4) and evaporated. The solid was stirred with CH3CN (100 mL) for 3 hours. The solid was filtered and dried and was shown by TLC and MS to be pure.
1H NMR (DMSOd3, 300 MHz) δ: 8.52-8.50 (q, CH pyridine 2H), 7.35-7.09 (m, 1H).
13C NMR (DMSOd3, 75 MHz) δ: 155.20, 149.37, 148.88, 145.68, 132.76, 129.77, 127.99, 127.58, 127.37, 127.24, 127.16, 126.52, 122.52, 79.64.
MS (El 70 eV) : M++1 296 and 298, 218, 220.
Example 95
Tris(8-dimethylaminocarbonylthio-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)-dioxole-4- yl)methane
Figure imgf000137_0001
Nal (1.135 g, 8.00 mmol) and Me3SiCl (1 mL, 8.0 mmol) were stirred in CH3CN (70 mL) at 0°C. Tris(8- dimethylaminocarbonylthio-2,2,6,6-tetramethylbenzo-[1,2- d:4,5-d']bis(1,3)-dioxole-4-yl)methanol (1.00 g, 0.9979 mmol (Example 43)) dissolved in CH3CN 10 mL) was added and the resulting solution stirred for 30 minutes when 1H NMR analysis of a small sample showed conversion to be complete. Na2S2O3 (sat., 30 mL) was added and the two phase system was stirred 30 minutes when more Na2S2O3 (sat. 30 mL) was added and the stirring was continued for 5 more minutes. The phases were separated and the organic layer was dried (MgSO4), filtered, the filter washed with diethyl ether (30 mL) and the solution was evaporated, yielding 1.16 g yellow to brown crystals. The crystals were dissolved in CH2Cl2, the solution was washed with NaHCO3 (30 mL, sat.) and H2O (30 mL), dried (MgSO4) and evaporated yielding 0.92 g of the pure title compound.
1H NMR (CDCl3, 300 MHz) δ: 5.38 (s, 1H) 3.04 (s, 9H), 2.94 (s, 9H), 1.51 (s, 36H).
13C NMR (CDCl3, 75 MHz) δ: 163.22, 142.11, 139.50,
117.93, 108.75, 90.79, 36.91, 30.96, 25.30.
MS (Thermospray): M++18 1003.
Example 96
Bis(8-methylmercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)dioxole-4-yl)-mono(2-methylmercaptopyrimidin-5-yl)methyl
Figure imgf000138_0001
Bis(8-methylmercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)dioxole-4-yl)-mono(2-methylmercaptopyrimidin-5-yl)methanol (0.075 g, 0.109 mmol (Example 60)) was dissolved in THF (75 mL, sodium benzophenone ketyl). BF3.0Et2 (0.475 mL, 1.853 mmol, 48% in diethyl ether) was added. The color changed from yellow to green. The solution was. stirred for 15 minutes and SnCl2 (0.103 g, 0.545 mmol) was added. 30 minutes later Zn (0.178 g, 2.725 mmol) was added and there followed an immediate color change to yellow/brown/greyish. More Zn (0.230 g, 3.51 mmol) was added one hour after the first addition. After leeting the Zn settle, a sample was taken with a gas tight syringe and an Overhauser
enhancement experiment was performed on this solution. The measured enhancement was 100 at 5W microwave power.
Example 97
Bis (8-methoxycarbonylmethylthio-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4-yl)- mono(8-ethoxycarbonylmethylthio-2,2.6,6- tetramethylbenzo[1,2-d:4.5-d']bis(1,3)dioxole-4- yl)methanol
Figure imgf000139_0001
The title product was isolated by HPLC as a by product from the reaction described in Example 12.
13C NMR (CDCl3, 75 MHz) δ: 169.50, 168.99, 141.33,
141.28, 138.64, 138.62, 117.77, 117.75, 112.53, 112.33, 96.66, 96.46, 72.48, 52.30, 35.45, 35.40, 25.42.
Example 98
Bis(8-mercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)dioxole-4-yl)-mono(8-methoxycarbonylmethyl- 2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4- yl)methanol
Figure imgf000140_0001
The title product was isolated by HPLC as a by product from the reaction described in Example 12.
13 C NMR (CDCl3, 75 MHz) δ: 169.52, 141.25, 140.13,
138.79, 138.68, 117.66, 116.95, 112.73, 111.90, 96.46, 96.34, 72.53, 35.36, 25.39, 25.34.
Example 99
Tris(benzothien-2-yl)methanol
Figure imgf000140_0002
Benzothiophene (5.42 g, 0.0382 mmol) was dissolved in diethyl ether (100 mL). n-Butyl lithium (20.0 mL, 2M) was added at -15°C under an argon atmosphere. The resulting mixture was allowed to reach room temperature and diethyl carbonate (1.54 mL) was added and when TLC showed the reaction to be complete. The mixture was worked up by adding Na2HPO4 buffer (100 mL, sat.), separating the phases and washing the organic phase with more buffer and water. Drying (MgSO4), evaporation and chromatographic separation yielded 1.40 g (25.7%) of the title compound.
13C NMR (CDCl3, 75 MHz) δ: 150.12, 140.08, 139.03,
124.48, 124.08, 123.44, 122.37, 50.80.
Example 100
4-Allylthio-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)dioxole
Figure imgf000141_0001
The title product was synthesized from 2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole (4.5 g, 0.02 mmol (Example 5)), n-butyl lithium (9.0 mL, 2.5 M), S8 (0.70 g) and allylbromide (2.42 g, 1.73 mL) in THF. Yield 4.9 g (83%) of a yellow brown oil.
13C NMR (CDCl3, 75 MHz) δ: 141.82, 139.90, 133.76,
118.25, 117.38, 98.31, 92.72, 36.66, 25.56. Example 101
Tris(8-di(methylcarbonyloxyethyl)
aminocarbonylmethylthio-2,2,6,6-tetramethylbenzo[1,2- d:4,5-d']bis(1,3)-dioxole-4-yl)methyl
Figure imgf000142_0001
Tris(8-di(methylcarbonyloxyethyl)
aminocarbonylmethylthio-2,2,6,6-tetramethylbenzo-[1,2- d:4,5-d']bis(1,3)-dioxole-4-yl)methanol (0.098 g, 0.066 mmol (Example 38)) was dissolved in THF (30 mL, Al2O3). BF3.OEt2 (3.00 mL, 11.77 mmol, 48% in diethyl ether) was added. The solution was stirred for 30 minutes and SnCl. (0.159 g, 1.122 mmol) was added. 30 minutes later Zn (0.108 g) was added and there followed an immediate color change from blue to brown. After letting the Zn settle, a sample was taken with a gas tight syringe and an Overhauser enhancement experiment was performed on this solution. The measured enhancement was 28 at 4 mW microwave power and 69 at 0.77 W.
ESR (200 G, THF solution) : One line, linewidth 187 mG. Example 103
Figure imgf000143_0001
The bromo oxazolidine thiophene of Example 81 is
trimerized to the corresponding trityl by treatment with one equivalent of n-butyl lithium in THF at -75°C for 30 minutes. 0.3 equivalents of diethyl carbonate is added at this temperature and the solution is allowed to reach room temperature over a period of several hours. The reaction mixture is worked up by pouring the solution on cold NH4Cl or cold Na2HPO4 buffer followed by extraction with diethyl ether or CH2Cl2. The organic phase is washed with water, dried (Na2SO4) and is evaporated to yield the crude carbinol. The pure compound is obtained by chromatography on either SiO2 or RP8 gel. The product is characterised by 1H NMR and 13C NMR as well as other spectroscopic methods. The methanol compound is either converted directly to the radical or first to the methane.
Example 104
Bis(8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']bis- (1,3)dioxole-4-yl)ketone
Figure imgf000143_0002
2,2,6,6-Tetramethylbenzo[1,2-d:4,5-d']bis-(1,3)dioxole (8.88 g, 0.040 mol (Example 5)) was dissolved in THF (250 mL) and cooled to -20 °C under a N2 atmosphere. n- Butyl lithium (19.2 mL, 2.5 M in toluene) was added and the temperature was allowed to increase to +10°C over a period of 10 minutes. The mixture was then cooled to -20°C and DMF (2.92 g, 0.040 mol) was added and the temperature was allowed to reach room temperature in 2 hours. The mixture was again cooled to -20°C and a second portion of n-butyl lithium (19.2 mL, 2.5 M in toluene) was added. The temperature was allowed to reach room temperature in 1 hour. After once again recooling to -20°C, dimethyl carbonate (1.19 g, 0.0132 mol) was added and the temperature was allowed to reach room temperature overnight. Water (300 mL) and acetic acid (2 mL) were added and the solution was extracted with ether (3x150 mL). The organic extracts were combined, dried (Na2SO4 and K2CO3) and the solvent evaporated leaving a semi-crystalline dark residue. The residue was crystallized twice from EtOAc:heptane 4:1 giving the title compound as a deep red crystalline product. Yield 3.0 g (43%).
1H NMR (CDCl3, 300 MHz) δ: 10.11 (s, CHO, 2H), 1.68 (s, CH3, 24H).
13C NMR (CDCl3, 75 MHz) δ: 185.25, 183.05, 141.08,
139.72, 121.48, 112.12, 108.09, 25.72.
IR (KBr) : 1700 (vs, C=) in CHO, 1670 (s, C=O).
Example 105
Tris(8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']bis- (1,3)dioxole-4-yl)methanol and bis(8-formyl-2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4-yl)- mono(2,2,6,6-tetramethylbenzo[1,2-di:4,5-d']bis- (1,3)dioxole-4-yl)methanol and mono(8-formyl-2,2,6,6- tetramethylbenzo[1,2-d:4.5-d']bis(1,3)dioxole-4-yl)- bis(2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']bis(1,3) dioxole-4-yl)methanol
Figure imgf000145_0001
Tris(2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']bis- (1,3)dioxole-4-yl)methanol (10.0 g, 0.0145 mol (Example 44)) was suspended in dry diethyl ether (300 mL). n- butyl lithium (29 mL, 0.0725 mol, 2.5 M in hexane) was added, under nitrogen, and the solution was heated slowly to reflux temperature (ca. 20 min.). A second portion of n-butyl lithium (9.8 mL, 2.5 M in hexane) was added and the heating was disrupted. 5 minutes after removal of the oil bath, DMF (130 mL, 0.169 mol) was added carefully. The resulting mixture was stirred at room temperature over night. Water (300 mL) and AcOH was (5 mL) was added to the solution. An orange colour appeared in the solution at this time. The mixture was extracted with diethyl ether (2x300 mL). The combined organic phase was washed with wather (3x100 mL), dried (Na2SO4, K2CO3), treated with charcoal and filtered through SiO2 (3 cm, i.d. 5 cm) and evaporated. The residual brown residue was dried under vacuum to leave a form weighing 11.1 g. This material was chromatographed on several columns of SiO2 with CH2Cl2:EtOAc 45:5 as eluent.
Yield of tris(8-formyl-2,2,6,6-tetramethylbenzo[1,2- d:4,5-d']bis(1,3)dioxole-4-yl)methanol 1.8 g (16.9%). 1H NMR (CDCl3, 300 MHz) δ: 10.08 (s, CHO, 3H), 4.32 (s, OH, 1H), 1.55 (s, CH3, 36H).
13C NMR (CDCl3, 75 MHz) δ: 185.41, 140.82, 139.25, 119 . 58 , 116. 58 , 105 . 76 , 72 . 71 , 25 . 62 .
MS (Thermospray) : M++23 (Na) 799 .
Yield of bis(8-formyl-2,2,6,6-tetramethylbenzo[1,2- d:4,5-d']bis-(1,3)dioxole-4-yl)-mono(2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']bis(1,3)dioxole-4-yl)- methanol 4.5 g (42%).
13C NMR (CDCl3, 75 MHz) δ: 185.51, 140.77, 140.31,
139.41, 138.62, 119.34, 117.53, 117.19, 110.80, 105.59, 92.31, 72.70, 25.60, 25.44.
MS (Thermospray) : M++23 (Na) 771.
Yield of mono (8-formyl-2,2,6,6-tetramethylbenzo[1,2- d:4,5-d']bis (1,3) dioxole-4-yl)-bis(2,2,6,6- tetramethylbenzo[1,2-d:4,5-d']bis(1,3) dioxole-4- yl)methanol 2.1 g (20.1%).
13C NMR (CDCl3, 75 MHz) δ: 185.69, 140.73, 140.19,
139.57, 138.81, 119.12, 118.58, 116.95, 111.67, 105.43, 91.98, 72.71, 25.59, 25.43.
MS (Thermospray): M++23 (Na) 743.
Example 106
4-Formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5-d']bis(1,3)- dioxole
Figure imgf000146_0001
2,2,6,6-Tetramethylbenzo[1,2-d:4,5-d']bis(1,3)-dioxole (20.0 g, 90 mmol (Example 5)) was dissolved in THF (300 mL) and cooled to -20°C. n-Butyl lithium (38.0 mL), 2.5 M in toluene, 100 mmol) was added and the
temperature was allowed to rise to 0°C. The mixture was recooled to -20°C and DMF (6.9 mL, 90.0 mmol) was added. The reaction mixture was stirred over night while allowing the temperature to increase to room
temperature. Water (200 mL) and AcOH (5 mL) was added. The color changed from light yellow to strong orange. The mixture was extracted with diethyl ether (3x300 mL) and the combined organic phase was washed with water (2xl00mL), dried (Na2SO4) and evaporated. The product was trituated twice with petroleum ether and dried, yielding the pure title compound; 16.3 g (72%).
13C NMR (CDCl3, 75 MHz) δ: 185.51, 140.84, 140.81,
120.17, 106.38, 98.26, 25.67.
Example 107
Bis(8-formylethylenecrlycolacetal-2,2,6,6- tetramethylbenzo[1,2-d:4.5-d']bis(1,3)-dioxole-4- yl)ketone
Figure imgf000147_0001
Bis(8-formyl-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)-dioxole-4-yl)ketone (2.0 g, 3.80 mmol
(Example 104)), ethyleneglycol (50 mL) and
methanesulfonic acid (0.01 mL) were mixed and stirred at room temperature over a weekend. TLC analysis (SiO2 CH2Cl2:Et2O 4:1) indicated that the reaction was
complete. Pyridine (0.5 mL) was added and the reaction mixture was partitioned between diethyl ether (200 mL) and water (250 mL). The aquous phase was extracted with more ether (2x200 mL). The combined organic phase was washed with water (100 mL), dried (Na2SO4) and filtered through Al2O3 (2.5 cm, i.d. 2 cm). The solvent was evaporated leaving a yellow crystalline product. Yield 2.12 g (90.9%).
1H NMR (CDCl3, 300 MHz) δ: 6.06 (s, O-CH-O, 2H) , 4.19-
4.14 (m, CH2, 4H) , 4.02-3.97 (m, CH2, 4H) , 1.61 (s, CH3,
24H) .
13C NMR (CDCl3, 75 MHz) δ: 184.06, 139.68, 138.93,
119.37, 109.27, 108.82, 97.94, 65.73, 25.66.
Example 108
Tris(2,5-dimethylthien-3-yl)methanol
Figure imgf000148_0001
2,5-Dimethyl-3-iodo-thiophene (see S. Gronowitz and R. Beselin, Arkiv for Kemi 21: 349-355 (1963)) (0.05 mol) was dissolved in diethyl ether (150 mL, dry) and n-butyl lithium (25.0 mL, 2.06 M) was added at -78°C under N2 and stirred for 30 minutes. Diethyl carbonate (2.0 mL, 0.0166 mol) in diethyl ether (3 mL, dry) was added and the mixture was stirred for 30 minutes. The cooling bath was removed and the temperature was allowed to reach +10°C. At this temperature the mixture was poured onto ice/water. The organic phase was separated and washed with water (2x50 mL), dried (MgSO4) and
evaporated. The resulting oil was taken up in petroleum ether. After cooling the product was filtered and washed with a little petroleum ether. Yield 41.6%, mp. 110-111°C.
1H NMR (C6D6, 300 MHz) δ: 6.46 (H4, 3H), 2.19 (s, CH3, 9H), 2.03 (s, CH3, 9H), 1.70 (COH, 1H).
MS (El 70 eV) : M+-1 361.
MS (Thermospray): M+-17 345. Example 109
Tris (2 , 5-dimethylthien-3-yl ) methane
Figure imgf000149_0001
Tris(2,5-dimethylthien-3-yl)methanol (Example 108)) was converted to tris(2,5-dimethylthien-3-yl)methane using
Me3SiCl, CH3CN and Nal as described in several previous
Examples, e.g. 17, 61, 62 and 95. Yield 67.8%, mp. 143-
144°C.
1H NMR (CDCl3, 300 MHz) δ: 6.28 (s, 3H), 5.07 (s, methane
CH, 1H), 2.34 (s, CH3, 9H), 2.18 (s, CH3, 9H).
Example 110
Tris(2,5-dimethylthien-3-yl)methanol
Figure imgf000149_0002
Tris(2,4,5-trimethylthien-3-yl)methanol
Figure imgf000149_0003
Bis(2,5-dimethylthien-3-yl)-mono-(2,3-dimethyl-4-iodothien-5-yl)-methanol
Figure imgf000150_0001
Bis(2,5-dimethylthien-3-yl)-mono(2,5-di-t-butyl-thien-3- yl)-methanol
Figure imgf000150_0002
The title carbinols were made according to the same general procedure: To a stirred solution of the
corresponding mono- or diiodinated thiophene (0.05 mol) in diethyl ether (150 mL, dry) was added n-butyl lithium (25.0 mL, 2.06 M) at -70°C under N2. The solution was stirred for 30 minutes at this temperature. The
appropriate ketone (see A. Wiersma and S. Gronowitz Acta Chem Scand 24: 2593-2611 (1970) and Ya L. Goldfarb and P.A. Konstantinov, Bull. Acad. Sci. USSR, Engl transl., 108 1959) (0.05 mol), dissolved in diethyl ether (150 mL), was added and the resulting solution was stirred for 30 minutes at this temperature. The cooling bath was removed and when the reaction mixture had reached +10°C the mixture was poured on ice and water. The workup was as described in Example 108.
Tris(2,5-dimethylthien-3-yl)methanol
MS (Thermospray) : M+-17 345
Tris(2,4,5-trimethylthien-3-yl)methanol
Yield: 3.5%
MS (Thermospray) : M*-17 723
Bis(2,5-dimethylthien-3-yl)-mono-(2,3-dimethyl-4-iodothien-5-yl)-methanol
Yield: 13.3%
MS (Thermospray) : M+-17 471
Bis(2,5-dimethylthien-3-yl)-mono(2,5-di-t-butyl-thien-3- y1)-methanol
Yield: 5.6%
MS (Thermospray) : M+-17 429
Example 111
(Phenyl)-(pyrid-4-yl)-(thien-2-yl)methane
Figure imgf000151_0001
NAI (2.27 g, 16.0 mmol) and Me3Sicl (2.02, 16.0 mmol) were stirred in CH3CN (70 mL) at 0°C. (Phenyl)-pyrid-4- yl-(thien-2-yl)methanol (0.534 g, 2.00 mmol (Example 93)) was added at 0°C and the resulting solution was stirred over night at room temperature. Na2S2O3 (sat., 20 mL) was added and the two phase system was stirred 5 minutes. The phases were separated and the organic layer was dried (MgSO4), filtered and evaporated. The resulting crystals were dissolved in CH2Cl2 (30 mL), the solution was washed with NaHCO3 (30 mL, sat.) and H2O (30 mL), dried (MgSO4) and evaporated yielding 0.41 g which was recrystallized in diisopropyl ether giving 0.22 g (43.8%) of the pure title compound.
1H NMR (CDCl3, 300 MHz) δ: 8.53 (m, 2H), 7.37-7.11 (m, 8H), 6.96 (q, 1H), 6.71 (dt, 1H) 5.64 (broad s, 1H). 13C NMR (CDCl3, 75 MHz) δ: 152.33, 149.91, 145.53,
141.98, 128.72, 128.63, 127.23, 126.73, 126.71, 125.04, 123.89, 51.37.
Example 112
Bis(thien-2-yl)-mono-(4-methoxyphenyl)methyl
Figure imgf000152_0001
The carbinol of Example 115 (0.140 g, 0.463 mmol) was dissolved in dry (Al2O3 filtered and Ar (g) saturated) THF (30 mL) and BF3.Et2O (1.12 g, 7.87 mmol) was added and stirring was maintained 30 minutes when SnCl2 (0.437 g, 2.31 mmol) was added. After stirring for another 30 minutes, Zn dust (0.756 g, 11.6 mmol) was added and the stirring was continued. 30 minutes after the Zn
addition a sample was taken with a gas tight syringe, after letting the Zn settle, and Overhauser measurements showed some radical formation to have occurred. Example 113
Tris(8-diethylaminocarbonylmethylthio-2,2,6,6- tetramethyl-benzo[1,2-d:4,5-d']bis(1.3)dioxole-4- yl)methanol
Figure imgf000153_0001
Tris(8-mercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)dioxole-4-yl)methanol (1.00 g, 1.269 mmol (Example 31)) was added to a solution consisting of CH3CN (50 mL), K2CO3 (5.0 g and BrCH2CONEt2 (0.776 g, 4.0 mmol) made from BrCH2COBr and HNEt2 in CH2Cl2) at -5°C under argon. The cooling bath was removed and the temperature increased to +23°C. A 1H NMR control of a small sample 20 minutes after the removal showed complete conversion to have occurred. Diethyl ether (50 mL) was added and the solution was filtered. The solvents were evaporated and the residual 1.28 g of oily material was heated in diisopropyl ether (30 mL, 40°C). The material did not dissolve but changed into crystalline form in this process. Filtration and drying gave 0.96 g (67.0%) of the title compound.
1H NMR (CDCl3, 300 MHz) δ: 4.16 (s, COH 1H), 3.36 (q, NCH2CH3, 6H), 3.32 (q, NCH2CH3, 6H), 1.50 (s, CH3, 36H), 1.18 (t, CH3, 9H, 1.08 (t, CC3, 9H).
13C NMR (CDCl3, 75 MHz) δ: 166.92, 141.20, 138.63,
117.57, 112.21, 97.18, 75.52, 42.44, 40.13, 35.97,
25.48, 14.30, 12.83. Example 114
Tris(8-diethylaminocarbonylmethylthio-2,2,6,6- tetramethyl-benzo[1,2-d:4,5']bis(1,3)dioxole-4-yl)methyl
Figure imgf000154_0001
Tris(8-diethylaminocarbonylmethylthio-2,2,6,6- tetramethylbenzo[1,2-d:4,5']bis(1,3)dioxole-4- yl)methanol (0.100 g, 0.0886 mmol) was dissolved in dry (Al2O3 filtered and Ar (g) saturated) THF (30 mL) and BF3°Et2O (0.214 g, 1.51 mmol) was added and the color changed immediately from yellow to blue, and stirring was maintained during 30 minute. SnCl2 was added (0.084 g, 0.443 mmol) and the stirring was continued for one hour. Zn dust (0.145 g, 2.22 mmol) was added and one hour later another portion of Zn dust (0.124 g, 1.89 mmol) was added. An experiment one later on a crude sample from the reaction mixture, after letting the Zn settle, showed a 108 fold Overhauser enhancement at 4 mW microwave power. Example 115
Bis(thien-2-yl)mono(4-methoxyphenyl)methanol
Figure imgf000155_0001
p-Bromo methoxybenzene (0.96 g, 5.2 mmol) was dissolved in THF (50 mL) and n-butyl lithium (2.08 mL, 2.5 M in toluene) was added at -70°C and stirred at this
temperature for 10 minutes when the thienyl ketone (1.0 g 5.2 mmol) (see JACS 74: 1733-36 (1952), JCS 1956, 698- 705 and Receuil j58.: 24 (1949)) dissolved in THF (5 mL) was added. The temperature was allowed to rise
gradually to room temperature over night. The mixture was hydrolysed with water (50 mL). Ether (150 mL) was added and the phases were separated, the aqueous phase was extracted with more ether (100 mL) and the combined organic phase was washed with water (70 mL), dried
(MgSO4) and the solvent evaporated leaving a semi- crystalline black residue. The black residue was dissolved in hot heptane/EtOAc (3:1) and chromatographed on a column of alumina with heptane:EtOAc 3:1 as eluent. The product was isolated in a yield of 0.72 g (46.0%). 1H NMR (CDCl3, 300 MHz) δ: 7.38 (d, armoatic H m to OCH3, 2H, J 9Hz), 7.29 (q, thiophene H α to S, 2H, J 5.1 Hz, J 1.2 HZ), 6.95 (q, thiophene H β to S, 2H, J 5.1 Hz, J 3.6 Hz), 6.86 (d, aromatic H o to OCH3 2H, J 9Hz), 6.85 (s, thiophene γ to S, 2H, J 3.6 Hz, J 1.2 Hz), 3.81 s. OCH3, 3H), 3.04 (S, OH, 1H).
13C NMR (CDCl3, 75 MHz) δ: 159.04, 152.05, 138.36,
126.38, 126.37, 125.60, 113.12, 77.65, 55.18.
MS (El 70 eV) : M+ 302 (10%), Kf-16 286 (100%), M+-17 285 (90%) .
Example 116
Tris(8-propargylthio-2,2,6,6-tetramethyl-benzo[1,2- d:4,5-d']bis(1,3)dioxole-4-yl)methanol
Figure imgf000156_0001
Tris(8-mercapto-2,2,6,6-tetramethylbenzo[1,2-d:4,5- d']bis(1,3)dioxole-4-yl)methanol (0.400 g, 0.50761 mmol (Example 31) ) was added to a solution consisting of CH3CN (50 mL), K2CO3 (5.0 g) and BrCH2CCH (2.389 g, 2.284 mmol) at -5°C under argon. The cooling bath was removed and the temperature increased to +23 °C. A1H NMR control of a small sample 20 minutes after the removal showed
conversion to be complete. Diethyl ether (50 mL) was added and the solution was filtered. The solvents were evaporated and the residual oil weighed 0.401 g (87%). 1H NMR (CDCl3, 300 MHz) δ: 4.15 (s, 1H, OH), 3.51 (d, 6H, CH2), 2.97 (t, 3H, CCH), 1.47 (s, CH3, 36H).
13C NMR (CDCl3, 75 MHz) δ: 141.35, 138.38, 11.49, 112.38, 96.31, 79.73, 72.32, 70.80, 25.26, 21.55.
The product may be substituted at the alkyne hydrogen by lithiation followed by reaction with carbon dioxide or with R*Lv where R* is the group (e.g. an alkyl group) to be introduced and Lv is a leaving group. Example 117
The following known free radicals were tested for
Overhauser enhancement:
Radical Power Overhauser enhancement
37mW 2 5 W 70
Figure imgf000157_0001
(See Bert et al JACS 54: 3250 (1932):
Dunnebacke et al Chem. Ber. [1989] 122 533;
Judeikis et al JACS [1961] 84, 1132;
Sinclair et al JACS [1968] 90, 5074.
37mW 6.5 5 W 107
Figure imgf000157_0002
(see Dunnebacke et al (supra)) Radical Power Overhauser enhancement
5 W 7
Figure imgf000158_0001
(ESR Linewidth 250mG)
(See Anderson et al Acta. Chem. Scand.
(1962), 16, 1817-1818;
Falle et al, Canad. J. Chem.
(1986), 44 1387;
Ziegier et al, Annalen (1927), 458,
248;
Allan et al, J.C.S. (1986), 440; and
Anderson et al, Acta. Chem. Scand,
(1962), 16, 1817).
Figure imgf000158_0002
5 W 3
(ESR linewidth 600mG
aH 1200 mG)
(see Gomberg JACS [1990], 22, 757)
Example 118
Figure imgf000158_0003
The title compound was prepared following the reaction scheme:
Figure imgf000159_0002
(Example 5)
Figure imgf000159_0001
The title compound showed Overhauser enhancements of 52 at 3.5W and 2 at 22mW. The ESR spectrum showed a linewidth of 65 mG. FORMULATION EXAMPLES
EXAMPLE I
Intravenous enhancement agent
An Overhauser MRI enhancement solution is prepared as follows:
The freeze dried radical e.g. that of Example 11 is dissolved in oxygen-free water containing sodium chloride to ensure isotonicity. The pH of the solution is adjusted with tris buffer to pH 7.4. CaNa EDTA is added to prevent metal
catalyzed oxidation. Ascorbic acid is added as an antioxidant.
An injectable solution is prepared which contains:
Radical 70 mmol
Sodium chloride q.s.
Tris buffer q.s.
CaNa EDTA 0.1 mmol
Ascorbic acid 0.01 mmol
Aqua purificata ad 500 ml
EXAMPLE II
Intravenous enhancement agent
An Overhauser MRI enhancement is prepared as follows:
The radical (e.g. that of Example 11) is dissolved in water containing NaCl, KCl, CaCl2 and MgSO4 in physiological ratios of the cations to ensure isotonic solution. The pH of the
solution is adjusted to pH 7.4 with HCl, NaOH or tris buffer.
A small amount of iron(III) chloride is added to prevent reduction of the radical.
An injectable solution is prepared which contains:
Radical 50 mmol
Sodium chloride q.s. KCl, CaCl2, MgSO4 q.s.
Tris buffer q.s.
FeCl3 0.01 mmol
Aqua purificata ad 400 ml
EXAMPLE III
Oral Overhauser MRI enhancement agent for abdominal studies
A suspension for oral Overhauser MRI studies is prepared as follows:
A radical (e,g, that of Example 11) is added to a vigorously stirred solution of hydroxyethylcellulose in water (pre-stirred for 2.5 h) containing CaNa EDTA to prevent metal-catalyzed oxidation. Aspartame and a solution of anis essence, and methyl and propyl parahydroxybenzoates in ethanol are slowly added. The suspension is filled into a 700 ml bottle. The suspension contains 5 mmol radical.
Radical 5 mmol
Hydroxyethylcellulose 7.9 g
Methyl parahydroxybenzoate 0.7 g
Propyl parahydroxybenzoate 0.14 g
Ethanol 10 g
Aspartame 0.2 g
Anis essence 0.2 g
CaNa EDTA 0.1 mmol
Water ad 700 ml
EXAMPLE IV
Preparation of capsules containing an Overhauser MRI
enhancement agent for oral use
Radical (e.g. of Example 11) 300 mg
Amylum may dis q.s.
The powders are mixed and filled into capsules. (Capsule size 0)
EXAMPLE V
Liposomal Overhauser MRI enhancement agents for intravenous administration
The radical (e.g. that of Example 11) is encapsulated in small unilamellar vesicles according to the method described in EP-A- 160552 (Vestas).
The purified liposome dispersion is filled into 50 ml vials and freeze dried. Each vial contains 1 mmol radical. The product is suspended in 30 ml saline before administration.
EXAMPLE VI
Low concentration intravenous enhancement medium
The enhancement media of Examples I and II are diluted, 1 part by volume with 99 parts by volume of water for injections to produce more dilute contrast media suitable for use with sensitive SQUID based magnetometers.
Still lower concentrations, e.g. at the 10-10 -10-6 M level, can be produced by further dilution.
EXAMPLE VII
Intravenous Overhauser MRI enhancement agent
An Overhauser enhancement solution is prepared as follows:
The radical (e.g. that of Example 11) is dissolved in water containing NaCl, KCl, CaCl2, MgSO4 in physiological ratio to ensure isotonicity solution. The pH of the solution is adjusted to pH 7.4 with HCl, NaOH or tris buffer.
A small amount of iron(III) chloride is added to prevent reduction of the radical.
An injectable solution is prepared which contains: Radical 50 mmol
Sodium chloride q.s.
KCl, CaCl2, MgS04 q. s.
Tris buffer q.s.
FeCl3 0.01 mmol
Aqua purificata ad 170 ml
EXAMPLE VIII
Intravenous Overhauser MRI enhancement agent
An Overhauser enhancement solution is prepared as follows:
The freeze dried radical (e.g. of Example 11) is dissolved oxygen-free water. The pH of the solution is adjusted with tris buffer to pH 7.4. CaNa EDTA is added to prevent metalcatalyzed oxidation. Ascorbic acid is added as an antioxidant.
An injectable solution is prepared which contains:
Radical 70 mmol
Sodium Chloride q.s.
Tris buffer q.s.
CaNa EDTA 0.1 mmol
Ascorbic acid 0.01 mmol
Aqua purificata ad 50 ml

Claims

Claims
1. The use of an inert carbon free radical for the
manufacture of a contrast medium for use in electron spin resonance enhanced magnetic resonance imaging.
2. Use as claimed in claim 1 of an inert triarylmethyl.
3. Use as claimed in claim 2 of a triarylmethyl wherein the aryl moieties, which may be the same or different, each
comprise an optionally substituted 6-membered carbocyclic or heterocyclic ring optionally carrying one or more fused carbocyclic or heterocyclic rings.
4. Use as claimed in claim 3 of a triarylmethyl wherein one or more of the aryl moieties carries at least one fused ring of formula
Figure imgf000164_0001
wherein each X, which may be the same or different, is an oxygen or sulphur atom and R7 represents hydrogen or an
optionally hydroxylated methyl group.
5. Use as claimed in claim 1 of a triarylmethyl of formula I
.CAr1 3 (I) where each group Ar 1, which may be the same or different, is an optionally substituted phenyl, 4-pyridinyl, 3-pyridinyl, 2- pyridinyl, 5-pyrimidyl or 4-pyrimidyl group.
6. Use as claimed in claim 5 of a triarylmethyl of formula I where each group Ar1 represents a 6-membered ring optionally substituted at the or any ortho carbon by a group R1, R2, R3 or R4, at the or any meta carbon by a group R2 or R3 and at any para carbon by a group R1,R2,R3 or R4, with the proviso that no more than two ring carbons are unsubstituted, each of R1 , R2, R3 or R4, which may be the same or different, independently
represents a group of formula -M, -XM, -XAr2 or -Ar2; M
represents a water solubilizing group, each group X, which may be the same or different, represents an oxygen or sulphur atom or a NH or CH2 group,
Ar2 represents a 5 to 10 membered aromatic ring optionally substituted by a solubilizing group M,
or groups R1 and/or R4 on different Ar1 groups may together represent bridging oxygen or sulphur atoms or NR5 or CR5 2 groups; where R5 represents a hydrogen atom or an optionally hydroxylated, optionally aminated, optionally alkoxylated, optionally carboxylated alkyl, oxo-alkyl, alkenyl or alkaryl group,
or groups R2 and R3 may also represent hydrogen atoms or alky groups,
or adjacent pairs of groups R1 , R2, R3 or R4 together with the two intervening carbon atoms may represent groups of formula
Figure imgf000165_0001
where R6 represents a hydrogen atom, a hydroxyl group, an optionally alkoxylated, optionally hydroxylated acyloxy or alkyl group or a solubilising group M; Z represents an oxyge or sulphur atom or a group NR5, CR7 2 or SiR2 7, each R7, which may be the same or different, represents a hydrogen atom, an alkyl, hydroxyalkyl, carboxy, alkoxycarbonyl or carbamoyl group or two R2 groups together with the atom to which they are bound represent a carbonyl group or a 5 to 8 membered
cycloalkylidene, mono- or di-oxacycloalkylidene, mono- or di- azacycloalkylidene, or mono- or di-thiacycloalkylidene group optionally with the ring attachment carbon replaced by a silicon atom and R7 where it is other than hydrogen, is
optionally substituted by a group R6,
or a salt thereof.
7. Use as claimed in claim 6 of a triarylmethyl of formula I wherein one or more of the aryl moieties is of formula
Figure imgf000166_0001
where each Y independently represents CH, CM, C-XM, C-Ar2, C- XAr2 or a nitrogen atom and R1 to R4, M, X and Ar2 are as defined in claim 6.
8. Use as claimed in claim 1 of a triarylmethyl wherein at least one of the aryl moieties is of formula
Figure imgf000166_0002
where R1 is as defined in claim 6.
A radical compound of formula la
Figure imgf000166_0003
wherein each Ar12 which may be the same or different represents a 6-membered carbocyclic or nitrogen-containing heterocyclic ring, at least one group Ar12 being a group Ar1 as defined in either of claims 5 and 6.
10. A compound of formula la as claimed in claim 9 wherein the Ar1 group or groups are of formula
Figure imgf000167_0001
where each Y independently represents CH, CM, C-XM, C-Ar2, C- XAr2 or a nitrogen atom where R1 to R4, X, M and Ar2 are as defined in claim 6.
11. A compound of formula la as claimed in either of claims 9 and 10 wherein each group Ar12 is a group Ar1.
12. A compound of formula la as claimed in any one of claims 9 to 11 wherein each group Ar1 carries two fused groups of formula
Figure imgf000167_0002
wherein X and Z are as defined in claim 6.
13. A compound of formula la as claimed in claim 12 wherein each group Ar1 carries two fused groups of formula
Figure imgf000168_0002
wherein R1 is as defined in claim 6.
14. A compound of formula la as claimed in claim 13 wherein each group Ar1 is of formula
Figure imgf000168_0001
wherein R1 is a group M or XM and X and M are as defined in claim 6.
15. A triarylmethyl radical-precursor for a radical compound as claimed in any one of claims 9 to 14.
16. A process for the preparation of a radical compound as claimed in any one of claims 9 to 14 comprising subjecting a radical-precursor as claimed in claim 15 to a radical
generation step and optionally subsequently modifying the substitution on the aryl moieties.
17. A process for the preparation of a triarylmethyl radical- precursor as claimed in claim 15 comprising one or more of the following steps: a) (to prepare a triarylmethanol of formula II
HO-C(Ar12)3 (II)
(wherein Ar12 is as defined in claim 9))
reacting a compound of formula XXIII
H-Ar12 (XXIII) with alkyl lithium and a compound of formula CO(OR")2 (where R" is an alkyl group); b) (to prepare a triarylmethanol of formula II)
reacting an organometallic compound comprising a metallinked Ar12 moiety with a compound of formula XXV, XXVI XXVII
R"OCOOR" (XXV)
Ar12COOR" (XXVI)
(Ar12) 2CO (XXVII) ; c) (to prepare a triarylmethanol of formula II)
hydrolysing a compound of formula III
Hal-C(Ar12)3 (III); d) (to prepare a triarylmethanol of formula II)
reacting a compound of formula XXVII with a compound of formula Hal-Ar12; e) (to prepare a triarylmethyl halide of formula III)
halogenating a triarylmethane of formula IV
H-C(Ar12)3 (IV)
or a triarylmethanol of formula II; f) (to prepare a triarylmethane of formula IV)
reacting a compound of formula XXIII with a
trialkoxymethane of formula XXVIII
(R"O)3CH (XXVIII); g) (to prepare a triarylmethane of formula IV)
hydrogenating or otherwise reducing a triarylmethyl hal of formula III or a triarylmethanol of formula II; h) (to prepare a triarylmethane of formula IV)
reacting a compound of formula XXIII with a compound of formula XXIX
(XXIX)
Figure imgf000169_0001
(wherein n1 is 0, 1 or 2 and n2 is 1, 2 or 3 and n1 plus n2 is 3); i) (to prepare a triarylmethane of formula IV)
reacting a compound of formula XXX
(Ar12)2 CHLv (XXX)
(wherein Lv is a leaving group) with an organometallic compound comprising a metal-linked Ar12 moiety; j) (to prepare a triarylacetic acid of formula XXXI
(Ar12)3CCOOH (XXXI))
reacting a triarylmethyl halide of formula III with carbon monoxide or a triarylmethyl organometallic compound with carbon dioxide; k) (to prepare a compound of formula XXXII
(Ar12)3CCOOOCOC(Ar12)3 (XXXII)
reacting a triarylacetic acid of formula XXXI with thionyl chloride and a peroxide; l) (to prepare a compound of formula XXXIII
(Ar12)3CN=NC(Ar12)3 (XXXIII))
oxidizing a triarylmethylamine halide of formula XXXIV (Ar12)CNHHal (XXXIV); and m) reacting a triarylmethyl radical precursor to modify the substitution on one or more of the aryl moieties.
18. A process as claimed in claim 17 wherein alkyl lithium is used to activate a starting material and wherein the resulting organo-lithium salt is filtered before further reaction.
19. A magnetic resonance imaging contrast enhancing
composition comprising a physiologically tolerable inert carbon free radical together with at least one pharmacologically acceptable carrier or excipient.
20. A composition as claimed in claim 18 wherein said free radical is a triarylmethyl as defined in any one of claims 2 to
14 .
21. A method of magnetic resonance investigation of a sample, said method comprising introducing into said sample an inert carbon free radical, exposing said sample to a first radiation of a frequency selected to excite electron spin transitions in said free radical, exposing said sample to a second radiation of a frequency selected to excite nuclear spin transitions in selected nuclei in said sample, detecting free induction decay signals from said sample, and, optionally, generating an image or dynamic flow data from said detected signals.
22. A tricylic aromatic compound comprising a central 5-6 membered carbocyclic or heterocyclic aromatic ring bearing two five-membered fused rings, each said fused ring comprising two ring heteroatoms selected from oxygen and suphur.
23. A compound as claimed in claim 22 of formula XL
(XL)
Figure imgf000171_0001
(where X and R7 are as defined in claim 2, Y1 is a group CH, N, CCOOR5, CSR5, CM or CXM, R5 and M are as defined in claim 6 and R40 is a hydrogen atom, or an optionally substituted hydroxyl, methyl or formyl group or a group
Figure imgf000171_0002
where Z''' is CHOH, C=O or CHHal and Hal is a halogen atom), or a salt thereof.
24. A compound of formula XL as claimed in claim 23 wherein each X is oxygen, each R7 is optionally hydroxylated methyl and Y1 is other than N.
25. A process for the preparation of a compound of formula XL, said process comprising condensing a compound of formula XLI
Figure imgf000172_0001
(wherein R40' and Y'' are groups R40 or Y1 as defined in claim 23 or protected such groups, and X is as defined in claim 23) with a compound of formula (R7')2 CX (where R7' is a group R7 as defined in claim 23 or a protected R7 group) under oxidizing conditions and if necessary removing any protecting groups, optionally after reduction (eg with Fe/HCl) of a compound of formula XLII
Figure imgf000172_0002
to yield the starting material of formula XLI.
PCT/EP1991/000285 1899-02-12 1991-02-12 Triarylmethyl radicals and the use of inert carbon free radicals in mri WO1991012024A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU72350/91A AU651570B2 (en) 1990-02-12 1991-02-12 Triarylmethyl radicals and the use of inert carbon free radicals in MRI
US07/916,974 US5599522A (en) 1899-02-12 1991-02-12 Triarylmethyl radicals and the use of inert carbon free radicals in MRI
EP91903934A EP0515458B1 (en) 1990-02-12 1991-02-12 Triarylmethyl radicals and the use of inert carbon free radicals in mri
DE69112384T DE69112384T2 (en) 1990-02-12 1991-02-12 TRIARYL METHYL RADICALS AND THE USE OF INERT CARBON-FREE RADICALS IN MRI.
FI923589A FI923589A (en) 1990-02-12 1992-08-11 TRIARYLMETHYLRADIKALER OCH ANVAENDNING AV INERTA FRIA KOLRADIKALER I MRI.
NO92923117A NO923117L (en) 1990-02-12 1992-08-11 TRIARYLRADICALS AND THE USE OF INERT FREE CARBON RADICALS
GR950403056T GR3017947T3 (en) 1990-02-12 1995-11-01 Triarylmethyl radicals and the use of inert carbon free radicals in mri.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9003105.5 1990-02-12
GB909003105A GB9003105D0 (en) 1990-02-12 1990-02-12 Compositions
GB9012300.1 1990-06-01
GB909012300A GB9012300D0 (en) 1990-06-01 1990-06-01 Compositions

Publications (1)

Publication Number Publication Date
WO1991012024A1 true WO1991012024A1 (en) 1991-08-22

Family

ID=26296651

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1991/000285 WO1991012024A1 (en) 1899-02-12 1991-02-12 Triarylmethyl radicals and the use of inert carbon free radicals in mri

Country Status (14)

Country Link
US (2) US5599522A (en)
EP (1) EP0515458B1 (en)
JP (1) JP3175940B2 (en)
AT (1) ATE126707T1 (en)
AU (1) AU651570B2 (en)
CA (1) CA2075818A1 (en)
DE (1) DE69112384T2 (en)
DK (1) DK0515458T3 (en)
ES (1) ES2076522T3 (en)
FI (1) FI923589A (en)
GR (1) GR3017947T3 (en)
IE (1) IE69365B1 (en)
NO (1) NO923117L (en)
WO (1) WO1991012024A1 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2252245A (en) * 1990-11-12 1992-08-05 Instrumentarium Corp Diagnostic composition and apparatus for use in magnetic resonance imaging
WO1993002710A2 (en) * 1991-08-09 1993-02-18 Nycomed Innovation Ab Use of persistent free radicals in magnetic resonance imaging
WO1993002711A1 (en) * 1991-08-09 1993-02-18 Nycomed Innovation Ab Use of persistent free-radicals in magnetic resonance imaging
US5530140A (en) * 1993-04-02 1996-06-25 Nycomed Imaging As Free radicals
WO1996039367A1 (en) * 1994-03-31 1996-12-12 Nycomed Imaging A/S Heterocyclic methyl free radicals as image enhancing agents
WO1998022148A1 (en) * 1996-11-20 1998-05-28 Washington University Mri contrast agents and ligands
US6013810A (en) * 1997-03-06 2000-01-11 Nycomed Imaging As Free radicals
WO2006011809A1 (en) 2004-07-30 2006-02-02 Ge Healthcare As Method of producing a composition, composition and its use
WO2006011811A2 (en) * 2004-07-30 2006-02-02 Ge Healthcare As Radicals and their use as paramagnetic agents in a dynamic nuclear polarisation process
WO2007064226A2 (en) 2005-12-01 2007-06-07 Ge Healthcare As Method of dynamic nuclear polarisation (dnp) using a trityl radical and a paramagnetic metal ion
WO2007066247A2 (en) 2005-12-08 2007-06-14 Koninklijke Philips Electronics, N.V. System and method for monitoring in vivo drug release using overhauser-enhanced nmr
WO2007069909A2 (en) * 2005-12-16 2007-06-21 Ge Healthcare As Method to produce hyperpolarised carboxylates of organic amines
WO2007111515A2 (en) * 2006-03-29 2007-10-04 Ge Healthcare As Method to produce hyperpolarised carboxylates and sulphonates
WO2008026937A1 (en) 2006-08-30 2008-03-06 Ge Healthcare As Method of dynamic nuclear polarisation (dnp) and compounds and compositions for use in the method
EP2072061A1 (en) 2007-12-19 2009-06-24 GE Healthcare Limited Composition and method for generating a metabolic profile using 13C-MR detection
EP2119457A1 (en) 1998-01-05 2009-11-18 GE Healthcare AS Method of magnetic resonance investigation with hyperpolarised contrast agents
WO2011029854A1 (en) 2009-09-10 2011-03-17 Ge Healthcare Limited 13c-mr detection using hyperpolarised 13c-fructose
WO2011124672A1 (en) 2010-04-08 2011-10-13 Bracco Imaging Spa Process for preparing hyperpolarized substrates and method for mri
EP2399913A1 (en) * 2010-06-25 2011-12-28 Universität Potsdam Fluorescent dye and its application
FR2967158A1 (en) * 2010-11-08 2012-05-11 Phosphoenix Sarl NEW TRIARYLMETHYL RADICALS: THEIR PREPARATION AND APPLICATION
WO2013053839A1 (en) 2011-10-12 2013-04-18 Bracco Imaging Spa Process for the preparation of hyperpolarized derivatives for use in mri analysis
WO2013083535A1 (en) 2011-12-05 2013-06-13 Bracco Imaging Spa Composition comprising acetic anhydride and a gadolinium complex, and method for the use in hyperpolarisation mri analysis
CN101316616B (en) * 2005-12-01 2013-06-19 通用电气医疗集团股份有限公司 Method of dynamic nuclear polarisation (DNP) using a trityl radical and a paramagnetic metal ion
WO2013149935A1 (en) 2012-04-02 2013-10-10 Bracco Imaging Spa Hyperpolarized amino acids
US8697034B2 (en) 2008-10-10 2014-04-15 The Board Of Regents Of The University Of Texas System Hyperpolarized 89-yttrium and methods relating thereto
US8703102B2 (en) 2008-04-04 2014-04-22 Millikelvin Technologies Llc Systems and methods for producing hyperpolarized materials and mixtures thereof
US8703201B2 (en) 2006-02-21 2014-04-22 Millikelvin Technologies Llc Hyperpolarization methods, systems and compositions

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10029075A1 (en) * 2000-06-13 2001-12-20 Bayer Ag Two- or three-stage preparation of high-purity 3,4-alkylenedioxythiophene-2,5-dicarboxylic derivatives or acids is effected without isolation of the intermediates
NL1017122C2 (en) * 2001-01-16 2002-07-17 Doornes Transmissie Bv Transverse element for a drive belt for a continuously variable transmission.
US7126332B2 (en) * 2001-07-20 2006-10-24 Baker Hughes Incorporated Downhole high resolution NMR spectroscopy with polarization enhancement
NO20031736D0 (en) * 2003-04-15 2003-04-15 Amersham Health As compounds
EP1940475A4 (en) * 2005-09-28 2010-05-26 Harvard College Hyperpolarized solid materials with long spin relaxation times for use as imaging agents in magnetic resonance imaging
US20080284429A1 (en) * 2005-12-10 2008-11-20 The President And Fellows Of Harvard College Situ Hyperpolarization of Imaging Agents
US20090252686A1 (en) * 2006-01-11 2009-10-08 President And Fellows Of Harvard College Ex Vivo Hyperpolarization of Imaging Agents
WO2008123504A1 (en) 2007-03-30 2008-10-16 Fujifilm Corporation Ultraviolet ray absorber composition
CN101821273A (en) 2007-08-16 2010-09-01 富士胶片株式会社 Heterocyclic compound, ultraviolet ray absorbent, and composition comprising the ultraviolet ray absorbent
JP2010059235A (en) 2008-09-01 2010-03-18 Fujifilm Corp Ultraviolet absorbent composition
US20100092390A1 (en) * 2008-10-09 2010-04-15 President And Fellows Of Harvard College Methods for Making Particles Having Long Spin-Lattice Relaxation Times
US8593141B1 (en) 2009-11-24 2013-11-26 Hypres, Inc. Magnetic resonance system and method employing a digital squid
US8970217B1 (en) 2010-04-14 2015-03-03 Hypres, Inc. System and method for noise reduction in magnetic resonance imaging
JP6026824B2 (en) * 2012-09-04 2016-11-16 紀本電子工業株式会社 Method for producing radical anion of aromatic nitro compound
JP7427354B2 (en) 2018-01-29 2024-02-05 日清オイリオグループ株式会社 Oil and fat composition for cooking rice, rice, and method for producing rice

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0133674A1 (en) * 1983-08-03 1985-03-06 Schering Aktiengesellschaft Nitroxyl compounds, process for their preparation and diagnostic agents containing them
WO1990002345A1 (en) * 1988-08-19 1990-03-08 Cockbain, Julian, Roderick, Michaelson Magnetic resonance imaging

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61448B1 (en) * 1987-06-23 1994-11-02 Hafslund Nycomed Innovation Improvements in and relating to magnetic resonance imaging

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0133674A1 (en) * 1983-08-03 1985-03-06 Schering Aktiengesellschaft Nitroxyl compounds, process for their preparation and diagnostic agents containing them
WO1990002345A1 (en) * 1988-08-19 1990-03-08 Cockbain, Julian, Roderick, Michaelson Magnetic resonance imaging

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Angew. Chem., Vol. 69, No. 10, 1957 Walter Theilacker et al.: "Neue Ergebnisse ~ber freie Kohlenstoff-Radikale ", *
Angew. Chem., Vol. 78, No. 1, 1966 Eugen M~ller et al.: "Anwendung und Grenzen magnetischer Methoden in der Radikalchemie ", *
J. Org. Chem., Vol. 47, 1982 M. Ballester et al.: "Inert Carbon Free Radicals. 2. Monofunctionalized Tetradecachlorotriphenylmethyl Radicals and Related Compounds ", *
J. Org. Chem., Vol. 47, 1982 Manuel Ballester et al.: "Inert Carbon Free Radicals. 3. Monofunctionalized Radicals from Perchlorotriphenylcarbenium Hexachloroantimonate ", *
J. Org. Chem., Vol. 48, 1983 M. Ballester et al.: "Inert Carbon Free Radicals. 4. Spin Labeling of Amino Acids and Peptides ", *
J. Org. Chem., Vol. 53, 1988 L. Julia et al.: "Inert Carbon Free Radicals. 9. The First Perchlorinated Triarylmethyl and Fluorenyl Radicals with a Heteroaromatic Ring, and Related Compounds ", *
Journal of the American Chemical Society, Vol. 84, 1962 Henry Judeikis et al.: "The E.s.r. Spectra of Some Substituted Triarylmethyl Radicals ", *
Journal of the American Chemical Society, Vol. 89, No. 9, April 1967 M.J. Sabacky et al.: "Triarylmethyl Radicals. Synthesis and Electron Spin Resonance Studies of Sesquixanthydryl Dimer and Related Compounds ", *
Journal of the American Chemical Society, Vol. 93, No. 9, May 1971 Manuel Ballester et al.: "Inert Carbon Free Radicals. I. Perchlorodiphenylmethyl and Perchlorotriphenylmethyl Radical Series ", *
Radiology, Vol. 147, No. 3, 1983 Robert C. Brasch,: "Work in Progress: Methods of Contrast Enhancement for NMR Imaging and Potential Applications ", *

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2252245A (en) * 1990-11-12 1992-08-05 Instrumentarium Corp Diagnostic composition and apparatus for use in magnetic resonance imaging
US5325854A (en) * 1990-11-12 1994-07-05 Instrumentarium Corporation Magnetic resonance imaging
GB2252245B (en) * 1990-11-12 1995-05-31 Instrumentarium Corp Improvements in and relating to magnetic resonance imaging
WO1993002710A2 (en) * 1991-08-09 1993-02-18 Nycomed Innovation Ab Use of persistent free radicals in magnetic resonance imaging
WO1993002711A1 (en) * 1991-08-09 1993-02-18 Nycomed Innovation Ab Use of persistent free-radicals in magnetic resonance imaging
WO1993002710A3 (en) * 1991-08-09 1993-03-18 Nycomed Innovation Ab Use of persistent free radicals in magnetic resonance imaging
US5530140A (en) * 1993-04-02 1996-06-25 Nycomed Imaging As Free radicals
US5728370A (en) * 1993-04-02 1998-03-17 Nycomed Imaging As Free Radicals
WO1996039367A1 (en) * 1994-03-31 1996-12-12 Nycomed Imaging A/S Heterocyclic methyl free radicals as image enhancing agents
AU709532B2 (en) * 1995-06-06 1999-09-02 Nycomed Imaging As Heterocyclic methyl free radicals as image enhancing agents
WO1998022148A1 (en) * 1996-11-20 1998-05-28 Washington University Mri contrast agents and ligands
US6013810A (en) * 1997-03-06 2000-01-11 Nycomed Imaging As Free radicals
EP2119457A1 (en) 1998-01-05 2009-11-18 GE Healthcare AS Method of magnetic resonance investigation with hyperpolarised contrast agents
WO2006011809A1 (en) 2004-07-30 2006-02-02 Ge Healthcare As Method of producing a composition, composition and its use
WO2006011811A3 (en) * 2004-07-30 2006-06-01 Amersham Health As Radicals and their use as paramagnetic agents in a dynamic nuclear polarisation process
US8431723B2 (en) 2004-07-30 2013-04-30 Ge Healthcare As Radicals and their use as paramagnetic agents in a DNP process
WO2006011811A2 (en) * 2004-07-30 2006-02-02 Ge Healthcare As Radicals and their use as paramagnetic agents in a dynamic nuclear polarisation process
US9023320B2 (en) 2004-07-30 2015-05-05 Ge Healthcare As Method of producing a composition, composition and its use
NO339934B1 (en) * 2004-07-30 2017-02-20 Ge Healthcare As Radicals, their use as paramagnetic agents and a compound containing radicals, as well as a method for dynamic nuclear polarization (DNP) of compounds containing carboxyl groups
WO2007064226A3 (en) * 2005-12-01 2007-10-18 Ge Healthcare As Method of dynamic nuclear polarisation (dnp) using a trityl radical and a paramagnetic metal ion
AU2006321057B2 (en) * 2005-12-01 2012-11-01 Ge Healthcare As Method of dynamic nuclear polarisation (DNP) using a trityl radical and a paramagnetic metal ion
US8951502B2 (en) 2005-12-01 2015-02-10 Ge Healthcare As Method of dynamic nuclear polarisation (DNP)
CN101316616B (en) * 2005-12-01 2013-06-19 通用电气医疗集团股份有限公司 Method of dynamic nuclear polarisation (DNP) using a trityl radical and a paramagnetic metal ion
WO2007064226A2 (en) 2005-12-01 2007-06-07 Ge Healthcare As Method of dynamic nuclear polarisation (dnp) using a trityl radical and a paramagnetic metal ion
WO2007066247A2 (en) 2005-12-08 2007-06-14 Koninklijke Philips Electronics, N.V. System and method for monitoring in vivo drug release using overhauser-enhanced nmr
US9272056B2 (en) 2005-12-16 2016-03-01 Ge Healthcare As Method to produce hyperpolarised carboxylates
WO2007069909A3 (en) * 2005-12-16 2007-10-18 Ge Healthcare As Method to produce hyperpolarised carboxylates of organic amines
WO2007069909A2 (en) * 2005-12-16 2007-06-21 Ge Healthcare As Method to produce hyperpolarised carboxylates of organic amines
US8703201B2 (en) 2006-02-21 2014-04-22 Millikelvin Technologies Llc Hyperpolarization methods, systems and compositions
WO2007111515A3 (en) * 2006-03-29 2008-04-24 Ge Healthcare As Method to produce hyperpolarised carboxylates and sulphonates
WO2007111515A2 (en) * 2006-03-29 2007-10-04 Ge Healthcare As Method to produce hyperpolarised carboxylates and sulphonates
WO2008026937A1 (en) 2006-08-30 2008-03-06 Ge Healthcare As Method of dynamic nuclear polarisation (dnp) and compounds and compositions for use in the method
EP2072061A1 (en) 2007-12-19 2009-06-24 GE Healthcare Limited Composition and method for generating a metabolic profile using 13C-MR detection
US8703102B2 (en) 2008-04-04 2014-04-22 Millikelvin Technologies Llc Systems and methods for producing hyperpolarized materials and mixtures thereof
US8697034B2 (en) 2008-10-10 2014-04-15 The Board Of Regents Of The University Of Texas System Hyperpolarized 89-yttrium and methods relating thereto
WO2011029854A1 (en) 2009-09-10 2011-03-17 Ge Healthcare Limited 13c-mr detection using hyperpolarised 13c-fructose
WO2011124672A1 (en) 2010-04-08 2011-10-13 Bracco Imaging Spa Process for preparing hyperpolarized substrates and method for mri
US9694090B2 (en) 2010-04-08 2017-07-04 Bracco Imaging S.P.A. Process for preparing hyperpolarized substrates and method for MRI
US8664410B2 (en) 2010-06-25 2014-03-04 Universitat Potsdam Fluorescent dye and use thereof
EP2399913A1 (en) * 2010-06-25 2011-12-28 Universität Potsdam Fluorescent dye and its application
WO2012062975A1 (en) 2010-11-08 2012-05-18 Phosphoenix Sarl Novel triarylmethyl radicals: preparation and use thereof
FR2967158A1 (en) * 2010-11-08 2012-05-11 Phosphoenix Sarl NEW TRIARYLMETHYL RADICALS: THEIR PREPARATION AND APPLICATION
US9511154B2 (en) 2011-10-12 2016-12-06 Bracco Imaging S.P.A. Process for the preparation of hyperpolarized derivatives for use in MRI analysis
WO2013053839A1 (en) 2011-10-12 2013-04-18 Bracco Imaging Spa Process for the preparation of hyperpolarized derivatives for use in mri analysis
WO2013083535A1 (en) 2011-12-05 2013-06-13 Bracco Imaging Spa Composition comprising acetic anhydride and a gadolinium complex, and method for the use in hyperpolarisation mri analysis
US9693828B2 (en) 2011-12-05 2017-07-04 Bracco Imaging S.P.A. Composition comprising acetic anhydride and a gadolinium complex, and method for the use in hyperpolarisation in MRI analysis
WO2013149935A1 (en) 2012-04-02 2013-10-10 Bracco Imaging Spa Hyperpolarized amino acids
US9925280B2 (en) 2012-04-02 2018-03-27 Bracco Imaging S.P.A. Hyperpolarized amino acids

Also Published As

Publication number Publication date
EP0515458B1 (en) 1995-08-23
IE69365B1 (en) 1996-09-04
FI923589A0 (en) 1992-08-11
ATE126707T1 (en) 1995-09-15
US5827501A (en) 1998-10-27
CA2075818A1 (en) 1991-08-13
AU7235091A (en) 1991-09-03
JP3175940B2 (en) 2001-06-11
NO923117L (en) 1992-10-08
DE69112384D1 (en) 1995-09-28
IE910462A1 (en) 1991-08-14
DK0515458T3 (en) 1995-09-25
NO923117D0 (en) 1992-08-11
AU651570B2 (en) 1994-07-28
DE69112384T2 (en) 1996-03-28
ES2076522T3 (en) 1995-11-01
JPH05506428A (en) 1993-09-22
FI923589A (en) 1992-08-11
US5599522A (en) 1997-02-04
GR3017947T3 (en) 1996-02-29
EP0515458A1 (en) 1992-12-02

Similar Documents

Publication Publication Date Title
EP0515458B1 (en) Triarylmethyl radicals and the use of inert carbon free radicals in mri
US5728370A (en) Free Radicals
US5435991A (en) Use of persistent heterocyclic free-radicals in magnetic resonance imaging
JPH08508729A (en) Contrast agent containing perfluoro-1H-1H-neopentyl and method of using the same
US6303101B1 (en) Bismuth compounds
WO1995001124A1 (en) Functionalized tripodal ligands for imaging applications
US4310546A (en) Novel retinoids and their use in preventing carcinogenesis
US5530140A (en) Free radicals
WO1996022994A1 (en) Bismuth compounds
EP0966414B1 (en) Triarylmethyl free radicals as image enhancing agents
WO1997009633A1 (en) A method of determining oxygen concentration in a sample
WO1993002710A2 (en) Use of persistent free radicals in magnetic resonance imaging
US6063360A (en) Free radicals comprising benzodithiole derivatives
Chen et al. Preparation and Imaging Study of Tumor-targeting MRI Contrast Agent Based on Fe3O4 Nanoparticles
WO2011131912A1 (en) Magneto-optical nano-objects for cancer detection
Ying‐Chun et al. Structural Characterization and Relaxivity Study of a New Paramagnetic Mn (II) Complex of DTPA‐BpABA
MXPA97005609A (en) Composite of bism

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1991903934

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2075818

Country of ref document: CA

Ref document number: 923589

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1991903934

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1991903934

Country of ref document: EP